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3TC  lamivudine
AASLD  American Association for the Study of Liver Diseases
ABC  abacavir
ALT  alanine aminotransferase
AST  aspartate aminotransferase
APRI  aminotransferase/platelet ratio index 
ART  antiretroviral therapy
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AUDIT  Alcohol Use Disorders Identification Test
AZT  zidovudine
BHIVA  British HIV Association
CD4  cluster of differentiation 4
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CUPIC  Compassionate Use of Protease Inhibitors in Viral C Cirrhosis (study)
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DAA  direct-acting antiviral (drug)
ddI  didanosine
DVR  delayed virological response
EASL  European Association for the Study of the Liver
EIA  enzyme immunoassay
EOT  end of treatment
eRVR  extended rapid virological response
ES  effect size
FBC  full blood count
FDA  (US) Food and Drug Administration
FTC  emtricitabine
gGT  gamma glutamyl transpeptidase
GRADE   Grading of Recommendations Assessment, Development and Evaluation
HAV  hepatitis A virus
HBV  hepatitis B virus
HCV  hepatitis C virus
IFN  interferon
INR  international normalized ratio
mhGAP  WHO Mental Health Gap Action Programme
ABBREVIATIONS AND ACRONYMS 
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NAT  nucleic acid testing
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RR  relative risk
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Acute HCV Presence of HCV within six months of acquiring infection
Chronic HCV Continued presence of HCV six months or more after acquiring 
infection
Delayed virological 
response (DVR)
More than 2 log decline in HCV RNA viral load but a detectable 
HCV RNA level at week 12 of treatment and an undetectable 
HCV RNA level at week 24 of treatment
Early virological response 
(EVR)
More than 2 log reduction in HCV RNA viral load at week 12 of 
treatment
Extended rapid virological 
response (eRVR)
Undetectable HCV RNA 4 weeks (rapid) and 12 weeks 
(extended) after the start of treatment
GRADE Grading of Recommendations Assessment, Development and 
Evaluation
Negative predictive value The probability that when a person’s test result is negative, they 
truly do not have the infection/disease
Non-response Detectable HCV RNA throughout treatment
Null response Less than 2 log drop in HCV RNA level by week 12 of treatment
Partial response 2 log drop in HCV RNA by week 12 of treatment but HCV RNA 
remains detectable at week 24 or end of treatment
Positive predictive value The probability that when a person’s test result is positive, they 
truly have the infection/disease. Predictive values are influenced 
by the prevalence of the disease in the population
Rapid virological response 
(RVR)
Undetectable HCV RNA 4 weeks after the start of treatment
Relapse Undetectable HCV RNA at the end of treatment but detectable 
HCV RNA within 24 weeks of completing treatment
Sensitivity of a test The ability of a test to correctly identify those with the infection/
disease. (True positives / true positives + false negatives)
Specificity of a test The ability of a test to correctly identify those without the infection/
disease. (True negatives / true negatives+ false positives)
Sustained virological 
response (SVR)
Undetectable HCV RNA three or six months after the end of 
treatment
Viral breakthrough Undetectable HCV RNA during treatment followed by detectable 
HCV RNA during treatment
GLOSSARY OF TERMS 
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EXECUTIVE SUMMARY
Background
According to recent estimates, more than 185 million people around the world 
have been infected with the hepatitis C virus (HCV), of whom 350 000 die each 
year. One third of those who become chronically infected are predicted to 
develop liver cirrhosis or hepatocellular carcinoma. Despite the high prevalence 
of disease, most people infected with the virus are unaware of their infection. 
For many who have been diagnosed, treatment remains unavailable. Treatment 
is successful in the majority of persons treated, and treatment success rates 
among patients treated in low- and middle-income countries are similar to those 
in high-income countries. 
These are the first guidelines dealing with hepatitis C treatment produced by the 
World Health Organization (WHO) and complement existing guidance on the 
prevention of transmission of bloodborne viruses, including HCV. They are intended 
for policy-makers, government officials, and others working in low- and middle-
income countries who are developing programmes for the screening, care and 
treatment of persons with HCV infection. These guidelines serve as a framework 
that can allow the expansion of clinical services to patients with HCV infection, as 
they provide key recommendations in these areas and discuss considerations for 
implementation. The guidelines are also intended for health-care providers who 
care for persons with HCV infection in low- and middle-countries and provide them 
guidance in the management of patients infected with HCV. 
Hepatitis C infection differs from other chronic viral infections, notably HIV 
infection, in that it can be cured by treatment. Several medicines are available 
to treat persons infected with HCV, and cure rates have steadily improved with 
the introduction of newer medicines. The field of HCV therapeutics is evolving 
rapidly, and a number of compounds are in various stages of development. These 
new compounds can cure more than 90% of persons with HCV infection and are 
effective against genotypes that were previously difficult to treat. Currently licensed 
treatments for HCV infection include pegylated and standard interferon alpha 
(IFN), ribavirin (RBV), the protease inhibitors boceprevir, telaprevir and simeprevir; 
and the NS5B nucleotide polymerase inhibitor inhibitor sofosbuvir. It is expected 
that in the next few years, a number of additional antiviral compounds will be 
licensed. This guidance includes recommendations for all medicines approved as 
of December 2013, and will be updated periodically as new compounds become 
available for use. 
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These guidelines were produced following the standard process for developing 
WHO guidelines as described in the WHO Handbook for Guideline Development, 
2012. The development process followed the Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) method, which provides 
guidance and tools to define research questions, develop an analytical framework, 
conduct systematic reviews, assess the overall quality of the evidence, and 
determine the direction and strength of the recommendations. The process 
involved multiple steps that included the formation of a Guidelines Development 
Group, and the development of a series of questions across the screening, care 
and treatment framework, which were structured in the PICO format (Population, 
Intervention, Comparison, Outcomes; Appendix 1). Systematic reviews of the best 
available evidence were conducted and the findings were assessed for quality and 
presented in GRADE evidence profiles (Appendices 2-4). Existing national and 
international guidelines were also evaluated and, where necessary, comprehensive 
reviews and technical reports obtained (Appendix 5).  The final recommendations 
were agreed upon by consensus during a meeting of the Guidelines Development 
Group in June 2013. 
By the time of the June 2013 meeting, it was clear that two additional medicines, 
simeprevir and sofosbuvir, would likely be approved in at least one country (the 
United States) prior to the release of these guidelines; therefore, it was decided 
to include recommendations for their use as well. Using the same approach as 
for all the recommendations in these guidelines, additional systematic reviews 
were commissioned, and evidence profiles and decision-making tables were 
prepared. These were reviewed by the Guidelines Development Group during a 
web-based meeting that took place in December 2013, and recommendations 
were developed for the use of simeprevir and sofosbuvir. The final version of the 
document was approved by the WHO Guidelines Review Committee. 
Summary of recommendations
Recommendations on screening for HCV infection
1. Screening to identify persons with HCV infection: It is recommended that 
HCV serology testing be offered to individuals who are part of a population 
with high HCV prevalence or who have a history of HCV risk exposure/
behaviour. (Strong recommendation, moderate quality of evidence)
2. When to confirm the diagnosis of chronic HCV infection: It is suggested that 
nucleic acid testing (NAT) for the detection of HCV ribonucleic acid (RNA) 
be performed directly following a positive HCV serological test to establish 
the diagnosis of chronic HCV infection, in addition to NAT for HCV RNA as 
part of the assessment for starting treatment for HCV infection. (Conditional 
recommendation, very low quality of evidence) 
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Recommendations on care of people infected with HCV
3. Screening for alcohol use and counselling to reduce moderate and high 
levels of alcohol intake: An alcohol intake assessment is recommended for 
all persons with HCV infection followed by the offer of a behavioural alcohol 
reduction intervention for persons with moderate-to-high alcohol intake. 
(Strong recommendation, moderate quality of evidence) 
4. Assessing degree of liver fibrosis and cirrhosis: In resource-limited settings, 
it is suggested that the aminotransferase/platelet ratio index (APRI) or FIB4 
tests be used for the assessment of hepatic fibrosis rather than other non-
invasive tests that require more resources such as elastography or Fibrotest. 
(Conditional recommendation, low quality of evidence)
Recommendations on treatment of HCV infection
5. Assessing for HCV treatment: All adults and children with chronic HCV 
infection, including people who inject drugs, should be assessed for antiviral 
treatment. (Strong recommendation, moderate quality of evidence) 
6. Treatment with pegylated interferon and ribavirin: Pegylated interferon in 
combination with ribavirin is recommended for the treatment of chronic 
HCV infection rather than standard non-pegylated interferon with ribavirin. 
(Strong recommendation, moderate quality of evidence)
7. Treatment with telaprevir or boceprevir: Treatment with the direct-acting 
antivirals telaprevir or boceprevir, given in combination with pegylated 
interferon and ribavirin, is suggested for genotype 1 chronic HCV 
infection rather than pegylated interferon and ribavirin alone. (Conditional 
recommendation, moderate quality of evidence)
8. Treatment with sofosbuvir: Sofosbuvir, given in combination with ribavirin 
with or without pegylated interferon (depending on the HCV genotype), is 
recommended in genotypes 1, 2, 3 and 4 HCV infection rather than pegylated 
interferon and ribavirin alone (or no treatment for persons who cannot tolerate 
interferon). (Strong recommendation, high quality of evidence)
9. Treatment with simeprevir: Simeprevir, given in combination with pegylated 
interferon and ribavirin, is recommended for persons with genotype 1b HCV 
infection and for persons with genotype 1a HCV infection without the Q80K 
polymorphism rather than pegylated interferon and ribavirin alone. (Strong 
recommendation, high quality of evidence)
Note: Recommendations 8 and 9 were made without taking resource use into 
consideration, as pricing information was not available for any country other than 
the United States at the time this recommendation was formulated.
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HCV screening
Screening for HCV infection requires an initial serologic screening test followed 
by an HCV RNA test (either quantitative or qualitative) to confirm the presence 
of viraemia, and therefore chronic infection, as 15–45% of those initially infected 
will spontaneously clear the virus, usually within six months of acquiring the 
infection. Persons who do not clear HCV within six months are defined as having 
chronic HCV infection and are diagnosed either during routine screening or 
when they develop symptoms of HCV-associated liver disease. Those at risk of 
infection include people undergoing medical procedures (such as the transfusion 
of infected blood or blood products, renal dialysis, reuse of syringes, catheters, 
needles and other medical equipment) in a clinical setting with substandard 
infection control practices, people who inject drugs using contaminated injection 
equipment and paraphernalia, and those who have used intranasal drugs or 
undergone cosmetic procedures (such as tattooing and body piercing). Sexual 
partners of people infected with HCV may become infected, although the risk is 
very low in heterosexual couples. Those at higher risk include HIV-infected men 
who have sex with men as well as others infected with HIV and infants born to 
mothers with HCV infection. The relative importance of these risk factors varies 
substantially, depending on the geographical location and population studied.  
WHO recommends that HCV serology testing be performed on individuals who 
are part of a population with high HCV seroprevalence or who have a history of 
HCV risk exposure and/or behaviour, rather than at the time of presentation with 
symptomatic disease. The application of this recommendation will require taking 
into consideration which populations meet these criteria. In some countries with 
a high seroprevalence of HCV or low level of infection control, HCV testing might 
be recommended for the general population. Clearly, this would have significant 
resource implications. 
In addition, it is suggested that NAT for HCV RNA be performed directly 
following an HCV seropositive test result to establish a definitive diagnosis of 
HCV infection in addition to the use of NAT as part of the evaluation for treatment 
eligibility. Earlier testing for the detection of RNA allows those patients who have 
spontaneously cleared the virus to know that they have resolved the infection 
and facilitates earlier identification of persons who require treatment. 
Persons at risk of HCV are also likely to be at risk for other bloodborne viruses, 
including hepatitis B virus (HBV) and HIV. Related WHO guidance recommends 
screening at-risk groups for these viruses also (see section 2.4).
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Care of patients infected with HCV
Decades can pass between the time of acquiring HCV infection and the 
development of HCV-related liver disease such as cirrhosis. During that time, 
it is important for clinicians to monitor and manage hepatic diseases due to 
other causes as well as the extrahepatic manifestations of HCV infection, 
including insulin resistance and diabetes. Addressing co-morbidities such as 
high body mass index and smoking is also important, as are measures to avoid 
reinfection through ensuring the availability of safe blood transfusions and sterile 
medical equipment. Of these various conditions or behaviours, the Guidelines 
Development Group assessed the value of conducting alcohol screening and 
behavioural interventions to limit alcohol intake. Alcohol use can accelerate the 
progression of HCV-related cirrhosis. Alcohol use in persons with HCV varies 
considerably in different geographical regions and in different risk groups. 
WHO now recommends that a brief alcohol intake assessment be conducted 
for all persons with HCV infection, followed by the offer of a behavioural alcohol 
reduction intervention in persons with moderate-to-high alcohol intake. The 
Guidelines Development Group proposed that the WHO ASSIST (Alcohol, 
Smoking and Substance Involvement Screening Test) package would be an 
appropriate framework to design alcohol screening and reduction interventions 
because it is evidence based, proposes a standardized approach, and is aimed 
at the primary health-care level. The ASSIST package includes tools for carrying 
out an assessment of the level of intake of alcohol and other substances, and 
instructions on implementing a brief counselling intervention.
Transmission of HCV through the sharing of contaminated injecting equipment 
among persons who inject drugs is the leading route of HCV transmission in 
some countries. Therefore, reducing this risk of transmission is an essential 
component of patient care. WHO recommends a comprehensive package of 
harm reduction interventions, which comprise nine activities specifically for 
people who inject drugs.a 
Previous WHO guidance exists regarding vaccination for hepatitis A virus (HAV) 
and HBV (acquisition of HAV or HBV may lead to more severe liver disease 
in HCV-infected individuals). Screening and testing for co-morbidities among 
people who use drugs is crucial for informing treatment plans (drug–drug 
interactions, potential hepatotoxicity, among others).
a. Advice on interventions for individuals using alcohol, injected and non-injected drugs is available at 
http://www.who.int/substance_abuse. The elements of the comprehensive package are described in: Technical guide 
for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users, 2012 
revision. http://www.who.int/hiv/pub/idu/targets_universal_access/en/
18
Assessment of liver fibrosis
Deciding when to initiate therapy for HCV infection is challenging and requires 
reliable assessment of the degree of liver fibrosis. For many years, liver biopsy 
was considered to be the gold standard for staging the degree of fibrosis, but 
this test is expensive, associated with a risk of complications including bleeding, 
and requires careful histological interpretation. In view of these considerations, 
the Guidelines Development Group assumed that liver biopsy was not a viable 
option in many of the countries where these guidelines would be used. Rather, 
it was assumed that non-invasive tests would be used. Non-invasive measures 
of hepatic fibrosis include indices based on combinations of blood tests (e.g. 
APRI, Fibrotest, FIB4), and an ultrasound-based technique called transient 
elastography. These tests perform less well than liver biopsy and can be difficult 
to interpret as there are different cut-off values for different fibrosis stages. The 
equipment for transient elastography is also very expensive. Based on a systematic 
review of the performance of these tests and taking cost into consideration, the 
APRI and FIB4 tests were considered by the Guidelines Development Group to 
be more suitable for resource-limited settings than more expensive options such 
as transient elastography. However, if transient elastography is available and the 
cost of the test is not a barrier to its use, it is also recommended. 
Patients with less advanced fibrosis respond better to treatment, while those 
with more advanced disease are at higher risk of developing cirrhosis and 
hepatocellular carcinoma. Therefore, recommendations regarding whom to treat 
are based on the balance between the benefits (cure and resulting lower risk of 
cirrhosis and hepatocellular carcinoma) and the potential harms (drug toxicity 
and cost). In most countries where these guidelines will be applied, treatment 
availability will be limited, and patients will need to be prioritized for treatment. 
In view of this, patients with advanced fibrosis and cirrhosis (METAVIR stages F3 
and F4) should be prioritized for treatment as they are at higher risk of developing 
cirrhosis and hepatocellular carcinoma. If resources permit, then persons with 
less advanced fibrosis (METAVIR stages F1 and F2) could also be considered 
for treatment. 
Treatment of hepatitis C
Because of the high cost of treatment, the requirement for sophisticated 
laboratory testing to monitor treatment response, and the high rate of adverse 
events to existing medications (interferon and ribavirin), the number of persons 
receiving treatment for HCV is very low in most low- and middle-income countries. 
Furthermore, even in many high-income countries, treatment is often denied to 
persons in certain groups, notably those who are current or former drug injectors. 
In some countries, standard interferon (IFN) continues to be used because of 
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its lower cost, despite evidence that it is less effective than pegylated interferon 
(PEG-IFN). To address these considerations, the Guidelines Development Group 
assessed the benefits of treatment for HCV and made recommendations regarding 
existing medicines. Four topics were considered with regard to treatment for 
HCV: (i) the utility of treatment versus no treatment; (ii) the efficacy of PEG-IFN 
versus standard IFN (in combination with ribavirin [RBV]); (iii) the efficacy of the 
direct-acting antivirals telaprevir, boceprevir and simeprevir in combination with 
PEG-IFN and RBV for those with genotype 1 infection; and (iv) the efficacy of 
sofosbuvir in combination with RBV or PEG-IFN/RBV for genotypes 1–4. 
The evidence of effectiveness of different IFN types (IFN or PEG-FN) in combination 
with RBV compared with placebo showed a clear benefit of treatment versus 
placebo in achieving sustained virological response, including in children, HIV-
infected individuals and people who inject drugs. Therefore, WHO recommends 
that all adults and children with chronic HCV infection, including people who 
inject drugs, should be assessed for receiving treatment for HCV. 
A systematic review of PEG-IFN versus standard IFN showed that PEG-IFN 
with RBV is superior to standard IFN with RBV, and increases the likelihood of 
a sustained virological response without increasing the side-effect profile. WHO 
recommends that PEG-IFN in combination with RBV be used for the treatment of 
chronic HCV infection rather than standard IFN with RBV.
The Guidelines Development Group recommends that persons with genotype 1 
HCV infection should be considered for treatment with the currently approved 
direct-acting antivirals (telaprevir, boceprevir or simeprevir), given in combination 
with PEG-IFN and RBV rather than only PEG-IFN and RBV. Genotyping is therefore 
indicated prior to selecting the appropriate regimen. In addition, persons with 
genotype 1a HCV infection treated with simeprevir/PEG-IFN/RBV require testing 
for the absence of the Q80K mutation, as this significantly reduces the efficacy of 
treatment with this combination. 
The Guidelines Development Group also recommends that persons with genotypes 
1, 2, 3 or 4 HCV infection should be considered for treatment with sofosbuvir and 
RBV with or without PEG-IFN, depending on the genotype. 
It is difficult to recommend one of these medicines over another as the only available 
data for the direct-acting agents are from drug registration trials; thus, there are no 
studies comparing the outcomes of one medicine versus another. Furthermore, 
data on safety of the newer compounds are also limited because of the small 
number of persons who have taken these medicines. As the manufacturers of the 
newer medicines had not fixed the price of these medicines, at the time of the 
development of these guidelines. For most countries, it is not possible to take cost 
into consideration while making treatment recommendations. Finally, it is likely 
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that in many countries, PEG-IFN and RBV will be the only available medicines 
for the next several years as the newer medicines have not been approved or 
licensed in most countries. This process can take more than one year. 
There are a number of other considerations that are important elements of 
treatment for HCV. These include the need for genotype and Q80K mutation 
testing, decisions related to duration of treatment, frequency of monitoring and 
contraindications of treatment. Because of the number and complexity of these 
parameters, they were not evaluated by the Guidelines Development Group and 
no recommendations were made. Rather, the following statements reflect either 
the standard of care or product registration information. 
• As the selection of medicines and duration of treatment depends on the 
HCV genotype, determining genotype is important, as is the determination 
of Q80K mutation if treatment with simeprevir is being considered.
• Accepted standards for treatment indicate that persons infected with 
genotypes 1 and 4 are treated with PEG-IFN/RBV for 48–72 weeks, while 
those infected with genotypes 2 and 3 are treated with PEG-IFN/RBV for 
24–48 weeks. The longer treatment durations are recommended for persons 
with advanced fibrosis or cirrhosis (F3 and F4), those coinfected with HIV 
and in those with a slow early virological response. In addition, persons with 
genotype 1 infection and an extended rapid virological response may be 
treated with a shortened course of 24 weeks of PEG-IFN/RBV. 
• Persons treated with direct-acting antivirals require different durations of 
treatment, depending on the genotype and previous response to treatment, 
as discussed further in Chapter 7. 
• Interferon-containing regimens are contraindicated in persons with 
decompensated cirrhosis because of the risk of accelerated decompensation. 
These persons do require follow up of liver function and monitoring 
for hepatocellular carcinoma. Consideration of liver transplant for such 
patients can be made in settings where this is available. Treatment is also 
contraindicated in pregnant women due to the risk of fetal abnormalities 
from the use of RBV. For this reason, women of childbearing age and their 
partners are advised to use two forms of contraception (including a barrier 
method) during and for six months after the end of treatment.
• HCV treatments require regular monitoring for toxicity and efficacy. Side-
effects range from mild to life threatening, and are detected by laboratory 
monitoring and on clinical review. 
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Issues related to treatment access
The aim of these guidelines is to facilitate the introduction and expansion of treatment 
services for persons with HCV infection, particularly in low- and middle-income countries. 
As discussed throughout this document, a number of technical, logistical, and financial 
challenges must be overcome for this to become a reality. 
HCV screening  
Most persons with HCV infection remain undiagnosed and few have access to HCV 
testing. National testing policies are needed as are increased investments in hepatitis C 
screening services based on the best assessment of the prevalence of HCV infection in 
the general population and in key populations.
Laboratory capacity 
The diagnosis and clinical management of HCV infection requires sophisticated laboratory 
capacity. Diagnosing HCV infections requires serologic testing followed by NAT to confirm 
the presence of chronic infection. Assessment for treatment requires NAT to measure 
HCV viral load and to determine HCV genotype, and if the use of simeprevir is being 
considered, the detection of the Q80K mutation. In many low-income countries there 
are no laboratories that can perform these tests. Even in countries where this capacity 
exists, it is available only in some large cities, and the tests are very expensive. The new 
direct-acting agents provide an opportunity to simplify the laboratory requirements for 
HCV therapy as combinations of these medicines will be effective against all genotypes, 
thus obviating the need for genotyping, and much safer, thus reducing the complexity of 
monitoring for adverse events. 
Health systems 
Currently, HCV therapy is provided in specialized centers by hepatologists or other 
subspecialists. For HCV therapy to be expanded, it will need to be administered by 
general-practice physicians and other health care workers in primary-care clinics. To 
accomplish this, clinics will need to be equipped and many more health care workers 
will need training in the clinical management of HCV infection. 
Selection of patients for treatment
A critical question is who needs HCV treatment. This decision is complicated as it is 
made while taking into consideration the health of the patient, in particular the degree 
of fibrosis or cirrhosis, as well as the cost, safety, and efficacy of the medicines.  Based 
on these considerations, currently patients with more advanced fibrosis and cirrhosis 
(METAVIR F3 and F4 stages) should be prioritized for treatment. However, there are no 
population-based data to indicate how many persons meet these criteria. Furthermore, 
this prioritization may change, as safer and more effective medicines become available, 
assuming that they are affordable. 
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Price of medicines
HCV treatment is expensive. Prices range from US$ 2 000 in Egypt for 48-weeks 
of PEG/IFN RBV to as much as US$84 000 in the US for a single 12-week course 
of sofosbuvir. At these prices, these treatments will remain unaffordable for most 
persons who need treatment. A concerted effort is needed to reduce the price of 
HCV medicines. The experience with HIV, where the price of antiretrovirals was 
reduced by nearly a hundred fold through the introduction of generic drugs, has 
shown that the key to achieving low prices for medicines is to use a multipronged 
approach. This can include voluntary licensing (where the patent owner licenses 
the medicine to generics-producing companies or a patent pool), tiered pricing 
(where the manufacturer sets different prices for different countries based on 
their income level and disease burden), and compulsory licensing (where a 
national government grants a license to companies producing generic drugs or 
importing the product). National governments, international agencies, donors, 
civil-society organizations, and the pharmaceutical industry will need to work 
together to help assure that hepatitis C treatment is affordable and accessible for 
all those who need treatment.
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1. SCOPE AND OBJECTIVES
Introduction and objectives
Most of the existing guidelines for the treatment of hepatitis C have been 
developed by specialist medical organizations and relate to the treatment of 
persons living in high-income countries. There are no evidence-based treatment 
guidelines that focus on persons living in low- and middle-income countries. In 
addition, these are the first WHO guidelines dealing with the topics of screening 
and management of HCV infection. The objective of these guidelines is to 
provide evidence-based recommendations on screening for HCV infection, and 
the care and treatment of persons with HCV infection. These guidelines are 
meant to provide a framework for the development or strengthening of hepatitis 
C treatment programmes in low- and middle-income countries. Although most 
of the recommendations deal with treatment issues, recommendations related 
to screening and care are included to reinforce the importance of the continuum 
of care that is a key element of the clinical management HCV infection. Each 
of these topics is complex and includes many dimensions that could not be 
assessed by the Guidelines Development Group. In the screening section, there 
is no discussion of the selection of laboratory tests; in the care section, the Group 
only assessed one intervention (alcohol reduction counselling), and in the area 
of treatment, there are no recommendations regarding the management of 
complications of HCV, including cirrhosis and hepatocellular carcinoma.
Target audience
These guidelines are primarily targeted at policy-makers in ministries of health 
working in low- and middle-income countries who formulate country-specific 
treatment guidelines and who plan infectious diseases treatment programmes. 
These guidelines are intended to assist officials as they develop national hepatitis 
C treatment plans and policy, and guideline documents. In addition, it is 
anticipated that nongovernmental agencies and health professionals organizing 
treatment and screening services for hepatitis C will use the guidelines to define 
the necessary elements of such services. These guidelines will also be a useful 
resource for clinicians who manage persons with HCV infection.
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Related WHO materials and guidelines
These are the first WHO guidelines on the screening, care and treatment of 
persons with HCV infection. They are intended to complement existing guidance 
on the primary prevention of HCV and other bloodborne viruses by improving 
blood and injection safety, and health care for people who inject drugs (PWID) 
and other vulnerable groups, including those living with HIV (see section 2.4 for 
related WHO guidelines). 
This guidelines document will be revised in 2016. Because a number of new 
medicines are expected to become available in the meantime, WHO will issue 
interim guidance twelve months after publication of these guidelines to provide 
recommendations regarding newly approved medicines. 
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2. BACKGROUND
2.1 Epidemiology of hepatitis C
According to recent estimates, more than 185 million people around the world 
have been infected with HCV, of whom 350 000 die each year.1,2 Most people 
infected with the virus are unaware of their infection and, for many who have 
been diagnosed, treatment remains unavailable.3 Treatment is successful in 
the majority of persons treated, and treatment success rates among persons 
treated in low- and middle-income countries are similar to those in high-income 
countries.4 One third of those who become chronically infected are predicted to 
develop liver cirrhosis or hepatocellular carcinoma.5
The prevalence of hepatitis C infection varies substantially around the world 
(Table 2.1). When countries are grouped into Global Burden of Disease regions, 
the estimated prevalence of HCV infection is highest in Central and East Asia and 
in the North Africa/Middle East regions. In view of the larger populations in Asia, 
the South Asia and East Asia regions have by far the largest number of persons 
living with HCV infection. 
TABLE 2.1  Global seroprevalence of HCV by region 
Region Prevalence (%) Estimated number of people infected
Asia Pacific 1.4 >2.4 million
Central Asia 3.8 >2.9 million
East Asia 3.7 >50 million
South Asia 3.4 >50 million
South-East Asia 2.0 >11 million
Australasia 2.7 >0.6 million
Caribbean 2.1 >0.7 million
Central Europe 2.4 >2.9 million
Eastern Europe 2.9 >6.2 million
Western Europe 2.4 >10 million
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Andean Latin America 2.0 >1.0 million
Central Latin America 1.6 >3.4 million
Southern Latin America 1.6 >0.9 million
Tropical Latin America 1.2 >2.3 million
North Africa/Middle East 3.6 >15 million
North America 1.3 >4.4 million
Oceania 2.6 >0.2 million
Central sub-Saharan Africa 2.3 >1.9 million
East sub-Saharan Africa 2.0 >6.1 million
South sub-Saharan Africa 2.1 >1.4 million
West sub-Saharan Africa 2.8 >8.4 million
Source: Adapted from Mohd Hanafiah et al., 20131
Certain groups are at higher risk of HCV infection, and estimates of the prevalence 
of HCV in these groups are shown in Table 2.2. The relative importance of risk 
factors for HCV infection varies substantially, depending on the geographical 
region and population studied. Greater access to HCV testing and better 
surveillance are important steps to both increase the number of persons 
diagnosed with HCV and to improve understanding of the distribution of HCV 
infection in the general population and groups at increased risk.
2.1.1 Routes of transmission
Population  Comment
 Persons who inject drugs6  PWID have the highest risk of infection: Globally, the prevalence 
of HCV is 67% among PWID.
Recipients of infected 
blood products or invasive 
procedures in health-care 
facilities with inadequate 
infection control practices7-16 
Risk of HCV infection varies depending upon the frequency of 
medical procedures (i.e. number of injections/person/year) and 
level of infection-control practices. High frequency of injections 
and low level of infection control can result in high prevalence of 
HCV in the general population (e.g. prevalence of chronic HCV 
infection confirmed by nucleic acid testing was 9.8% in Egypt in 
2008)
Children born to mothers 
infected with HCV17, 18 
HCV transmission risk is estimated as 4–8% among mothers 
without HIV infection 
Transmission risk is estimated as 17-25% among mothers with 
HIV infection
TABLE 2.2  Populations at increased risk of HCV infection  
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Population  Comment
 Persons who inject drugs6  PWID have the highest risk of infection: Globally, the prevalence 
of HCV is 67% among PWID.
Recipients of infected 
blood products or invasive 
procedures in health-care 
facilities with inadequate 
infection control practices7-16 
Risk of HCV infection varies depending upon the frequency of 
medical procedures (i.e. number of injections/person/year) and 
level of infection-control practices. High frequency of injections 
and low level of infection control can result in high prevalence of 
HCV in the general population (e.g. prevalence of chronic HCV 
infection confirmed by nucleic acid testing was 9.8% in Egypt in 
2008)
Children born to mothers 
infected with HCV17, 18 
HCV transmission risk is estimated as 4–8% among mothers 
without HIV infection 
Transmission risk is estimated as 17-25% among mothers with 
HIV infection
People with sexual partners 
who are HCV-infected19,20-23
There is low or no risk of sexual transmission of HCV among 
HIV-uninfected heterosexual couples and HIV-uninfected men 
who have sex with men (MSM). The risk of sexual transmission 
is strongly linked to pre-existing HIV infection.
People with HIV infection23-31 Persons with HIV infection, in particular MSM, are at increased 
risk of HCV infection through unprotected sex. 
People who have used 
intranasal drugs32
Non-injecting drug use (e.g. through sharing of inhalation 
equipment for cocaine) is associated with a higher risk of HCV 
infection. 
People who have had tattoos 
or piercings33
Tattoo recipients have higher prevalence of HCV compared with 
persons without tattoos (odds ratio = 2.24, 95%CI 2.01,2.50)
Health-care associated transmission
Hepatitis C virus infection is strongly associated with health inequity; in low- and 
middle-income countries, infection with HCV is most commonly associated with 
unsafe injection practices and procedures such as renal dialysis and unscreened 
blood transfusions.15,34 Between 8 and 12 billion injections are administered yearly 
around the world and 50% of these are considered to be unsafe (mainly in sub-
Saharan Africa and Asia).35 In low- and middle-income countries, infection with 
HCV is frequently associated with unsafe injection practices and unscreened (or 
inadequately screened) blood transfusions. According to the latest WHO report 
on blood safety (2011), 39 countries do not routinely screen blood transfusions 
for bloodborne viruses.36 The most well documented example of health-care 
associated transmission is the generalized epidemic of HCV infection resulting 
from unsafe injection practices in Egypt, where HCV prevalence is 25% in some 
regions.8 Persons who received untested blood products prior to the introduction 
of screening of blood for HCV in high-income countries are also at risk. Universal 
access to safe blood transfusion requires the implementation of key strategies to 
ensure access to a safe and sufficient blood supply, including the implementation 
of 100% voluntary blood donation and 100% quality-assured testing of donated 
blood. WHO has developed guidelines on best practices in phlebotomy and best 
practices for injections and related procedures.37 
People who inject drugs
In middle- and high-income countries, most HCV infections occur among people 
who use unsterile equipment to inject drugs and contaminated drug solutions. 
Of the estimated 16 million people in 148 countries who actively inject drugs, 10 
million are infected with HCV.6 PWID infected with HCV are at increased risk of 
all-cause mortality, reflecting the role of injecting drug use, low socioeconomic 
status, poor access to health care and environmental factors.38  
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Mother-to-child transmission
The risk of transmission of HCV from a mother to her child occurs in 4–8% of 
births to women with HCV infection and in 17–25% of births to women with HIV 
and HCV coinfection (Table 2.2).17,18 
Sexual transmission
Sexual transmission of HCV occurs infrequently in heterosexual couples.39 It is more 
common in HIV-positive persons, particularly in men who have sex with men (MSM).40 
In several recent outbreaks of HCV infection among MSM in Europe, Australia and 
the US, transmission has been linked to sexual exposure as well as potentially to 
underreported use of non-injecting recreational drugs.41,42 HIV-infected heterosexual 
partners of HCV-infected people are also more likely to acquire HCV; this may be 
due to sexual transmission or other exposure to blood or due to unreported injection 
or non-injection drug use, such as sharing of straws for inhaling cocaine.41 
Other
Other routes of transmission of HCV include intranasal drug use and other 
modes of bloodborne transmission, such as acquisition by health-care workers, 
cosmetic procedures (such as tattooing and body piercing), scarification and 
circumcision procedures.33,43  
2.1.2 Coinfections
HIV and HCV coinfection
HIV and HCV have common routes of transmission, and it is estimated that, globally, 
4–5 million persons are coinfected with these two viruses.44 With the widespread 
use of antiretroviral therapy (ART), which reduces the risk of HIV-associated 
opportunistic infections, HCV-related liver disease has started to overtake AIDS-
defining illnesses as a leading cause of death in some high-income countries.45
HBV and HCV coinfection
Hepatitis B virus (HBV) and HCV coinfection is commonly found in HBV-endemic 
countries in Asia, sub-Saharan Africa and South America. Up to 25% of HCV-
infected persons may be coinfected with HBV in some areas.46-51 HBV and HCV 
coinfection is discussed further in Chapter 9.
Tuberculosis and HCV coinfection
Groups at increased risk of infection with HCV are also at risk of infection with 
tuberculosis (TB). TB is endemic in many countries where blood products are 
not screened routinely. TB is the most common AIDS-defining illness and the 
leading cause of HIV-associated mortality. PWID are more at risk of developing TB, 
regardless of their HIV status. Among PWID who develop TB, two out of three will 
have HCV antibodies. People who live with HIV and inject drugs have a two- to 
sixfold increased risk of developing TB compared with non-injectors. Prisoners, 
who have a high risk of acquiring HCV, are also at increased risk of coinfection 
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with TB; incarceration is associated with a 23 times higher risk of TB than in the 
general population.52,53 Appropriate care for persons being considered for hepatitis 
C treatment would include screening for active TB, as the co-management of such 
persons needs sound clinical judgement and the provision of treatment that takes 
into consideration the side-effects and interactions of the drugs used to treat HIV, 
TB and viral hepatitis.
2.2 Hepatitis C virus
The hepatitis C virus is a small, positive-stranded RNA-enveloped virus that is 
approximately 9.6 kb in length. The genetic sequence was first characterized in 
1989,54 placing the virus in the Hepacivirus genus within the Flaviviridae family.55,56 
It has a highly variable genome and multiple genotypes and subgenotypes.57 The 
distribution of HCV genotypes and subgenotypes varies substantially in different 
parts of the world (Figure 2.1). Some genotypes are easier to treat and, thus, 
the duration of and recommended medicines for therapy vary by genotype. For 
this reason, determining a patient’s genotype is important to appropriately tailor 
therapy. It is possible that this advice may change when antiviral agents that are 
active against all genotypes (referred to as pangenotypic) are licensed.
FIGURE 2.1  Global distribution of genotypes of HCV
Source: Hussain Z. Genomic heterogeneity of hepatitis viruses (A–E): role in clinical implications and treatment. In: Serviddeo G, editor. 
Practical management of chronic viral hepatitis. Rijeka, Croatia: InTech; 2013. (www.intechopen.com/books/practical-management-of-
chronic-viral-hepatitis/genomic-heterogeneity-of-hepatitis-viruses-a-e-role-in-clinical-implications-and-treatment, accessed 10 February 2014).
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2.3 Natural history of HCV infection
Hepatitis C virus causes both acute and chronic infection. Acute HCV infection 
is defined as the presence of HCV within six months of exposure to and infection 
with HCV. It is usually clinically silent, and is only very rarely associated with 
life-threatening disease. Spontaneous clearance of acute HCV infection occurs 
within six months of infection in 15–45% of infected individuals in the absence 
of treatment. Almost all the remaining 55–85% of persons will harbour HCV for 
the rest of their lives (if not treated) and are considered to have chronic HCV 
infection. Anti-HCV antibodies develop as part of acute infection and persist 
throughout life. In persons who have anti-HCV antibodies, a nucleic acid test 
(NAT) for HCV RNA, which detects the presence of virus, is needed to confirm 
the diagnosis of chronic HCV infection.58,59 
Left untreated, chronic HCV infection can cause liver cirrhosis, liver failure 
and hepatocellular carcinoma (HCC; Figure 2.2). Of those with chronic HCV 
infection, the risk of cirrhosis of the liver is 15–30% within 20 years.60,61,62 The 
risk of HCC in persons with cirrhosis is approximately 2–4% per year.63
The risk of cirrhosis and HCC varies depending upon certain patient 
characteristics or behaviours. For example, men, persons who consume excess 
alcohol, persons with hepatitis B or HIV coinfection and immunosuppressed 
individuals are all at higher risk of developing cirrhosis or HCC.64 Disease associated 
with HCV is not confined to the liver. Extrahepatic manifestations of HCV include 
cryoglobulinaemia, glomerulonephritis, thyroiditis and Sjögren syndrome, insulin 
resistance, type-2 diabetes mellitus, and skin disorders such as porphyria cutanea 
tarda and lichen planus. Persons with chronic HCV infection are more likely to 
develop cognitive dysfunction, fatigue and depression.65 These outcomes may 
FIGURE 2.2  Natural history of HCV infection 
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infection
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infection 
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be associated with replication of the virus in the brain; however, the causal link 
between these manifestations and chronic HCV infection is not certain.66
Natural history of HIV/HCV coinfection
Coinfection with HIV adversely affects the course of HCV infection, and coinfected 
persons have a significantly accelerated progression of liver disease to cirrhosis, 
decompensated liver cirrhosis and HCC than HCV-monoinfected persons, 
particularly those with advanced immunodeficiency (CD4 count <200 cells/mm3).67-70 
In high-income countries, death due to HCV-associated liver disease has become a 
leading cause of death in people living with HIV in the era of combination ART,45,71,72 
accounting for around 47% of deaths in one series from the United States. 
It remains unclear whether HCV infection accelerates HIV disease progression, as 
determined by AIDS-related events or death.73 Two large European cohorts have 
shown that after ART initiation, CD4 recovery was impaired in HIV/HCV-coinfected 
persons when compared to those infected with HIV alone. HIV/HCV-coinfected 
persons also demonstrated more rapid HIV disease progression compared 
to those who were HIV-infected alone, and had an impaired recovery of CD4 
cells. However, other studies have shown no such differences in response.73-77 
Assessment of the impact of HCV infection on HIV disease progression may be 
confounded by the negative health consequences of injecting drug use, which is 
strongly linked to HCV infection.78,79 In persons with HIV infection, HCC tends to 
occur at a younger age and within a shorter time period.80
2.4 Prevention of HCV infection
In the absence of a vaccine for hepatitis C, prevention of HCV infection depends 
upon reducing the risk of exposure to the virus. This is challenging because of 
the various routes of transmission and the different populations that are affected. 
Globally, most HCV infections occur in health-care settings as a result of inadequate 
infection control procedures, for example, the reuse of injection equipment. HCV 
infections in health-care settings also occur through the transfusion of blood that 
has not been screened for HCV antibodies. WHO has published guidelines with 
recommendations to prevent health-care associated HCV infection (Table 2.3).
PWID are at great risk of HCV infection through the use of contaminated injection 
equipment as well as non-injection drug use. WHO, United Nations Office on 
Drugs and Crime (UNODC), and the Joint United Nations Programme on HIV/
AIDS (UNAIDS) have developed a set of nine core interventions for the prevention, 
care and treatment of HIV infection among PWID (Table 2.4). These interventions 
are also relevant for the prevention and management of viral hepatitis in this 
population. In addition, WHO has developed guidelines with recommendations for 
preventing transmission of viral hepatitis among PWID (Table 2.5).
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TABLE 2.3  WHO guidance on prevention of HCV infection in health-care settings
TABLE 2.4  WHO/UNODC/UNAIDS comprehensive package of interventions for HIV 
prevention treatment and care in PWID
Focus of guidance documents:
• Hand hygiene: including surgical hand preparation, hand washing and use of gloves
• Safe handling and disposal of sharps and waste
• Safe cleaning of equipment
• Testing of donated blood
• Improved access to safe blood
• Training of health personnel
References 
WHO guidelines on hand hygiene in health care. Geneva: World Health Organization; 2009. (http://
whqlibdoc.who.int/publications/2009/9789241597906_eng.pdf, accessed 20 January 2014).
Safe abortion: technical and policy guidance for health systems. Second edition. Geneva: World 
Health Organization; 2012. (http://apps.who.int/iris/bitstream/10665/70914/1/9789241548434_
eng.pdf, accessed 20 January 2014).
Universal access to safe blood transfusion. Geneva: World Health Organization; 2008. (http://www.
who.int/bloodsafety/publications/UniversalAccesstoSafeBT.pdf, accessed 20 January 2014).
Blood donor selection: guidelines on assessing donor suitability for blood donation. Geneva: World 
Health Organization; 2012. (http://www.who.int/bloodsafety/publications/bts_guideline_donor_
suitability/en/index.html 2012, accessed 20 January 2014). 
WHO guidelines on drawing blood: best practices in phlebotomy. Geneva: World Health 
Organization; 2010. (http://www.who.int/injection_safety/sign/drawing_blood_best/en/index.html, 
accessed 20 January 2014).
Interventions
1. Needle and syringe programmes including other drug-using paraphernalia
2. Opioid substitution therapy and other drug dependence treatment
3. HIV testing and counselling
4. Antiretroviral therapy
5. Prevention and treatment of sexually transmitted infections
6. Condom programmes for people who inject drugs and their sexual partners
7. Targeted information, education and communication for people who inject drugs and 
their sexual partners
8. Vaccination, diagnosis and treatment of viral hepatitis
9. Prevention, diagnosis and treatment of tuberculosis.
References 
WHO, UNODC, UNAIDS. Technical guide for countries to set targets for universal access to HIV 
prevention, treatment and care for injecting drug users. 2012 Revision. Geneva: World Health 
Organization; 2012. (http://www.drugsandalcohol.ie/19190/1/IDU-Technical_Guide_2012_
Revision.pdf accessed 30 January 2014).
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Focus of guidance documents:
• Hand hygiene: including surgical hand preparation, hand washing and use of gloves
• Safe handling and disposal of sharps and waste
• Safe cleaning of equipment
• Testing of donated blood
• Improved access to safe blood
• Training of health personnel
References 
WHO guidelines on hand hygiene in health care. Geneva: World Health Organization; 2009. (http://
whqlibdoc.who.int/publications/2009/9789241597906_eng.pdf, accessed 20 January 2014).
Safe abortion: technical and policy guidance for health systems. Second edition. Geneva: World 
Health Organization; 2012. (http://apps.who.int/iris/bitstream/10665/70914/1/9789241548434_
eng.pdf, accessed 20 January 2014).
Universal access to safe blood transfusion. Geneva: World Health Organization; 2008. (http://www.
who.int/bloodsafety/publications/UniversalAccesstoSafeBT.pdf, accessed 20 January 2014).
Blood donor selection: guidelines on assessing donor suitability for blood donation. Geneva: World 
Health Organization; 2012. (http://www.who.int/bloodsafety/publications/bts_guideline_donor_
suitability/en/index.html 2012, accessed 20 January 2014). 
WHO guidelines on drawing blood: best practices in phlebotomy. Geneva: World Health 
Organization; 2010. (http://www.who.int/injection_safety/sign/drawing_blood_best/en/index.html, 
accessed 20 January 2014).
Interventions
1. Needle and syringe programmes including other drug-using paraphernalia
2. Opioid substitution therapy and other drug dependence treatment
3. HIV testing and counselling
4. Antiretroviral therapy
5. Prevention and treatment of sexually transmitted infections
6. Condom programmes for people who inject drugs and their sexual partners
7. Targeted information, education and communication for people who inject drugs and 
their sexual partners
8. Vaccination, diagnosis and treatment of viral hepatitis
9. Prevention, diagnosis and treatment of tuberculosis.
References 
WHO, UNODC, UNAIDS. Technical guide for countries to set targets for universal access to HIV 
prevention, treatment and care for injecting drug users. 2012 Revision. Geneva: World Health 
Organization; 2012. (http://www.drugsandalcohol.ie/19190/1/IDU-Technical_Guide_2012_
Revision.pdf accessed 30 January 2014).
TABLE 2.5  WHO recommendations for prevention of HCV infection among people who  
inject drugs, in addition to interventions described in Table 2.4
TABLE 2.6  WHO guidance on prevention of sexual transmission of HCV infection
Recommendations
• Offer people who inject drugs the rapid hepatitis B vaccination regimen.
• Offer people who inject drugs incentives to increase uptake and completion of the hepatitis 
B vaccination schedule.
• Implement sterile needle and syringe programmes that also provide low dead-space syringes 
for distribution to people who inject drugs.
• Offer peer interventions to people who inject drugs to reduce the incidence of viral hepatitis.
• Offer opioid substitution therapy to treat opioid dependence; reduce HCV risk behaviour and 
transmission through injecting drug use; and increase adherence to HCV treatment.
• Integrate treatment of opioid dependence with medical services for hepatitis.
References 
Guidance on prevention of viral hepatitis B and C among people who inject drugs. Geneva: World 
Health Organization; 2012. (http://apps.who.int/iris/bitstream/10665/75357/1/9789241504041_
eng.pdf, accessed 20 January 2014).
WHO guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. 
Geneva: World Health Organization; 2009. (http://www.who.int/substance_abuse/publications/
opioid_dependence_guidelines.pdf, accessed 20 January 2014).   
Focus of guidance documents:
• Promotion of correct and consistent condom use
• Routine screening of sex workers in high-prevalence settings 
• Integrated action to eliminate discrimination and gender violence and to increase access to 
medical and social services for vulnerable persons
References 
Prevention and treatment of HIV and other sexually transmitted infections for sex workers in low- and 
middle-income countries: recommendations for a public health approach. Geneva: World Health 
Organization; 2012. (http://apps.who.int/iris/bitstream/10665/77745/1/9789241504744_eng.pdf, 
accessed 20 January 2014).
Prevention and treatment of HIV and other sexually transmitted infections among men who have sex 
with men and transgender people. Geneva: World Health Organization, Department of HIV/AIDS; 
2011. (http://www.who.int/hiv/pub/guidelines/msm_guidelines2011/en/, accessed 20 January 2014).  
The risk of sexual transmission of HCV varies depending on the type of exposure. 
The risk is lowest among heterosexual couples and highest among MSM with 
HIV coinfection. Existing guidelines for prevention of HCV infection through 
sexual exposure are listed in Table 2.6. 
34
Prevention of mother-to-child transmission of HCV is difficult as there are 
no proven interventions to reduce this risk. Neither mode of delivery nor 
breastfeeding are reliably linked with transmission. The development of effective 
drugs against HCV that can be given safely during pregnancy might be a future 
option. 
2.5 Screening for HCV infection
Screening for HCV infection is done using HCV serological testing. If positive, 
a NAT for HCV RNA assay is needed to confirm chronic HCV infection. Several 
screening assays have been evaluated by WHO, and sensitivity, specificity, and 
positive and negative predictive value results are available.81 It is important to 
consider the possibility of infection with other bloodborne viruses in persons with 
HCV, and to offer screening for HBV and HIV in addition to HCV. Screening for 
other infections, for example TB, is also indicated in some groups at risk, such 
as people living with HIV, prisoners and PWID.
2.6 Care of patients with HCV infection 
The spectrum of disease in persons infected with HCV extends from mild 
fibrosis to cirrhosis and HCC. Compensated cirrhosis may progress over time 
to decompensated cirrhosis associated with ascites, oesophageal and gastric 
varices, and eventually to liver failure, renal failure and sepsis, all of which are 
life-threatening. HCC may also occur at a rate of 2–4% per year in persons 
with cirrhosis. The diagnosis of decompensated liver disease is based on both 
clinical examination and laboratory monitoring, and therefore a careful medical 
examination of patients must be made prior to commencing therapy. The stage 
of disease may be assessed by liver biopsy or by using a variety of non-invasive 
methods. These are discussed further in Chapter 6.2.
Staging of HCV infection is important as it results in the identification of 
patients with advanced disease, a group that requires enhanced monitoring 
and prioritization for treatment before the onset of decompensated cirrhosis. In 
many high-income countries, all persons with chronic HCV infection who do not 
have a contraindication for therapy are considered to be suitable for treatment 
(although many persons with mild-to-moderate disease may elect to wait for 
newer, less toxic and more efficacious medicines). In low- and middle-income 
countries, where access to treatment is limited, the stage of fibrosis may be used 
to prioritize treatment for patients with more advanced disease (e.g. patients with 
cirrhosis or those with ≥F2 fibrosis).  
Patients infected with HCV often have other co-morbidities such as HBV, HIV, TB 
and substance use. Related WHO guidance is available for persons who inject 
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drugs and for those infected with HIV (see section 2.4). Excessive alcohol use 
is common in some populations infected with HCV and can accelerate disease. 
WHO guidance on alcohol reduction is discussed in detail in Chapter 6.1.
2.7 Treatment of patients with HCV infection
HCV is a now a curable disease, and advances in HCV therapy have resulted in 
steadily higher cure rates. Identification and treatment of chronic HCV infection 
has a prevention benefit, as persons who are cured of HCV cannot transmit 
the virus to others. HCV cure is also beneficial for the patient’s health, as it 
reduces the risk of development of HCC among persons at all stages of fibrosis 
by >75%.82,83 At the time of writing (December 2013), six drugs are licensed for 
the treatment of HCV – standard interferon (IFN) or pegylated interferon alpha 
(PEG-IFN), ribavirin (RBV), the protease inhibitors (PIs) boceprevir, simeprevir 
and telaprevir, and the nucleotide analog polymerase inhibitor sofosbuvir. The 
limitations of treatment include high cost, the need for sophisticated laboratory 
tests and trained clinicians, as well as the limited efficacy and high toxicity of 
some of the medicines. It is anticipated that the number of medicines for the 
treatment of HCV will expand rapidly over the coming years, and WHO plans to 
periodically update these guidelines to include newly licensed drugs.  
Before treatment for HCV can be commenced, it is necessary to genotype the 
virus as different genotypes require different types and durations of treatment, 
and the protease inhibitors boceprevir, simeprevir and telaprevir are licensed 
only for genotype 1 infection. Current therapy for genotype 1 infection is a 
combination of PEG-IFN, RBV and a PI or nucleotide polymerase inhibitor, which 
results in high rates of sustained virological response (SVR; a negative HCV RNA 
test three or six months after the end of treatment).84-87 Dual therapy with PEG-
IFN and RBV or sofosbuvir with RBV is used for genotypes 2 and 3 infections.88,89 
Patients with genotype 4 infection treated with treated with sofosbuvir, PEG-IFN 
and RBV have similar response rates when compared with genotype 1-infected 
individuals. Small studies of genotypes 5- and 6-infected patients have shown 
similar SVR rates to genotypes 2- and 3-infected ones.90,91 Larger studies in 
these groups are required to confirm these results and to identify predictors of 
response or non-response to treatment. 
Treatment with some HCV medicines may result in marked side-effects and 
therefore careful patient assessment and close monitoring is required.92,93,94  
2.8 Cost–effectiveness of treatment
Among the major hurdles in setting up a treatment service for patients with HCV 
are the high cost of medications, need for regular monitoring, setting up, running 
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and maintaining appropriate facilities, and assuring adequate numbers and 
training of staff. The benefits of instituting treatment programmes include the 
benefit to individual patients as well as the potential reduction of transmission of 
infection from treated persons who are no longer infected with HCV.
In high-income settings, HCV treatment with PEG-IFN/RBV and with PEG-IFN/
RBV and telaprevir or boceprevir has been evaluated as being cost–effective.95,96 
PEG-IFN and RBV treatment in current PWID has also been shown to be 
cost–effective in high-income settings, despite the potential risk of reinfection, 
and may be even more cost–effective than treatin≤g those with lower risks of 
transmission to others.97,98 HCV case-finding and treatment in specialist drug 
dependency services has also been shown to be cost–effective. The higher the 
treatment rates, the more cost–effective HCV case-finding becomes, as more of 
those identified will be treated, and a greater population impact would be seen.97
In low- and middle-income countries, data on cost–effectiveness are limited but 
have been evaluated in some settings, for example, in Egypt and Viet Nam.99,100 
Where the availability of medication is restricted, treatment of persons with more 
advanced disease may be the most cost–effective strategy.100 
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3. GUIDING PRINCIPLES 
The overarching objective of WHO is to achieve the highest possible level of health 
for all people. These guidelines have been developed with this principle in mind 
and that of the United Nations Universal Declaration of Human Rights.101 People 
infected with HCV are commonly subject to discrimination and stigma, and it is 
thus essential that these guidelines and policies derived from them incorporate 
basic human rights, including the right to confidentiality and informed decision-
making when considering whether to be screened and treated for HCV infection.
3.1 Human rights
The protection of human rights for all persons infected with HCV is a central 
precept of these guidelines. People with HCV infection frequently come from 
vulnerable groups because of low socioeconomic status, poor access to 
appropriate health care, or because they belong to groups that are marginalized 
or stigmatized such as PWID or prisoners. Thus, screening for HCV must not be 
used as a means to discriminate against those testing positive, for example, by 
denying them employment or education. The promotion of human rights and 
equity in access to testing and treatment are guiding principles central to these 
guidelines. 
3.2 Access to health care
Access to health care is a basic human right and applies equally to men, women 
and children, regardless of gender, race, sexual preference, socioeconomic 
status or behavioural practices, including drug use. Policy-makers should 
ensure that antidiscrimination laws protect vulnerable groups and confidentiality 
principles, as outlined in the Declaration of Geneva, 2006.102
3.3 Service provision
Providing quality screening, care and treatment for persons with HCV infection 
requires involvement of appropriately trained individuals as well as facilities 
suitable for the regular monitoring of patients, especially those on therapy. 
Facility requirements for providing treatment for HCV will depend on the setting, 
but will always require access to appropriate laboratory facilities for monitoring 
the toxicity and efficacy of treatment, and adequate supplies of medication 
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(including refrigeration facilities for PEG-IFN). Operating testing services under 
quality management systems is essential for the provision of quality testing results. 
The protection of confidentiality and a non-coercive approach are fundamental 
principles of good clinical practice. Acceptability of services is a vital component 
of health care, and service delivery should ideally involve patient-representative 
organizations and peer-support groups.
3.4 Integrated health care
Persons infected with HCV often require additional health care. Rates of 
depression in HCV-infected populations are high, opioid dependency is common 
in PWID and persons coinfected with HIV require additional treatment. Prisoners 
or people with a history of incarceration such as PWID have high rates of HCV 
infection and may be at risk of infection with TB in many settings, in particular, 
multidrug-resistant TB. Screening for co-morbidity is therefore an important 
consideration in patients who will be screened and potentially treated for HCV. 
Integration of health-care services requires adaptation to the services available 
in individual countries. Consultation with and involvement of community 
organizations (including drug-user organizations) is central to the principle of 
integrated health care.
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4. METHODS
WHO guideline development process 
These WHO guidelines were produced following the recommendations for standard 
guidelines as described in the WHO Handbook for guideline development, 
2012.103 The Grading of Recommendations Assessment, Development, and 
Evaluation (GRADE) framework was followed for this process.104 A Guidelines 
Development Group was formed with care taken to ensure representation from 
various stakeholder groups, including members of organizations that represent 
persons living with HCV infection and PWID, advocacy groups, academicians, 
researchers, clinicians, and programme managers. Geographical representation 
and gender balance were also important considerations in selecting Group 
members. Following an initial scoping and planning process, a meeting was 
held by members of the Guidelines Development Group in December 2012 in 
order to formulate questions and determine patient-important outcomes. These 
were selected with an emphasis on answering questions most applicable to low- 
and middle-income settings and did not include questions already addressed by 
existing WHO guidance (for example, guidance already formulated for PWID). 
Each member of the Group initially nominated at least three issues, which they felt 
were essential for inclusion in WHO guidance. These were discussed in working 
groups and a preliminary ranking was formulated. The group then arrived at a 
consensus on the seven most important questions across the screening, care 
and treatment framework. These questions were structured in PICO format 
(Population, Intervention, Comparison, Outcomes; Appendix 1) and patient-
important outcomes were identified for each research question. These outcomes 
were refined and ranked based on their importance to the patient population.105 
The guidelines methodologists further refined the research questions. 
Systematic reviews and meta-analyses of the primary literature were commissioned 
to address the research questions and patient-important outcomes. Criteria for 
inclusion and exclusion of literature (e.g. study design, sample size, duration of 
follow up) for the reviews were based on the evidence needed and available to 
answer the research questions. Existing national and international guidelines 
were also evaluated and, where necessary, comprehensive reviews and technical 
reports obtained (Appendix 5). Search strategies and summaries of evidence 
are available in Appendix 3. Systematic reviews were externally commissioned 
through the Burnet Institute, Australia and Glasgow Caledonian University/
Health Protection Scotland, UK.  
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The quality of the evidence was assessed and either rated down or rated up based 
on the following criteria: rated down based on (i) risk of bias (using the Cochrane 
Risk of Bias assessment tool) including publication bias; (ii) inconsistency or 
heterogeneity; (iii) indirectness (addressing a different population than the one 
under consideration); or (iv) imprecision. Conversely, the quality of the evidence 
was rated up if it met any of three criteria: (i) large effect size; (ii) dose–response; 
or (iii) plausible residual confounders (i.e. when biases from a study might be 
reducing the estimated apparent intervention effect). Based on the rating of the 
available evidence, the quality of evidence was categorized as high, moderate, 
low or very low (Table 4.1). Summaries of the quality of evidence to address 
each outcome were entered in the GRADE profiler software (GRADEpro 3.6,) 
(Appendix 2).
TABLE 4.1  GRADE categories of quality of evidence106  
High
We are very confident that the true effect lies close to that of the estimate of the effect
Moderate
We are moderately confident in the effect estimate: the true effect is likely to be close to the 
estimate of the effect, but there is a possibility that it is substantially different
Low
Our confidence in the effect estimate is limited: the true effect may be substantially different from 
the estimate of the effect
Very low
We have very little confidence in the effect estimate: the true effect is likely to be substantially 
different from the estimate of the effect
At the June 2013 meeting of the Guidelines Development Group, for each of the 
PICO questions, the results of the systematic reviews were presented, and the 
evidence profiles and decision-making tables were reviewed to ensure that there 
was understanding of and agreement on the scoring criteria. Recommendations 
were then formulated based on the overall quality of the evidence, in addition to 
the balance between benefits and harms, values and preferences, and resource 
implications. These were assessed through discussions among members 
of the Guidelines Development Group. The strength of recommendations 
was rated as either strong (the panel was confident that the benefits of the 
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High
We are very confident that the true effect lies close to that of the estimate of the effect
Moderate
We are moderately confident in the effect estimate: the true effect is likely to be close to the 
estimate of the effect, but there is a possibility that it is substantially different
Low
Our confidence in the effect estimate is limited: the true effect may be substantially different from 
the estimate of the effect
Very low
We have very little confidence in the effect estimate: the true effect is likely to be substantially 
different from the estimate of the effect
intervention outweighed the risks) or conditional (the panel considered that 
the benefits of the intervention probably outweighed the risks). The results of 
those discussions are summarized in the decision-making tables (Appendix 
4). Recommendations were then formulated and the wording finalized by the 
entire group. Implementation needs were subsequently evaluated and areas and 
topics requiring further research identified. At both meetings, declarations of 
interest were reported according to WHO standard requirements.
At the June 2013 meeting of the Guidelines Development Group, presentations 
were made by external experts on fibrosis assessment and cost–effectiveness 
of fibrosis assessment tests (Louise Longworth and Emmanuel Tsochatzis), 
cost–effectiveness of treatment in low- and middle-income settings (Yazdan 
Yazdapanah), treatment of PWID (Natasha Martin) and frequency of laboratory 
monitoring during therapy (Emma Thomson). Resource use was considered based 
on the available evidence and presentations from invited external expert speakers.
The final recommendations were agreed on by consensus during a face-to-face 
meeting in June 2013. After all of the comments and questions from members 
of the Guidelines Development Group were addressed, to document consensus, 
the Chairs asked each Group member individually whether he/she agreed with 
the recommendation. For all of the recommendations, there was unanimous 
agreement of Group members. 
The intended scope of these guidelines was to include all HCV medicines that 
had received regulatory approval in at least one country. At its meeting in June 
2013, the Guidelines Development Group considered that two new medicines 
(simeprevir and sofosbuvir) were likely to gain approval by at least one national 
regulatory body prior to the release of the guidelines and agreed that, if this 
was the case, recommendations should be formulated concerning their use. 
Systematic reviews for sofosbuvir and simeprevir were conducted by the 
same individuals who had done the other reviews and included peer-reviewed 
articles, conference abstracts, and data submitted to the US Food and Drug 
Administration (FDA) as part of the drug registration applications. Evidence 
profiles and decision-making tables were prepared using the same methods as 
for the other recommendations, and these were reviewed and recommendations 
formulated during a web-based meeting that was held in December 2013. 
Members of the Guidelines Development Group were asked to submit an email 
indicating their agreement with the wording of the two new recommendations 
to confirm consensus. All Group members agreed with the recommendations.
A draft document was prepared and circulated to the members of the Guidelines 
Development Group and the WHO Steering Committee. Suggested changes 
were incorporated into subsequent drafts. If comments were not clear, reviewers 
were contacted to provide clarification. Thereafter, a draft was circulated to 
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the external peer reviewers and the draft document furher revised to address 
their comments. Suggested changes to the wording of the recommendations or 
suggested modifications to the scope of the document were not considered, but 
otherwise there were no comments that suggested conflicting changes. 
Roles
The Guidelines Development Group formulated the PICO questions, reviewed 
the evidence profiles and decision-making tables, formulated and agreed upon 
the wording of the recommendations and reviewed drafts of the guidelines 
document.
The peer reviewers reviewed the draft guidelines document and provided 
comments and suggested editorial changes.
Guideline methodologists ensured that the GRADE framework was appropriately 
applied throughout the guidelines development process. This included the 
formulation of the PICO questions, ensuring the comprehensiveness and quality 
of the systematic reviews, and preparing evidence profiles and decision-making 
tables. The methodologists also provided guidance to the Guidelines Development 
Group in the formulation of the wording and strength of the recommendations. 
Declarations of interest
In accordance with WHO policy, all members of the Guidelines Development 
Group were required to complete and submit a WHO Declaration of Interests 
form. The Secretariat then reviewed and assessed the declarations submitted by 
each member and presented a summary to the Guidelines Development Group.
Individuals from civil society organizations whose organizations received most of 
their funding from private (primarily pharmaceutical) companies or individuals 
who received honoraria from such companies were classified as having potential 
conflicts of interest. These persons were partially excluded from the Guidelines 
Development Group by not participating in the formulation of recommendations. 
These Group members contributed to the development of PICO questions, and 
provided technical expertise in reviewing the evidence summaries. Persons 
who were partially excluded were: Vladimir Chulanov, Charles Gore, Anna Lok, 
Masashi Mizokami and Manal El-Sayed. 
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5. RECOMMENDATIONS ON SCREENING
5.1 Screening to identify persons with HCV infection
Background
In many countries, people have very limited access to HCV testing and thus 
remain undiagnosed until they present at a health centre with symptoms of 
cirrhosis or liver cancer.107 Testing at this time is referred to as “symptomatic 
testing”. At this point, HCV-induced liver damage is often advanced and therapy 
may be contraindicated. Therefore, it is critical to identify approaches that will 
lead to a diagnosis of chronic HCV infection earlier in the course of disease. 
The Guidelines Development Group considered the value of a risk group-based 
and prevalence-based approach. These approaches, where testing is based on 
whether a person belongs to a group that practises behaviours that place them at 
risk of HCV infection or belongs to a population of known high HCV prevalence, 
are recommended in many high-income countries.108,109 The difficulty in 
considering these approaches is that the relative importance of risk factors and 
history of behaviours linked to HCV infection vary substantially, depending on the 
geographical setting and population studied (Table 5.1). 
It is recommended that HCV serology testing be offered to individuals who are part of 
a population with high HCV seroprevalence or who have a history of HCV risk exposure/ 
behaviour.
Strong recommendation, moderate quality of evidence 
Notes: The WHO list of prequalified serological diagnostic tests for hepatitis C infection are 
available at. http://www.who.int/diagnostics_laboratory/evaluations/en/hcv_rep1.pdf and 
http://www.who.int/diagnostics_laboratory/evaluations/en/hcv_rep2.pdf
This list will be updated in 2014. 
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Summary of the evidence 
A systematic review was conducted to examine the effectiveness of interventions 
to promote HCV testing before persons develop symptoms of liver damage due 
to HCV infection. Outcomes assessed included the number of HCV tests carried 
out, the number of seropositive cases detected, the number of referrals to a 
specialist, the number commencing treatment for HCV, disease progression, 
SVR, quality of life and all-cause mortality.
Sixteen studies were reviewed; five randomized controlled trials (RCTs), four 
non-randomized controlled trials, three before/after studies and four time-
series analyses (Appendix 3). Of these, 12 studies reported on practitioner-
based targeted HCV testing interventions. The interventions that were evaluated 
included awareness-raising of practitioners through in-service training sessions 
or mailed information, provision of additional clinic staff, routine offer of testing 
to all patients, or placing reminders in medical records. Four studies reported on 
media-/information-based targeted HCV testing interventions such as invitations 
to information sessions for care providers, leaflets or posters on HCV testing for 
use in service settings, and TV/radio awareness-raising campaigns.
Practitioner-based targeted HCV testing approaches were found to be more 
effective than media-/information-based targeted approaches in increasing the 
number of people being tested, detecting HCV antibody-positive cases, and the 
number of attendances and referrals to specialist care. This evidence was rated 
as being of moderate quality because of inconsistency and imprecision of the 
relative risks (RRs).
TABLE 5.1  Populations with high HCV prevalence or who have a history of HCV risk exposure/
behaviour  
• Persons who have received medical or dental interventions in health-care settings where 
infection control practices are substandard
• Persons who have received blood transfusions prior to the time when serological testing 
of blood donors for HCV was initiated or in countries where serological testing of blood 
donations for HCV is not routinely performed
• Persons who inject drugs (PWID)
• Persons who have had tattoos, body piercing or scarification procedures done where 
infection control practices are substandard
• Children born to mothers infected with HCV
• Persons with HIV infection 
• Persons who have used intranasal drugs
• Prisoners and previously incarcerated persons
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• Persons who have received medical or dental interventions in health-care settings where 
infection control practices are substandard
• Persons who have received blood transfusions prior to the time when serological testing 
of blood donors for HCV was initiated or in countries where serological testing of blood 
donations for HCV is not routinely performed
• Persons who inject drugs (PWID)
• Persons who have had tattoos, body piercing or scarification procedures done where 
infection control practices are substandard
• Children born to mothers infected with HCV
• Persons with HIV infection 
• Persons who have used intranasal drugs
• Prisoners and previously incarcerated persons
A targeted approach to testing increased HCV testing uptake compared to no 
targeted intervention (RR 2.9, 95% CI 2.0, 4.2). A practitioner-based approach 
to targeted testing increased both the number of people tested for HCV and 
the number who tested seropositive for HCV (RR 3.5, 95% CI 2.5, 4.8; and RR 
2.3, 95% CI 1.5, 3.6, respectively). A media-/information-based approach to 
targeted testing was, however, less effective than practitioner-based measures 
in increasing the number of people tested for HCV and the number who 
tested seropositive (RR 1.5, 95% CI 0.7, 3.0; and RR 1.3, 95% CI 1.0, 1.6, 
respectively). Targeted testing versus no targeted testing was associated with 
increased referrals to a specialist (RR 3.0; 95% CI 1.8, 5.1) and increased 
attendance at specialist appointments (RR 3.7; 95% CI 1.9, 7.0). 
Although testing interventions were associated with an increase in the uptake of 
HCV treatment, this did not result in an increased likelihood of SVR or reduced 
mortality. This is possibly due to the short period of follow up in most studies. 
Although there was no direct evidence showing that targeted testing resulted in 
reduced mortality, it was felt that this was likely to occur based on an increased 
referral and treatment rate, and that longer-term studies would be likely to show 
this effect.
Rationale for the recommendation
The summary of evidence demonstrated that practitioner-based and media-
based interventions are effective in increasing uptake of testing, identifying 
HCV-infected individuals and referring them to care. However, the approaches to 
achieve these results were different in the studies that were evaluated. Therefore, 
the Guidelines Development Group could not recommend a specific intervention 
to increase the uptake of HCV testing. Instead, the Group recommended a more 
general approach of focusing testing efforts on persons who belong to populations 
with a known high prevalence of HCV or who have a history of behaviours that 
place them at risk of HCV infection (Table 5.1). In some countries where unsafe 
injection practices and invasive medical procedures are common, much of the 
general population would be considered to be “of known high prevalence”. The 
identification of approaches to implement this recommendation will vary, based 
on the composition of the high-prevalence groups in a country, as well as the 
availability of resources, and clinical and outreach testing services. 
Balance of benefits and harms: Targeted testing of persons belonging to risk 
groups and those with high HCV prevalence is likely to increase the number of 
HCV-infected people identified, referred to a specialist and provided access to 
treatment, resulting in a higher likelihood of treatment success. An additional 
benefit is that knowing one’s HCV infection status provides the opportunity 
to reduce transmission to others by avoiding behaviours such as sharing 
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of injection equipment that place others at risk of HCV infection. Potential 
undesirable outcomes were not assessed in the studies that were reviewed, but 
the Guidelines Development Group recognized that persons with HCV infection 
can face stigma, discrimination and potential loss of employment and health 
benefits. Thus, it is vital that testing is voluntary and that confidentiality be 
maintained as part of approaches to enhance testing. Members of the Guidelines 
Development Group also expressed concern that persons with HCV identified 
through enhanced screening efforts in low- and middle-income countries might 
not have access to care and treatment. Despite these concerns, the Guidelines 
Development Group felt that persons have the right to know their HCV status, 
and an increase in the number of persons who are aware of their diagnosis could 
lead to an increased demand for treatment. The Guidelines Development Group 
concluded that the desirable outcomes outweighed the undesirable outcomes. 
WHO is developing separate screening and testing guidelines for hepatitis B and 
C, which will address many of these issues in greater detail. 
Values and preferences: In populations where HCV infection is higher in 
groups that are marginalized (e.g. PWID), targeted HCV testing that is linked to 
prevention and treatment services could lead to reductions in health disparities. 
Assuming that screening efforts were conducted taking into consideration the 
above-mentioned elements (lack of coercion, confidentiality, cultural sensitivity, 
linkage to health services), the Guidelines Development Group felt that screening 
would be acceptable by the affected groups.
Resource considerations: Moving away from symptomatic testing as the primary 
strategy for diagnosis of infected persons to a model that targets screening 
of specific high-risk or high-prevalence populations will require additional 
resources, including medical training, staffing and equipment for phlebotomy, 
counselling and serological screening. Furthermore, a positive HCV serology 
test result needs additional testing to confirm the presence of chronic infection 
(see Section 5.2). Monitoring of laboratory and clinical facilities are additionally 
required to ensure high standards of practice. Targeted testing has different 
costs associated with different settings – if HCV is prevalent in the general 
population, a substantial screening effort would be indicated and would result in 
significant costs. Members of the Guidelines Development Group emphasized 
the importance of assuring access to treatment following screening. The 
Guidelines Development Group agreed that the infrastructure for both screening 
and treatment is necessary for screening to have an impact on key outcomes, 
including quality of life and mortality; therefore, resources put into screening 
need to be matched with increased resources for treatment. 
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Implementation 
The implementation of this recommendation will require an assessment of the 
epidemiology of HCV in a specific country or region seeking to expand testing. 
This is difficult, as many countries have no or very little data on the prevalence 
of HCV infection. Two approaches are taken in high-income countries to expand 
HCV testing. The first is to specify the risk groups for testing, while a second 
approach recommended in the US is to define demographic groups using age 
criteria.108,109 Risk group identification is challenging because many individuals 
do not wish to acknowledge behaviours that are stigmatized, such as drug use. 
In either case, successful implementation would require developing a national 
HCV testing policy with suggestions for implementation. Considerable resources 
are needed to purchase test kits, train health-care workers and laboratory staff, 
and implement quality assurance programmes. Another challenge is to ensure 
that patients who are diagnosed are referred for appropriate care. This would 
include evaluation for therapy, provision of lifestyle advice to reduce progression 
of liver disease (for example, by reducing alcohol intake), as well as measures 
taken to prevent transmission. 
Considerations in persons with HIV/HCV coinfection 
In the United States and western Europe, it is recommended that all persons 
with HIV infection be screened for HCV at the time of enrolment into HIV care, 
and that those who are not infected with HCV but practice behaviours that place 
them at risk for HCV infection, such as injection drug use, be retested annually. 
Rates of HCV infection in persons with HIV infection are higher than in the 
general population, but vary widely by country. 
Research gaps
There is a lack of direct evidence that HCV testing interventions positively affect 
treatment outcomes and HCV-related morbidity and mortality. Further research 
in this area focusing on the longer-term outcomes of testing interventions for 
HCV would be useful, particularly in low-income settings. Operational research 
is needed to evaluate different approaches to increase the reach and uptake 
of screening services, particularly among marginalized populations and in low-
income settings. 
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5.2 When to confirm a diagnosis of chronic HCV 
infection
Background
Approximately 15–45% of persons who are infected with HCV will spontaneously 
clear the infection.58,59 These persons are HCV seropositive but are no longer 
infected with HCV. A nucleic acid test (NAT) for HCV RNA, which detects the 
presence of the virus, is needed to distinguish persons with chronic HCV infection 
from those who have cleared the infection. It is therefore standard of care to carry 
out a NAT for HCV RNA for persons who are found to be HCV antibody positive. A 
NAT for HCV RNA is also important prior to commencing and during treatment to 
assess the response to treatment.110-112 The Guidelines Development Group felt it 
important to assess whether, in addition to a NAT for HCV RNA prior to initiation of 
treatment, there is a benefit to confirming the presence of chronic HCV infection 
directly following a positive HCV serological test result. 
Summary of the evidence 
A systematic review was conducted to compare whether there was a benefit 
to performing an HCV-RNA NAT directly following a positive serological test 
result (called “immediate testing”) as compared with testing carried out at the 
time of assessment for antiviral therapy (called “delayed testing”) (Appendix 3). 
Outcomes assessed included the number of cases of HCV transmission, the 
number achieving SVR, the number of cases of decompensated liver disease 
and HCC, mortality and quality of life.  
Eight articles were obtained for full-text appraisal. 113-120 No study matched the 
complete inclusion criteria as all of them lacked a comparison arm and were 
primarily designed to address other research questions; thus, the quality of 
evidence was graded as very low. As the aims were different, these studies did 
not directly report on the outcomes of interest specified in the PICO question. 
It is suggested that nucleic acid testing for the detection of HCV RNA be performed 
directly following a positive HCV serological test to establish the diagnosis of chronic HCV 
infection, in addition to nucleic acid testing for HCV RNA as part of the assessment for 
starting treatment for HCV infection. 
Conditional recommendation, very low quality of evidence
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Therefore, no studies were included for qualitative or quantitative assessment, 
and in the absence of any directly relevant studies, neither narrative synthesis 
nor meta-analysis could be performed. To address this data gap, a broadened 
search was conducted of systematic reviews, comment papers and other 
study types to capture relevant studies relating to the timing of NAT, including 
comparisons of NAT at any time versus no NAT. This also yielded no citations of 
primary studies or systematic reviews. 
Articles were then analysed for indirect evidence related to the question. 
There was indirect evidence showing that HCV-RNA NAT is underutilized in 
populations in which it is indicated.116,118-120 Rongey found that HCV-RNA NAT 
among a cohort of anti-HCV-positive US veterans was more likely to be carried 
out in patients with abnormal transaminases, in those with non-HCV hepatitis, 
and those with decompensated liver disease, while those aged over 65 years and 
PWID were significantly less likely to be tested for HCV RNA.116
Rationale for the recommendation
Balance of benefits and harms: In the absence of direct or indirect evidence 
from the systematic reviews, members of the Guidelines Development Group 
discussed the implications of not conducting an immediate HCV-RNA NAT. These 
included labelling persons as being infected with HCV when, in fact, they had 
spontaneously cleared the infection. Such individuals could unnecessarily face 
stigma and discrimination, including difficulties with employment and procuring 
health services. Knowing whether someone has chronic HCV infection allows 
health staff to provide prevention messages to protect the infected individual 
(e.g. alcohol reduction counselling) as well as the health of their family or 
contacts (e.g. PWID networks) by informing them of methods to reduce the risk 
of transmission of HCV. Knowing someone’s HCV status provides an opportunity 
to link him or her with appropriate care. 
A potential harm of knowing one’s HCV infection status is the psychological 
stress related to having a life-threatening infection, particularly if HCV treatment 
is not available. Despite this, the expert opinion of the Guidelines Development 
Group panel was that the benefits of immediate testing versus delayed testing 
outweighed the potential harms.
Values and preferences: Immediate testing was considered likely to be acceptable 
to key stakeholders. Patients with resolved HCV infection following spontaneous 
clearance would be reassured and those who learn of their infection can take 
steps to protect their health and that of others. 
Resource considerations: The resources required for NAT for HCV RNA were, 
however, considered to be substantial. The cost of the test is high, ranging from 
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US$ 30–200 per test. Furthermore, the laboratory equipment is expensive 
and requires technicians with specialized training. As the infrastructure for 
immediate NAT is also needed for HCV viral load testing (quantitative HCV 
RNA) to commence and monitor treatment for HCV, the incremental cost to 
implement this recommendation would be associated with additional reagent 
cost and technician time, and the cost of repeat testing before initiation of 
treatment. Therefore, although an increase in cost associated with earlier testing 
was considered to be likely, the Guidelines Development Group considered that 
the incremental cost was smaller than the net benefit, and immediate NAT was 
considered to be feasible in countries where pre-treatment NAT is already being 
performed.
Implementation
The Guidelines Development Group emphasized that HCV testing should 
be voluntary, the results of the test should be confidential and that referral 
for treatment should be considered in all persons with detectable HCV RNA. 
Laboratories should operate within a quality-assurance framework, which is 
essential for accurate testing results. The possibility of reinfection with HCV after 
spontaneous clearance or successful treatment was considered, and persons 
with undetectable HCV RNA but who are still at active risk (e.g. current PWID) 
should be advised to be retested. 
Considerations among persons with HIV/HCV coinfection
Persons who are infected with both HIV and HCV can have false-negative HCV 
serological test results. This may occur in up to 6% of persons with HIV who 
undergo testing using a second-generation anti-HCV enzyme immunoassay 
(EIA),121,122 but may occur more often among persons with advanced 
immunosuppression due to HIV and during early HCV infection.123,124 As the 
range of CD4 counts in persons with a false-negative HCV antibody test were 
so different in the various studies, it was not possible to suggest a specific CD4 
cut-off level below which all those with a negative HCV antibody test should have 
HCV RNA testing performed. 
Research questions
Further research into the optimal timing of NAT for HCV RNA is warranted 
to compare the effect of immediate testing with delayed testing on patient 
outcomes, including HCV transmission, morbidity, mortality and quality of life. 
Research evaluations are needed of novel laboratory techniques that would 
allow confirmation of HCV infection without the need for expensive laboratory 
equipment or trained personnel.
 
51
6. RECOMMENDATIONS ON CARE OF 
PEOPLE INFECTED WITH HCV
6.1 Screening for alcohol use and counselling to reduce 
moderate and high levels of alcohol intake 
An alcohol intake assessment is recommended for all persons with HCV infection followed 
by the offer of a behavioural alcohol reduction intervention for persons with moderate-to-
high alcohol intake.
Strong recommendation, moderate quality of evidence
Note: The WHO ASSIST141 screening questionnaire can be used to quantify the level of 
alcohol intake as low, moderate or high, based on the responses to eight screening questions 
that assess the frequency of use and presence of alcohol-associated problems
Background
In many persons with chronic HCV infection, decades can pass between the 
time of infection and when they develop fibrosis and cirrhosis. During that time, 
there are health conditions and behaviours that can accelerate the progression 
of liver damage, including alcohol consumption and obesity. The Guidelines 
Development Group assessed various interventions that slow the rate of liver 
damage among persons with HCV and decided to evaluate interventions to 
reduce alcohol intake because alcohol consumption is common, has been 
shown to accelerate the progression of liver disease among people with HCV125 
and it was felt that persons with HCV infection would be amenable to such 
measures. Reducing the use of cannabis in persons with HCV was discussed 
by the Guidelines Development Group but was not considered as part of a 
systematic review process due to a paucity of data and conflicting reports on any 
association with progression of liver disease.126  
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A heavy intake of alcohol, of between 210 and 560 g/week (a glass of wine 
or can of beer contains 10–14 g alcohol), doubles the risk of cirrhosis, and 
even moderate alcohol consumption can be detrimental.127 The purpose of the 
systematic review was to investigate the effectiveness of behavioural interventions 
to reduce alcohol intake among people with HCV, in terms of HCV treatment 
outcomes, liver disease progression and quality of life.  
Alcohol use in persons with HCV varies considerably in different geographical 
regions and in different risk groups. Many countries have no published prevalence 
rates of alcohol use in HCV-infected individuals. Some countries, such as Egypt 
and Saudi Arabia, report extremely low or negligible alcohol use in persons with 
HCV.127,128 Considerably higher alcohol use is found in other countries, especially 
among PWID and prisoners. In China, the majority of PWID in one region was 
found to use alcohol regularly prior to starting injecting drug use.129 In one study 
from Russia, 26–30% of PWID drank moderate-to-heavy amounts of alcohol.130 
In Brazil, HCV-infected youth offenders had high rates of alcohol use131 and 
in a study among Nigerian prisoners, 59% with HCV also drank alcohol.132 
Alcohol intake has also been found to be high in other groups of HCV-infected 
individuals; 37% of male and 9% of female commercial plasma donors infected 
with HCV in Guan, China were found to drink >40 g of alcohol per day.113,b In 
view of these figures, the Guidelines Development Group considered that even 
in countries where alcohol intake is low among the general population, alcohol 
reduction advice might have an impact.
Evidence
A systematic review was conducted of studies examining a brief behavioural 
alcohol reduction intervention versus no behavioural intervention for HCV-
infected individuals. The outcomes considered were reduction or cessation of 
alcohol intake, SVR, liver fibrosis, decompensated liver cirrhosis, HCC, quality 
of life and mortality. 
Five trials were identified that met the PICO criteria for assessment (Appendix 3); 
two RCTs134,135 and three cohort studies.136-138 These studies evaluated different 
interventions and used different measures of alcohol intake. The interventions 
that were evaluated included four sessions of motivational enhancement 
therapy, six two-hour group counselling sessions, 24-week integrated alcohol 
reduction and health-promotion counselling, and two studies with a single 
“brief” counselling session. These studies provided some evidence that alcohol 
reduction interventions can reduce alcohol consumption among people with 
moderate-to-high alcohol intake living with chronic HCV. However, the evidence 
b. Further information collected by WHO on alcohol use by country is available online: http://www.who.int/substance_
abuse/publications/global_alcohol_report/profiles/.
53
was graded as being of moderate quality because of considerable heterogeneity 
in the intervention and comparison groups, and measures of alcohol intake 
across these studies. 
There are more studies evaluating brief alcohol reduction counselling among 
HCV-uninfected individuals. A Cochrane review conducted by Kaner et al.139 
found that among 5 860 hazardous or dependent drinkers followed in 22 studies, 
screening for HCV followed by a brief intervention (compared with no intervention) 
significantly reduced mean weekly alcohol consumption of 313 g per week by 38 
g per week. Klimas et al.140 investigated the efficacy of psychosocial interventions 
for drinkers who concurrently used illicit drugs. Among 594 participants across 
four studies, alcohol-focused interventions resulted in significant reductions in 
alcohol consumption at 3 months (RR 0.32) and 9 months (RR 0.16) compared 
to treatment as usual. The quality of the evidence overall was considered to be 
moderate since there was variability in the type of interventions. Although these 
studies were conducted among persons without HCV infection, the Guidelines 
Development Group felt that the benefits demonstrated in these studies would 
apply to persons with HCV infection. One limitation is that most of the studies 
included in these reviews were from North America and Europe; thus, it is 
uncertain how generalizable they are to other parts of the world. 
Rationale for the recommendation
In summary, the Guidelines Development Group concluded that there was 
evidence of moderate quality that alcohol reduction interventions would reduce 
alcohol consumption among persons with chronic HCV infection who consume 
moderate-to-large amounts of alcohol. Although there are no data on whether 
longer-term important outcomes including treatment response, morbidity, 
mortality and quality of life are affected by alcohol reduction interventions, 
the opinion of the Group was that these outcomes are likely to be improved. 
The Guidelines Development Group also felt that this intervention would be 
acceptable to key stakeholders.
Balance of benefits and harms: The evidence in favour of an alcohol reduction 
intervention was considered to be of moderate quality and the likelihood of 
undesirable effects minimal. However, the relevance of this advice is likely to 
be context specific and countries with low alcohol use may not wish to commit 
as much time and resources to carrying out alcohol reduction interventions as 
other countries.
Values and preferences: An intervention delivered in the context of a liver health 
assessment was felt to be acceptable to persons with HCV infection, assuming 
that confidentiality was maintained. Regarding equity, members of the Guidelines 
Development Group felt that alcohol use should not preclude treatment for HCV. 
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Resource considerations: The principal costs of implementing a brief alcohol 
reduction intervention were considered to be related to the training of clinicians 
and counsellors, and the additional time required to deliver counselling. 
Nevertheless, a brief 5–10 minute alcohol reduction intervention was considered 
to be unlikely to substantially increase costs and would be likely to be feasible to 
implement in most health-care settings.
Implementation
An important challenge to implementing a brief alcohol reduction intervention 
is deciding on which approach to consider. The Guidelines Development Group 
proposed that the WHO ASSIST (Alcohol, Smoking and Substance Involvement 
Screening Test) package141 would be an appropriate framework to design alcohol 
screening and reduction interventions because it is evidence based, proposes 
a standardized approach, and is aimed at the primary health-care level. The 
ASSIST package includes tools for carrying out an assessment of the level of 
intake of alcohol and other substances, and instructions on implementing a brief 
counselling intervention.  
The elements of the ASSIST approach are outlined in Table 6.1 and include 
the administration of a questionnaire regarding the use of alcohol and other 
substances, classification of the level of consumption and, if needed, alcohol-
reduction counselling or referral. 
This approach is more fully described in the WHO Mental Health Gap Action 
Programme (mhGAP) guidelines for mental health, neurological and substance 
use disorders in non-specialized settings in low- and middle-income countries.142
Research questions
Additional research is required to fully assess the impact of a brief behavioural 
intervention such as the ASSIST intervention on other outcomes, including 
morbidity, mortality and quality of life, particularly in different geographical 
settings. Measuring alcohol consumption is complex and different instruments 
are used across studies, making comparisons and synthesis of the evidence 
difficult. Future research should consider using validated and standardized tools 
for measuring alcohol consumption where possible. Operational research is 
needed to evaluate approaches of integrating alcohol screening and counselling 
in different geographical settings.
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TABLE 5.1  ASSIST – The Alcohol, Smoking and Substance Involvement Screening Test141  
The ASSIST package has been developed in response to the public health burden associated 
with psychoactive substance use worldwide. It is designed for use in primary health-care settings 
to assess levels of dependence and to detect harmful substance use in non-dependent persons. 
The ASSIST approach is designed to be cross-culturally effective.
The elements of the ASSIST package are described in three manuals:
1. The ASSIST screening test: a manual for use in primary care
2. The ASSIST-linked brief intervention for hazardous and harmful substance use: a manual for 
use in primary care
3. Self-help strategies for cutting down or stopping substance use: a guide
The elements of the ASSIST approach are: 
• A screening questionnaire that takes 5–10 minutes and can be administered in primary 
health-care settings;
• Determination of the “risk score” based on the questionnaire, which allows the patient to be 
categorized according to risk. The categories determine the intervention type are as follows: 
 - lower risk means no treatment is needed
 - moderate risk calls for a brief intervention 
 - high risk leads to referral to a for specialist assessment and treatment. 
• The brief intervention manual assists health-care workers in conducting a simple brief 
intervention for patients at risk.
• The self-help guide is a resource for the patient to use to help change substance-use 
behaviour. 
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Background
Decisions regarding treatment initiation for HCV are based on a patient’s 
degree of fibrosis and the balance between the likelihood of cure versus that 
of serious side-effects from the treatment. Patients with less advanced fibrosis 
respond better to HCV treatment, with a higher SVR rate. However, some of 
these individuals would never progress to cirrhosis, and thus are unnecessarily 
exposed to potentially toxic drugs. On the other hand, individuals with more 
advanced fibrosis and compensated cirrhosis respond less well to treatment, with 
a lower SVR rate. If they do achieve SVR, they benefit more than persons with 
less advanced cirrhosis as they are at much higher risk of dying from advanced 
liver disease if they do not receive treatment. According to guidelines developed 
for high-income countries, therapy should be considered for all persons with 
chronic HCV infection.110,111 In lower-income countries, where the availability of 
treatment can be severely restricted, prioritizing, or even limiting, treatment to 
those persons at highest risk of morbidity and mortality may be necessary. Thus, 
the Guidelines Development Group felt it important to identify low-cost, effective 
methods of assessing the degree of fibrosis that would be widely available in low- 
and middle-income countries. 
Liver biopsy is considered the gold standard method for fibrosis assessment, 
but it is not widely used in low-income countries because of its high cost, 
invasiveness, patient discomfort, risk of complications, as well as the need for 
expert histological interpretation. Several liver biopsy-scoring systems have been 
developed, of which the METAVIR system is most widely used (Table 6.2). 
6.2 Assessing the degree of liver fibrosis and cirrhosis 
In resource-limited settings, it is suggested that aminotransferase/platelet ratio index 
(APRI) or FIB4 be used for the assessment of hepatic fibrosis rather than other non-
invasive tests that require more resources such as elastography or Fibrotest. 
Conditional recommendation, low quality of evidence 
Note: This recommendation was formulated assuming that liver biopsy was not a feasible 
option. Fibroscan, which is more accurate than APRI and FIB4, may be preferable in settings 
where the equipment is available and the cost of the test is not a barrier to testing.
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TABLE 6.2  METAVIR liver biopsy scoring system143  
METAVIR 
stage
F0 F1 F2 F3 F4
Definition No fibrosis Portal fibrosis 
without septa
Portal fibrosis 
with septa
Numerous 
septa without 
cirrhosis
Cirrhosis
A variety of non-invasive fibrosis tests based on blood indices and imaging 
modalities are now available, which may be more suitable for low- and middle-
income countries (Table 6.3). These include serum tests such as the APRI, 
FIB4 scores, which measure indirect markers of fibrosis such as alanine 
aminotransferase (ALT), aspartate aminotransferase (AST) and platelet count 
(Figure 6.1); tests that should be available at all clinics treating patients with 
HCV. Other serum tests such as Fibrotest measure direct markers of fibrosis 
such as haptoglobin. These tests are patented, must be performed in laboratories 
that meet certain quality standards, and are thus more expensive and less 
readily available. Not all of these tests can assess all stages of fibrosis as well as 
cirrhosis. For example, FIB4 was evaluated only for the diagnosis of significant 
fibrosis (METAVIR stage ≥F2), while APRI was validated for the diagnosis of 
both significant fibrosis and cirrhosis. More recently, new techniques have been 
developed that are based on ultrasound technology and assess the degree of 
fibrosis and cirrhosis by measuring liver stiffness. Of these, transient elastography, 
which is performed with Fibroscan (Echosens, Paris) has been the most widely 
evaluated. Characteristics that limit the use of transient elastography include the 
high cost of the equipment, the need for regular recalibration, trained operators 
and the lack of validated cut-off values for specific fibrosis stages.
FIGURE 6.1  APRI and FIB4 formulas 
APRI = [{AST (IU/L)/ AST_ULN (IU/L)}×100]/ platelet count (109/L)
FIB4= age (yr) x AST(IU/L)/platelet count (109/L x [ALT(IU/L)1/2]
ALT - alanine aminotransferase 
AST - aspartate aminotransferase
IU - international unit
ULN - upper limit of normal
58
Summary of evidence
The PICO question for this recommendation was based on two assumptions. 
First, that liver biopsy would not be available for the reasons listed above, and 
second, that all sites would have access to the laboratory tests needed to calculate 
APRI and FIB4 indices. Thus, the results of systematic reviews were analysed 
to assess the benefit of more complex and expensive tests (e.g. Fibrotest or 
Fibroscan) compared with APRI and FIB4. A systematic review was conducted 
to evaluate the diagnostic accuracy of non-invasive fibrosis assessment tests in 
adult patients with chronic HCV infection (Appendix 3). The systematic review 
included full papers and abstracts, without language restrictions, which: (i) 
evaluated non-invasive tests in the staging of liver fibrosis using liver biopsy 
as the reference standard, (ii) reported on the data necessary to calculate the 
true-positive, false-positive, true-negative and false-negative diagnostic results 
of the non-invasive tests based on a defined index test cut-off point, and (iii) 
had a maximum of six months of elapsed time between the liver biopsy and 
the index test. For data synthesis and analysis, the histological scores used in 
individual studies were transformed to the METAVIR staging system. Significant 
fibrosis (METAVIR stage ≥F2) and cirrhosis (F4) were assessed as outcome 
variables. Overall, the quality of evidence was found to be low, primarily because 
of potential bias due to the absence of predetermined index test cut-offs for 
diagnosing specific fibrosis stages, and low or unreported quality of liver biopsy 
samples. Summary sensitivity and specificity results and relevant confidence 
intervals are available in Appendix 3.
Non-invasive tests provide a numerical value, while histological staging of liver 
biopsies yields descriptive semi-quantitative categories. For the non-invasive 
TABLE 6.3  Selected non-invasive tests to assess liver fibrosis 143-148 
Test Components Requirements Cost
APRI AST, platelets Simple serum and 
haematology tests
+
FIB4 Age, AST, ALT, platelets Simple serum and 
haematology tests
+
Fibrotest gGT, haptoglobin, bilirubin, 
A1 apolipoprotein, α2-
macroglobulin
Specialized tests. Testing at 
designated laboratories
++
Fibroscan Transient elastography Dedicated equipment +++
APRI aminotransferase/platelet ratio index; ALT alanine aminotransferase; AST aspartate aminotransferase; gGT gamma glutamyl transpeptidase
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TABLE 6.4  Low and high cut-off values for the detection of significant cirrhosis and fibrosis 
APRI (low 
cut-off)
APRI (high 
cut-off)
FIB4 (low 
cut-off)
FIB4 (high 
cut-off)
Transient 
elastography
(Fibroscan)
Significant 
fibrosis
(METAVIR ≥F2)
0.5 1.5 1.45 3.25 7–8.5 kPa
Cirrhosis
(METAVIR F4)
1.0 2.0 – – 11–14 kPa
APRI aminotransferase/platelet ratio index; kPa kilopascal
tests, thresholds exist that correlate with specific histological stages and, in the 
cases of APRI and FIB4, these cut-offs have been validated. APRI and FIB4 
have two cut-off values for diagnosing specific fibrosis stages, as the use of a 
single cut-off would result in suboptimal sensitivity and specificity: a high cut-
off with high specificity (i.e. fewer false-positive results) and a low cut-off with 
high sensitivity (i.e. fewer false-negative results). A staging strategy that uses a 
combination of these two values uses the low cut-off to rule out the presence of 
a particular stage of fibrosis and the high cut-off to confirm that the patient has 
fibrosis that is greater than or equal to a particular stage (e.g. >F2). However, 
a number of patients will fall in the indeterminate range of test results (i.e. 
their score will be between the low and the high cut-off) and such patients will 
need either alternative testing or future retesting. Transient elastography uses 
a single cut-off; however, there are no uniformly established and validated cut-
offs for specific fibrosis stages. Therefore, reported sensitivities and specificities 
of Fibroscan are probably overestimated. The established high and low cut-off 
values of the APRI and FIB4 tests along with a range of the most commonly 
reported cut-offs of Fibroscan for diagnosing ≥F2 stage fibrosis and cirrhosis are 
presented in Table 6.4. The summary sensitivity and specificity of these tests 
and Fibroscan for the detection of significant fibrosis (≥F2 stage) and cirrhosis 
(F4 stage) are listed in Table 6.5.
Having established the sensitivity and specificity of the non-invasive tests 
compared with liver biopsy as the reference test (Table 6.5), the Guidelines 
Development Group considered the comparative performance of the non-
invasive tests. For this analysis, APRI and Fibroscan were selected to illustrate 
clinical trade-offs, as these tests can assess both F2 and F4 cut-offs (i.e. F0–1 
vs F2–4; and F0–3 vs F4). 
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TABLE 6.5  Summary of sensitivity and specificity of APRI, FIB4 and Fibroscan for the  
detection of advanced cirrhosis and fibrosis (all values are percentages)
APRI (low 
cut-off)
APRI 
(high cut-
off)
FIB4 (low 
cut-off)
FIB4 (high 
cut-off)
Transient 
elastography
(Fibroscan)
Significant 
fibrosis
(METAVIR 
≥F2)
Sensitivity
(95% CI)
82
(77–86)
39
(32–47)
89
(79–95)
59
(43–73)
79
(74–84)
Specificity
(95% CI)
57
(49–65)
92
(89–94)
42
(25–61)
74
(56–87)
83
(77–88)
Cirrhosis
(METAVIR 
F4)
Sensitivity
(95% CI)
77
(73–81)
48
(41–56)
– –  89  
(84-92)
Specificity
(95% CI)
78
(74–81)
94
(91–95)
– – 91
(89–93)
APRI aminotransferase/platelet ratio index; kPa kilopascal
A strategy that uses a combination of the high and low cut-off values was 
assessed. Using this strategy, patients with values above the APRI high cut-off 
value would be prioritized for treatment as they have a high probability (94%) 
of having F4 cirrhosis. For patients with an APRI score below the low cut-off 
value, treatment could be deferred as they have a very low probability (18%) of 
having advanced fibrosis (F2 fibrosis or higher) and could thus be reassured and 
reassessed periodically. Those patients with APRI values between low and high 
cut-off values could either be retested every one or two years or, if resources are 
available, could be treated. 
A number of caveats were considered. First, the APRI scoring system may be less 
reliable in persons with HIV due to the possibility of thrombocytopenia associated 
with HIV infection rather than cirrhosis. However, HIV-related thrombocytopenia 
would result in a higher APRI score, and thus earlier treatment. Although this was 
not assessed in the current analysis, a meta-analysis showed that the diagnostic 
accuracy of APRI did not significantly differ between HCV-monoinfected 
and HCV/HIV-coinfected patients.149 Theoretically, the FIB4 test could also 
be affected by thrombocytopenia but this scoring system was first evaluated 
in patients with HIV and was found to perform well.150 Transient elastography 
values may be artificially increased by a number of factors, including acute liver 
inflammation, liver congestion (e.g. cardiac failure), a recent meal, amyloidosis 
and cholestasis. Moreover, the lack of validated cut-offs for the diagnosis of 
specific stages of fibrosis could hinder the interpretation of the test results.
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Rationale for the recommendation
The use of non-invasive monitoring was considered by the Guidelines 
Development Group to be preferable to invasive testing, particularly in low- and 
middle-income countries, as liver biopsy is an expensive and invasive procedure 
associated with patient discomfort, a small risk of serious bleeding and requires 
specialist histological examination for accurate staging. On the basis of the results 
of the systematic review discussed above, the Group considered that APRI, FIB4 
and transient elastography were the most useful tests for assessing the stage of 
liver disease. The advantage of APRI as compared with FIB4 is that it is validated 
for the diagnosis of F4 fibrosis, and would thus be useful for identifying persons 
at greatest risk of morbidity who, therefore, could be prioritized for treatment. It 
was also recommended that persons who tested negative for significant fibrosis 
and/or cirrhosis could be retested periodically, and could thus be treated if their 
APRI or FIB4 indices increased. 
Balance of benefits and harms: The principal undesirable outcomes of this 
recommendation would be due to treatment decisions based on either a false-
positive or false-negative APRI or FIB4 test result. A false-positive test result 
would lead to a patient being potentially treated earlier than necessary, which 
would expose him or her to the risk of harm from drug-related side-effects and 
would also increase resource use. A false-negative result would mean that a 
person who needs treatment would not receive it, resulting in the possibility 
that the person would develop cirrhosis or HCC that could potentially have been 
prevented by treatment for HCV. Despite this, the potential increase in treatment 
availability resulting from increased access to low-cost, non-invasive monitoring 
and reduced risk of adverse events from liver biopsy was felt to outweigh the 
potential harms of false-positive and false-negative case identification.
Values and preferences: APRI and FIB4 tests require only phlebotomy; thus, 
the Guidelines Development Group felt that these tests would be acceptable 
to patients. Similarly, transient elastography is non-invasive and thus would 
probably be acceptable. 
Resource considerations: The lower cost of the serum-based non-invasive tests 
was the most important factor that drove the recommendation. The blood tests 
that are needed to calculate APRI and FIB4 scores are inexpensive and would be 
available at health facilities providing treatment for HCV infection, as they are also 
needed to monitor patients before and after the commencement of treatment. In 
contrast, the cost of acquiring, running and maintaining a transient elastography 
machine such as the Fibroscan is very high. The cost of a fixed machine 
is US$ 100 000 and for a portable one it is US$ 30 000. The cost of yearly 
maintenance is US$ 4 700. For these reasons, the use of transient elastography 
was considered to be not feasible in most low- and middle-income countries. 
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Implementation considerations
The calculation of the APRI score should be easy to implement as it relies on tests 
that are available in most clinics. Evaluation of the results is more challenging 
because of the need to assess two cut-off values. However, the above-mentioned 
strategy provides an approach that should be feasible and will allow clinicians to 
decide who should be treated. As persons with advanced fibrosis and cirrhosis 
(METAVIR F3 and F4 stages) are at highest risk of dying from complications of 
HCV, they need to be prioritized for treatment. If resources allow, treatment of 
persons with less advanced stages of cirrhosis could be considered.
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7. RECOMMENDATIONS ON TREATMENT
7.1 Assessment for HCV treatment
All adults and children with chronic HCV infection, including people who inject drugs, 
should be assessed for antiviral treatment. 
Strong recommendation, moderate quality of evidence 
Background
Over the past two decades, the success of treatment for HCV infection as 
measured by SVR has steadily increased. Early treatments with standard IFN 
resulted in SVR rates of 30–60% depending on the genotype. The introduction 
of PEG-IFN increased SVR rates to 40–70%, and the more recent introduction 
of direct-acting antivirals (DAAs) increased the SVR rate for genotype 1 from 
40% to greater than 90%. Despite these advances, very few persons in low- 
and middle-income countries have been treated for HCV infection. The reasons 
for this are many and include the high cost of treatment, requirement for 
expensive laboratory equipment and tests to evaluate eligibility for and response 
to treatment, and lack of health-care workers trained in administering treatment 
for HCV infection. Regimens based on PEG-IFN and RBV also result in high rates 
of adverse events, which can be debilitating and even life threatening. Thus, the 
Guidelines Development Group felt it important to evaluate the relevant evidence 
of the benefits and harms of treatment versus no treatment of HCV infection. 
Evidence
A systematic review was conducted to investigate the utility of treatment versus 
no treatment for HCV infection in adults and children. The outcome measures 
were rates of SVR, decompensated liver disease, HCC, liver-related and all-
cause mortality, treatment-related adverse events leading to discontinuation and 
quality of life.  
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Fourteen systematic reviews were included in the final synthesis (Appendix 3). 
Six reviews reported data comparing IFN to placebo151-156 and six combined and 
compared different types of IFN (standard IFN or PEG-IFN) to placebo.157-162 No 
studies were available comparing placebo to triple therapy (PEG-IFN, RBV and 
a PI) as the standard of care at the time of institution of triple therapy was dual 
therapy with PEG-IFN and RBV. One review evaluated RBV monotherapy against 
placebo.163 All reviews of IFN, PEG-IFN or RBV versus placebo were RCTs that 
used appropriate meta-analytical methods with no significant indirectness or 
imprecision, and thus contained high-quality evidence according to the GRADE 
criteria.
The analysis showed that IFN was superior to placebo in achieving SVR. The 
effects of IFN on HCC, liver-related morbidity and all-cause mortality were 
inconsistent or statistically non-significant. No studies were found that reported 
quality-of-life changes with IFN versus placebo. 
The systematic reviews of effectiveness of different interferon types (IFN or 
PEG-IFN), in combination with RBV compared with placebo showed a clear 
benefit of treatment versus placebo in achieving SVR. There were inconsistent 
or statistically non-significant effects of PEG-IFN/RBV on HCC, liver-related 
morbidity and all-cause mortality. One study comparing RBV with placebo 
showed no significant beneficial effect of RBV in achieving SVR, reducing all-
cause mortality or quality of life.163 
The systematic reviews showed that the most common adverse events were 
flu-like syndromes and depression due to IFN and anaemia due to RBV. The 
frequency of discontinuation of treatment approached 20% in one study of 
patients being evaluated for liver transplants compared with 0% among placebo 
recipients.158 
Treatment success rates are similar in adults and children, although fewer 
studies have been carried out in children.153 One systematic review reported on 
the virological outcomes and adverse effects of treatment among children.153 This 
review included four RCTs and 31 non-randomized studies. The overall SVR rate 
for PEG-IFN and RBV was 30–100%, which is comparable to SVR rates seen 
in adults. Adverse effects were primarily flu-like symptoms and neutropenia. 
Data were insufficient to assess the applicability of stopping therapy at week 
12 if there was less than a 2 log drop in HCV RNA or the efficacy of shortening 
treatment duration to 24 weeks in children with genotypes 2 and 3 infection.
In studies conducted among persons with HIV coinfection, there were 110 more 
treatment discontinuations and 830 more cases of flu-like symptoms per 1 000 
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persons treated than among persons receiving placebo. Studies showing the 
benefit of therapy among persons with HIV/HCV coinfection are described in 
Section 7.2. 
PWID are excluded from most clinical trials; thus data on the benefits of treatment 
among them come from observational studies. A systematic review of treatment 
outcomes among PWID (both former and current users), of whom approximately 
half were concurrently injecting drugs, demonstrated an SVR of 56% (37% for 
genotypes 1/4 and 67% in genotypes 2/3), a treatment discontinuation rate 
of 22% and a high level of drug adherence. These outcomes were similar to 
those observed among non-drug users.164 In addition, economic modelling data 
evaluating the cost–effectiveness of treating HCV infection among PWID was 
considered by the Guidelines Development Group. In this group, treatment was 
considered to be cost–effective in a variety of settings. Additional benefits of 
treating PWID is that treatment for HCV infection may prevent transmission and 
reduce prevalence of HCV infection in this population.98,99
Rationale for the recommendation
Balance of benefits and harms: IFN-based therapy, whether using standard 
or PEG-IFN, increases the likelihood of SVR. Although the studies assessed 
were not able to show a survival or quality-of-life benefit from achieving SVR, 
other studies with longer periods of follow up have shown this link.165 There 
is evidence, primarily from observational studies, for the efficacy of treatment 
for HCV infection among PWID, including those who continue to inject drugs 
during treatment. Treatment for HCV infection is also effective among persons 
coinfected with HIV. 
The risk of adverse events from therapy for HCV infection is high, with many 
persons discontinuing therapy due to adverse reactions. The most significant 
risks are depression, increased risk of severe infection and anaemia. In addition, 
a flu-like syndrome occurs frequently among persons receiving IFN-based 
therapy. Additional harms that were considered were the financial burden placed 
on patients who are required to pay for the expensive and lengthy treatment. 
Despite this, in view of the substantial morbidity and mortality from untreated 
HCV infection, the Guidelines Development Group concluded that the benefits 
of treatment clearly outweighed the potential harms. The Group considered that 
the risk of harms would be reduced with the introduction of the new DAAs, 
which have shorter durations of therapy and more favourable safety profiles.  
Values and preferences: Many persons who are eligible for treatment are reluctant 
to be treated because of the fear of adverse events due to the medications, 
particularly PEG-IFN. This reluctance is likely to lessen with the introduction of 
medicines that are safer and easier to administer. 
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Resource considerations: The cost of treatment for HCV infection is high. 
A treatment regimen of PEG-IFN plus RBV costs between US$ 2 000 and 
US$ 28 000 per person.166 This wide range in prices reflects the success in 
some countries of negotiating with the manufacturers for price reductions. 
Treatment for HCV requires the clinical and laboratory infrastructure for follow 
up and monitoring on therapy; therefore, the feasibility of providing treatment 
is challenging. Several middle-income countries have successfully expanded 
treatment for HCV. Egypt provides the most impressive example where more 
than 300 000 persons living with HCV have been treated. Treatment is also 
delivered in several other low- and middle-income countries such as Brazil, 
China, India, and Pakistan. An economic analysis based on data from Egypt 
indicated that treating patients with more advanced disease (METAVIR F4) 
was considered more cost-effective than treating patients with less advanced 
fibrosis.100 Economic evaluations indicate that treatment for PWID is cost–
effective and may be more cost–effective in some scenarios than treating those 
with no ongoing risk of infection, because transmission of HCV infection may 
be averted. These model projections also show that scaling up treatment for 
HCV could be critical to reducing chronic HCV prevalence among PWID98,99 
(Chapter 8: Monitoring).
Research questions
Operational research is needed to assess different models of care. This could 
include evaluation of task shifting and integration of HCV treatment services 
with other clinical services such as those in TB or HIV clinics. Also, it would be 
important to evaluate ways of providing treatment services to groups that are 
marginalized such as PWID and who find standard clinical services difficult to 
access.  
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Pegylated interferon in combination with ribavirin is recommended for the treatment of 
chronic HCV infection rather than standard non-pegylated interferon with ribavirin.
Strong recommendation, moderate quality of evidence 
Note: In settings where access to treatment for HCV infection is limited, priority for treatment 
should be given to patients with advanced fibrosis and cirrhosis (METAVIR stages F3 and 
F4).
Background
All genotypes of HCV respond to and repetition with RBV and either standard 
IFN or PEG-IFN. PEG-IFN is the accepted standard of care in high-income 
countries because it has a longer half-life, resulting in the need for less frequent 
injections and because it results in higher SVR rates. Despite this, standard IFN 
continues to be used in some low- and middle-income countries because it is 
much less expensive than PEG-IFN. The Guidelines Development Group felt that 
it was important to analyse the evidence and provide a clear recommendation on 
which form of IFN was preferable. 
Evidence
A systematic review was conducted to assess the efficacy of PEG-IFN and RBV 
versus IFN and RBV in treatment-naive adults and children with chronic HCV 
infection. Outcomes assessed were SVR, decompensated liver disease, HCC, 
all-cause mortality, adverse events and quality of life. 
Twenty-five articles were included in the analysis, and evidence for the outcome of 
SVR from these studies was considered to be of high quality due to the precision 
and consistency of the results, and the low risk of bias. The available evidence 
indicated that the use of PEG-IFN and RBV is more effective at achieving SVR 
among people with chronic HCV compared with standard IFN and RBV (RR 0.81; 
95% CI 0.76, 0.86). The anticipated absolute effect estimates that 661 per 1 000 
persons treated with standard IFN would fail to reach SVR (which equates to an 
SVR of 33.9%) while 535 per 1 000 persons would fail to reach SVR with PEG-IFN 
(which equates to an SVR of 46.5%) (Appendix 3). Increased efficacy of PEG-IFN 
was observed in infection with genotype 1 and non-genotype 1, in persons with 
and without cirrhosis, and in treatment-naive and -experienced individuals.  
7.2 Treatment with pegylated interferon and ribavirin
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The studies found no difference in treatment discontinuation rates due to adverse 
events when comparing PEG-IFN versus standard IFN. The data on adverse 
events were evaluated as being of moderate quality and revealed no significant 
difference in the rate of study termination due to adverse events among patients 
administered PEG-IFN versus standard IFN. Limited data were available on 
some outcomes, including liver-related mortality, hepatic decompensation and 
HCC. From the data available, 14 fewer cases of HCC per 1 000 occurred with 
PEG-IFN (baseline 21 per 1 000), 3 fewer cases of hepatic decompensation 
(from 17 per 1 000) and 5 fewer cases of liver-related mortality (from 15 per 
1 000). One more patient per 1 000 terminated treatment due to adverse events 
(from 118 per 1 000).
Three studies have been carried out in persons with HIV/HCV coinfection.167-169 
The ACTG 5071, RIBAVIC and APRICOT studies compared standard IFN and 
RBV with PEG-IFN and RBV. In the APRICOT study, the SVR rate was significantly 
higher in those who received PEG-IFN and RBV than in those who received 
standard IFN and RBV, and reached 62% in genotype 2 or 3 infection but only 
29% in genotype 1 infection. In the RIBAVIC study, SVR rates were higher in 
the PEG-IFN and RBV arms (27% versus 20%) but lower than in APRICOT; 
this was likely to have been related to a very high treatment discontinuation rate 
(42%). In the ACTG 5071 study, overall, SVR rates for genoptypes 1 and non-1 
combined were 27% and 12%, respectively. Treatment discontinuation rates 
were also higher in the standard IFN arm. 
Rationale for the recommendation
Balance of benefits and harms: The Guidelines Development Group concluded 
that there is high-quality evidence that PEG-IFN and RBV are more effective 
than standard IFN and RBV. Furthermore, there was no difference in the rates 
of adverse events or longer-term outcomes. Therefore, the Group felt that the 
benefits of PEG-IFN versus standard IFN clearly outweighed the risks.
Values and preferences: The option was considered to be likely to be acceptable 
to patients as PEG-IFN is easier to administer. It requires less frequent injections 
than standard IFN and is associated with a substantially higher chance of SVR 
without an increase in side-effects. 
Resource considerations: The reason that standard IFN continues to be used in 
some countries is because it is less expensive than PEG-IFN. The principal barrier 
to more extensive use of PEG-IFN is its high cost. PEG-IFN is manufactured by 
a limited number of companies, and the cost of a 48-week regimen of PEG-IFN 
and RBV varies between US$ 2 000 in Egypt and US$ 28 000 in Viet Nam. 
Modelling has shown that treatment of patients with compensated cirrhosis 
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is cost–effective in this context.100 Feasibility is likely to vary substantially in 
different clinical settings. Treatment requires clinical infrastructure for follow up 
and monitoring on therapy but has been successfully rolled out in several low- 
and middle-income countries. In particular, Egypt has made treatment available 
to large numbers of patients.
Implementation
The recommended duration of treatment varies, depending on the genotype, stage 
of disease, coinfection with HIV and initial response to treatment. Furthermore, 
PEG-IFN is recommended only for children older than two years of age. Additional 
considerations regarding adjustment of duration of therapy based on genotype, 
and monitoring for side-effects and efficacy are discussed in Chapter 8. 
Duration of treatment for HCV
In persons with HCV monoinfection as well as those with HIV/HCV coinfection, 
PEG-IFN and RBV are recommended for 48 weeks in those with genotype 1 
infection (this can be extended to 72 weeks in those with a delayed virological 
response or shortened to 24 weeks in those with a rapid virological response). In 
persons with HCV monoinfection with genotypes 2 or 3, 24 weeks of treatment 
is recommended (unless the patient has cirrhosis or HIV coinfection, when 
treatment extension to 48 weeks may be considered). Treatment should be 
discontinued in persons who have failed to achieve at least a 2 log drop in 
HCV RNA below baseline by 12 weeks of therapy, since SVR is unlikely to be 
achieved.168
Research questions
There is a lack of research examining the safety and efficacy of PEG-IFN versus 
standard IFN in low- and middle-income countries and among persons with 
HIV/HCV coinfection who have genotypes 2 or 3 infection. Testing of different 
treatment delivery models, including decentralized models that may rely in 
part on community-based services, was also considered an important area for 
research by the Guidelines Development Group.
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7.3 Treatment with telaprevir or boceprevir
 
Treatment with telaprevir or boceprevir, given in combination with pegylated interferon 
and ribavirin, is suggested for genotype 1 chronic hepatitis C infection rather than 
pegylated interferon and ribavirin alone. 
Conditional recommendation, moderate quality of evidence 
Treatment regimens 
• Treatment duration of telaprevir/PEG-IFN/RBV for treatment-naive patients 
is 24–48 weeks depending on the response to treatment (telaprevir is given 
for 12 weeks only).
• Treatment duration of boceprevir/PEG-IFN/RBV in treatment-naive patients 
is 28–48 weeks depending on the response to treatment. 
• Treatment duration in previously treated patients varies by previous response 
to treatment. 
Background  
The PIs boceprevir and telaprevir, used in combination with PEG-IFN and 
RBV, have substantially increased SVR rates in persons with genotype 1 HCV 
infection.84,85,170 These PIs have limited activity against other genotypes and are 
therefore licensed for use only in persons infected with HCV genotype 1. The 
availability of newer DAAs for HCV will expand rapidly over the coming years and 
the treatment guidelines will be updated accordingly as these are licensed for 
use; these have a broader spectrum of activity and are likely to be suitable for 
non-genotype 1 infections. The use of PIs adds substantial costs to treatment 
regimens and increases the likelihood of adverse events and thus the need 
for frequent monitoring for side-effects. Current administration schedules are 
discussed in Chapter 8: Monitoring.  
Evidence
A systematic review of the DAAs telaprevir and boceprevir versus PEG-IFN/RBV 
alone for adults with chronic genotype 1 HCV infection provided high-quality 
evidence for the outcome of SVR; DAA/PEG-IFN/RBV would result in 315 
per 1 000 fewer virological failures compared with PEG-IFN/RBV given alone 
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(baseline failure rate 643 per 1 000). Triple therapy was found to be effective in 
persons with both mild and advanced liver fibrosis. 
The incidence of side-effects was higher in persons treated with triple therapy 
and there was moderate-quality evidence that the inclusion of a PI increased 
the treatment discontinuation rate from a baseline of 95 cases per 1 000 by 
17 additional cases per 1 000. In addition, there was high-quality evidence 
that a PI given with PEG-IFN and RBV was associated with 41 additional cases 
of grade 3 or 4 anaemia (Hb <8.5 g/dL) per 1 000 persons (baseline with 
IFN and RBV only: 22 cases of anaemia per 1 000 persons). Evidence of an 
increase in cases of grade 3 or 4 neutropenia was moderate and increased 
the risk from 174 cases per 1 000 by 106 additional cases per 1 000. Deaths 
occurred less frequently, however, in persons treated with a PI (from 6 deaths 
per 1000 to 3 deaths per 1 000). The CUPIC (Compassionate Use of Protease 
Inhibitors in Viral C Cirrhosis) study171 revealed a higher risk of side-effects 
in treatment-experienced persons with compensated cirrhosis. Among 497 
persons who completed at least 16 weeks of treatment with PEG-IFN/RBV and 
either telaprevir or boceprevir, 40% of patients developed a serious adverse 
event and 11.7% had to stop therapy. Those patients with a starting serum 
albumin level of <35 g/L or a platelet count ≤100 x109/L were at highest risk.172 
The use of DAAs has been inadequately studied in children as they were 
excluded from the phase III studies of boceprevir and telaprevir.84,85 Boceprevir 
and telaprevir are approved only for adults (>18 years of age).
Triple therapy with boceprevir or telaprevir and PEG-IFN/RBV is currently being 
tested in HIV-positive patients in phase III clinical trials. A major potential problem 
is that of drug–drug interactions (see Table 8.3). Both boceprevir and telaprevir 
are inhibitors of CYP3A4, which mediates many drug metabolic pathways and 
therefore any potential interaction must be carefully evaluated before commencing 
treatment.c Boceprevir has been been evaluated in HIV-positive individuals who 
were either not on ART or were treated with two nucleoside reverse transcriptase 
inhibitors (NRTI)s plus one of the following agents: efavirenz, raltegravir, lopinavir/
ritonavir, atazanavir/ritonavir or darunavir/ritonavir. Data from these studies has 
led to the FDA recommendation that efavirenz and PIs should not be used with 
boceprevir but that raltegravir can be co-prescribed. Telaprevir is currently in 
phase III trials in patients receiving a dual NRTI backbone plus one of efavirenz 
(telaprevir must be given in a higher dose), raltegravir or atazanavir/ritonavir. 
Further studies exploring the potential for drug–drug interactions between ART 
c. A useful resource for searching for drug–drug interactions can be found at the following website:  
http://www.hep-druginteractions.org.
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regimens and newer compounds under development for the treatment of HCV 
are eagerly awaited and phase III trials of simeprevir, faldaprevir, and the NS5A 
inhibitor daclatasvir are under way among persons with HIV infection. 
Rationale for the recommendation
Balance of benefits and harms: The consideration of the Guidelines Development 
Group was that the addition of telaprevir or boceprevir to a PEG-IFN and RBV-
based regimen provided the benefit of an increased likelihood of SVR. Persons 
treated with these DAAs had an estimated SVR almost twice that of persons 
receiving only PEG-IFN and RBV. However, these two DAAs also considerably 
increased the likelihood of harms, in particular, anaemia and neutropenia. 
The use of these medicines among persons with more advanced liver disease 
resulted in high rates of treatment discontinuation. Despite this, the Guidelines 
Development Group concluded that the benefit of increased SVR outweighed 
the increased risk of side-effects, and that triple therapy for genotype 1 HCV 
infection was preferable to dual therapy.
Values and preferences: The inclusion of a DAA to a PEG-IFN and RBV-based 
regimen was considered to be likely to be acceptable due to the substantially 
higher chance of SVR. The considerable risk of adverse events would be a 
deterrent to individuals, particularly as safer medicines are now available. No 
difficulties were anticipated in relation to unforeseen consequences or cultural 
contexts. Some difficulty in obtaining high-fat meals for cultural reasons, for 
example during Ramadan, was considered by the Group but it was thought likely 
that stakeholders would approve use in the context of medical illness.
Resource considerations: The resources required to treat patients with a PI in 
addition to PEG-IFN/RBV include treatment costs and the costs associated with 
increased frequency of laboratory and clinical monitoring. An important barrier 
to the use of boceprevir and telaprevir is their high cost (US$ 55 000 and US$ 
37 000, respectively, in the United Kingdom for a single course of treatment), 
in addition to the cost of PEG-IFN/RBV.95,96 Additional costs are related to the 
need for greater frequency of monitoring for and treatment of adverse events 
while using these medicines. In high-income settings, an assessment by the 
National Institute for Health and Clinical Excellence in the UK evaluated DAAs 
as being cost–effective.95,96 For patients with mild disease (METAVIR F0–F1), 
the incremental cost was considered to be small relative to the net benefit. For 
more advanced disease (F4), due to the increased risk of severe adverse events, 
this was considered to be less certain and would be likely to require increased 
monitoring, particularly for evidence of anaemia.
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Feasibility is variable in different infrastructure and health-care service settings. 
While DAA therapy is associated with a marked increase in SVR rate, it is also 
associated with an increase in the incidence of adverse reactions. Monitoring 
for these adverse reactions does not require different laboratory tests from 
those used to monitor IFN and RBV therapy, but does require more frequent 
clinic visits (primarily to assess rash) and laboratory tests (primarily to assess 
anaemia). Thus, policy-makers will need to consider the impact on the health 
system of these additional tests and visits.
Athough persons with more advanced disease have more side-effects and a 
lower chance of SVR, the potential benefits of achieving SVR are significantly 
higher. The availability of enhanced monitoring is likely to be highly context-
specific in low- and middle-income countries. In countries that can afford triple 
therapy, it was considered by the Group that it should be feasible to also fund 
appropriate monitoring.
Implementation 
First-generation triple therapy should be given in centres where appropriate 
clinical and laboratory monitoring can be carried out and where experienced 
clinicians are available for advice. The availability and cost of first-generation 
DAAs varies in different countries and is likely to affect the feasibility of roll-
out, especially in low-income settings. The duration of therapy is dependent on 
treatment response and previous response to antiviral therapy (see Section 8.2).
HCV/HIV-coinfected persons treated with PEG-IFN/RBV and a first-generation 
PI who require HIV therapy should be treated with compatible ART (Table 8.3). 
They require regular monitoring of CD4 counts during treatment.173
Research questions
Data on the use of first-generation DAAs in children is an important area for future 
research. Improvements in virological response may lead to improvements in 
liver-related morbidity and mortality. However, there are no direct data available 
from studies to make definite conclusions about longer-term outcomes. Data are 
also missing on the use of these medicines in low- and middle-income countries. 
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7.4 Introduction to recommendations concerning 
sofosbuvir and simeprevir
A number of new medicines to treat HCV infection are in various stages of 
development. Treatment duration with these medicines is shorter (12–24 weeks) 
and is associated with fewer side-effects. Some can be administered without 
IFN and, in some clinical trials, have shown SVR rates of more than 90%. On 
22 November 2013, the FDA approved simeprevir and on 5 December 2013, 
it approved sofosbuvir. On 16 January 2014, the European Medicines Agency 
approved sofosbuvir for use in the European Union. 
7.5 Treatment with sofosbuvir
Sofosbuvir, given in combination with ribavirin with or without pegylated interferon 
(depending on the HCV genotype), is recommended in genotypes 1, 2, 3 and 4 HCV 
infection rather than pegylated interferon and ribavirin alone (or no treatment for 
persons who cannot tolerate interferon).
Strong recommendation, high quality of evidence. This recommendation was made 
without taking resource use into consideration, as pricing information was not available 
for any country other than the United States at the time this recommendation was 
formulated.
Treatment regimens 
• For infection with HCV genotypes 1 and 4, sofosbuvir/RBV/PEG-IFN may be 
given for 12 weeks.
• In persons with genotype 1 infection who are IFN intolerant, sofosbuvir/RBV 
may be given for 24 weeks, but this regimen will result in substantially lower 
SVR rates than a PEG-IFN-containing regimen.
• For infection with HCV genotype 2, sofosbuvir/RBV may be given for 12 
weeks.
• For infection with HCV genotype 3, sofosbuvir/RBV may be given for 24 
weeks or PEG-IFN/RBV/sofosbuvir may be given for 12 weeks.
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Background  
Sofosbuvir is an HCV viral polymerase nucleotide inhibitor. When used in 
combination with RBV alone or RBV in combination with PEG-IFN, it is 
associated with high SVR rates in persons infected with HCV genotypes 1, 2, 3 
and 4. At present, treatment with sofosbuvir and RBV is the only all-oral IFN-
free treatment available for HCV infection. Eventually, this medicine, whether 
combined with RBV or other DAAs, may greatly facilitate treatment for HCV and 
its use may be expanded to health facilities with less sophisticated infrastructure. 
This medicine is approved for use in North America and Europe, and according 
to its manufacturer (Gilead Sciences), the wholesale price in the US for a single 
12-week regimen is US$ 84 000, which equates to US$ 1 000 per pill. 
Evidence
Evidence was considered for trials of sofosbuvir given either with RBV or with 
RBV/PEG-IFN for infection with HCV genotypes 1, 2, 3 and 4. Only limited data 
were available for efficacy in persons infected with HCV genotypes 5 or 6. 
Data from two studies were reviewed to assess the benefit of 12 weeks of 
sofosbuvir/PEG-IFN/RBV for treatment-naive persons infected with genotypes 1 
and 4.89,174 Neither study included patients who were treated only with PEG-IFN/
RBV (one was a single-arm study and the other compared sofosbuvir/PEG-IFN/
RBV to placebo). To assess the treatment benefit of sofosbuvir, a conservative 
comparator SVR estimate of 65% for PEG-IFN/RBV was assumed.86 Despite the 
lack of a direct comparator arm, the quality of evidence for achieving an SVR was 
considered to be high because of a very large effect size and evidence of a clear 
dose–response effect (Appendix 4). The combined SVR rate among persons 
treated with sofosbuvir/PEG-IFN/RBV was 90.3%, and persons receiving this 
regimen had 253 fewer failures at achieving SVR per 1 000 persons treated than 
did persons treated with PEG-IFN/RBV. Based on one placebo-controlled trial, the 
risk of sofosbuvir-associated adverse events leading to treatment discontinuation 
was estimated to be similar to that among placebo recipients (quality of evidence 
downgraded to moderate due to imprecision). 
No data were available regarding the use of sofosbuvir-based regimens among 
persons with genotype 1 infection who had been previously treated with PEG-
IFN/RBV. 
An assessment was made of the oral IFN-free regimen sofosbuvir and RBV given for 
24 weeks in genotype 1 infection in treatment-naive persons versus no treatment 
(assuming IFN intolerance or contraindication).87 As above, the quality of evidence 
for efficacy for achieving SVR was considered to be of high quality despite the lack 
of a direct comparator arm in the studies considered because of a very large effect 
size and evidence of a clear dose–response effect. The use of RBV/sofosbuvir 
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therapy was associated with 745 fewer SVR failures per 1 000 people treated as, in 
the single placebo-controlled study where this was evaluated, all patients with HCV 
infection in the placebo group failed to achieve an SVR. Despite the lack of direct 
comparisons between the two regimens, 12 weeks of sofosbuvir with PEG-IFN and 
RBV results in higher SVR rates than 24 weeks without PEG/IFN.
For persons with genotype 2 infection, the use of 12 weeks of sofosbuvir/
RBV versus no treatment was assessed for treatment-naive and -experienced 
persons. Five single-arm cohorts were considered,87,88,89,175,176 and 918 fewer 
SVR failures per 1 000 persons treated (which corresponds to an SVR of 91.8%) 
was estimated versus 1 000 failures per 1 000 untreated individuals (high quality 
of evidence, as above).  
Four studies were considered in which treatment-naive or -experienced persons 
with genotype 3 infection were treated with 12 weeks of sofosbuvir/RBV.87-89,176 
An estimated 487 fewer SVR failures per 1 000 were predicted in those treated 
for 12 weeks but heterogeneity was present due to much lower SVR rates in 
treatment-experienced patients. In contrast, prolonging treatment to 24 weeks for 
this group resulted in an estimated 850 fewer SVR failures in those treated with 
24 weeks of sofosbuvir/RBV (high quality of evidence). The use of PEG-IFN/RBV/
sofosbuvir for 12 weeks versus RBV/sofosbuvir for 24 weeks was predicted to 
result in 233 fewer SVR failures per 1 000 but 16 more adverse events per 1 000 
(very low quality of evidence due to imprecision and indirect comparisons). This 
analysis included one study with a high prevalence of cirrhosis in the patients.177 
Rationale for the recommendation
Balance of benefits and harms: The Guidelines Development Group concluded 
that the benefits of using sofosbuvir far outweighed the risks. The efficacy of 
sofosbuvir either with RBV alone or RBV and PEG-IFN resulted in much higher 
SVR rates and a low rate of sofosbuvir-associated adverse events. Persons 
infected with HCV genotypes 1 and 2 could benefit from a shorter duration 
of PEG-IFN, and those infected with HCV genotypes 2 and 3 could avoid the 
difficulties and toxicities associated with PEG-IFN altogether. No significant 
adverse events were identified in the clinical trials. The Group noted that these 
results are based on a small number of studies with relatively few participants 
(a total of approximately 3 000 persons have received sofosbuvir in the various 
phases 2 and 3 registration trials of sofosbuvir). Although the data were obtained 
from trials conducted in North America and Europe, they did include some 
persons of Asian or African origin. No differences in treatment response or safety 
profile were noted in these persons. The Group also noted that these studies do 
not include several important subgroups, in particular, treatment-experienced 
patients with genotype 1 HCV infection and very little data are available for 
patients with HCV genotype 5 and 6.
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Values and preferences: The Group felt that sofosbuvir would be acceptable 
to patients because of the higher expected SVR rate and the convenience of a 
shorter treatment course. Patients with genotype 2 or 3 infection would also benefit 
from an oral-only regimen with few side-effects. For patients with genotype 1 or 
4 infections, however, the acceptability may be lowered by the fact that sofosbuvir 
must be administered with RBV and PEG-IFN, thereby exposing patients to the 
inconvenience of IFN injections and the toxicity of these two medicines.
Resource considerations: At the time of the meeting of the Guidelines Development 
Group, pricing information for sofosbuvir was available only from the US where the 
price for a single 12-week regimen is US$ 84 000. Clearly, the current high price of 
the medicine will be a significant barrier to its use in all countries. The manufacturer 
has stated that it “is developing a hepatitis C treatment access programme, focusing 
on those countries with the greatest HCV burden”. However, few details are yet 
available.178 Thus, policy-makers might be reluctant to approve the use of the 
medicine in their country in view of its high price.
For the medicine to be used in other countries, it must be registered with the 
national drug regulatory agency. This process can take 1–2 years. It will be 
important for national and international agencies, civil society organizations and 
pharmaceutical companies to work together to assure rapid approval of this 
medicine and that it is available at an affordable price.  
Implementation
The Guidelines Development Group felt that implementation strategies would 
be similar for treatment programmes using sofosbuvir in addition to PEG-IFN/
RBV treatment regimens as compared with those using PEG-IFN/RBV alone. 
RBV/sofosbuvir regimens would probably be easier to implement because the 
complexities of administering IFN could be avoided in infection with some 
genotypes, the course of treatment is shorter than PEG-IFN/RBV regimens for all 
genotypes, and monitoring for adverse reactions would be less complex. 
Research questions 
Evaluation of sofosbuvir in patients who had prior IFN-treatment failure is lacking. 
The efficacy of sofosbuvir in patients with low levels of adherence requires 
evaluation In addition, the efficacy of sofosbuvir in patients with genotype 5 and 
6 needs further study. 
In February 2014, Gilead Sciences announced that it would license sofosbuvir to four generics manufacturers 
for sale in 60 low-income countries. In March 2014, the manufacturer announced that in Egypt it would market 
sofosbuvir for US$900 for a 12-week regimen.
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7.6 Treatment with simeprevir
Treatment regimens
• Simprevir in combination with PEG-IFN/RBV is given for 12 weeks followed by 
an additional 12 weeks of PEG-INF/RBV for a total of 24 weeks treatment for 
all treatment-naive and prior relapsed patients (including those with cirrhosis). 
• Prior non-responder patients (including partial or null-responders) should undergo 
an additional 36 weeks of PEG-INF/RBV for a total of 48 weeks of treatment. 
• HCV RNA should be monitored and treatment discontinued if it is >25 IU/
mL at weeks 4, 12 or 24. 
Background
The simeprevir is associated with high SVR rates when given in combination with 
PEG-IFN/RBV for treatment-naive and -experienced patients with HCV genotype 1 
infection. For the time being, the medicine is approved for use only in the US and 
Canada, according to its manufacturer (Janssen Pharmaceuticals), the wholesale 
price in the US for a single 12-week regimen is US$ 66 000.
Evidence
Data were considered from four RCTs comparing simeprevir/RBV/PEG-IFN with 
PEG-IFN/RBV in persons with chronic HCV infection.86,179-181 The combined 
SVR rate for patients treated with simeprevir/RBV/PEG-IFN was 79.2%, and for 
patients treated with PEG-IFN/RBV it was 45.6% (Appendix 4). This difference 
would result in 332 fewer SVR failures per 1 000 persons treated (high quality 
of evidence) and two more serious adverse events per 1 000 persons treated 
(moderate quality of evidence due to imprecision). Persons with genotype 1a 
infection with the Q80K mutation (approximately 30% of patients in the included 
studies) were found to have SVR rates similar to those who received PEG-IFN 
Simeprevir, given in combination with pegylated interferon and ribavirin, is recommended 
for persons with HCV genotype 1b infection and for persons with HCV genotype 1a infection 
without the Q80K polymorphism rather than pegylated interferon and ribavirin alone. 
Strong recommendation, high quality of evidence. This recommendation was made without 
taking resource use into consideration, as pricing information was not available for any 
country other than the United States at the time this recommendation was formulated.
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and RBV only. And therefore simeprevir is not recommended for persons infected 
with genotype 1a infection in which the Q80K mutation has been detected. The 
analysis did not include persons infected with HIV but one single-arm study was 
available and showed an SVR rate of 74%, similar to that reported in RCTs in 
HIV-negative individuals.182
Rationale for the recommendation
Balance of benefits and harms: The Guidelines Development Group concluded 
that the benefits of simeprevir were considerable in view of the shorter duration 
of therapy, the much higher SVR, and the low rate of side-effects. The Group 
considered that the total number of patients treated with this medicine is small, 
and that the trials were conducted primarily in Europe and North America. These 
trials did include persons of Asian and African origin who responded similarly 
to other persons. Taking into consideration all of these factors (the high SVR 
rate, shorter duration of treatment and favourable safety profile), the Guidelines 
Development Group felt that the benefits clearly outweighed the risks.  
Values and preferences: It was felt that this medicine would be acceptable to patients 
because of the shorter duration of therapy and the expectation of a higher SVR. 
However, the acceptability may be lowered by the fact that it must be administered 
with RBV and PEG-IFN, thereby exposing patients to the inconvenience of IFN 
injections and the toxicity of these two medicines. Simeprevir sometimes causes 
photosensitivity, and the resulting rash may also reduce acceptability. 
Resource considerations: At the time of the meeting of the Guidelines Development 
Group, simeprevir was approved for use only in North America where the wholesale 
price for a single treatment costs approximately US$ 66 000. The anticipated high 
cost of simeprevir in other countries is likely to be a significant barrier to its use. 
Policy-makers might be reluctant to introduce simeprevir into national treatment 
programmes in view of its high price.
Implementation 
Although simeprevir results in high SVR rates, the fact that it is administered with 
PEG-IFN and RBV means that frequent monitoring for side-effects is necessary. 
Also, since the Q80K mutation reduces the efficacy of simeprevir, patients must 
be tested for the presence of this mutation prior to treatment. The availability of 
this test may be limited in many countries. 
Research questions
Combinations of different DAAs not requiring the use of PEG-IFN are being 
tested in clinical trials. The use of simeprevir in genotype 4 infection also requires 
further evaluation.
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8. CLINICAL CONSIDERATIONS
A number of clinical considerations are important for the management of 
persons with chronic HCV infection. Some of these have been included in the 
Recommendations discussed in Chapter 7. Because of the complexity of the 
questions involved, the Guidelines Development Group did not formally assess 
a number of additional considerations. Rather, existing recommendations, 
guidelines and package insert guidance were reviewed and discussed. These are 
presented here to assist policy-makers and medical professionals in considering 
the essential components of a treatment service for HCV infection. A typical 
patient treatment pathway is shown in Figure 8.1.
FIGURE 8.1  Patient treatment pathway
APRI aminotransferase/platelet ratio index; HBV hepatitis B virus; HCC hepatocellular carcinoma; HCV hepatitis C 
virus; IFN interferon; OST opioid substitution therapy; TE transient elastography
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Genotype testing
In most countries, there is a mix of HCV genotypes among persons with chronic 
HCV infection (see Figure 2.1). Certain medicines for treating HCV (e.g. boceprevir, 
telaprevir and simeprevir) are active only against specific genotypes, while the 
duration of treatment with other medicines needs to be adjusted based on the 
genotype. Therefore, knowing a patient’s genotype is important to determine the 
most appropriate treatment regimen. Genotyping is usually carried out following 
sequencing of the 5’UTR (untranslated region) or of the NS5b region of the HCV 
genome. Genotype determination, however, is expensive and not available in all 
settings. Where genotype information is unavailable, pragmatic decision-making 
may be required, taking into account the common genotypes circulating in the 
affected population. This advice would only be practicable in countries such as 
Egypt, where almost all persons are infected with a single genotype.
Q80K mutation testing
A reduction in the efficacy of treatment with simeprevir was observed in persons 
with genotype 1a hepatitis C virus where the NS3 Q80K polymorphism was 
present. The simeprevir drug label therefore includes a recommendation to 
screen for the presence of this strain prior to beginning therapy and to consider 
alternative therapy if the Q80K strain is detected. This test is expensive and is 
not widely available in low- and middle-income countries.
IL28B testing
A number of polymorphisms within the IFN (IL28B) gene have been associated 
with the likelihood of response to treatment. Favourable genotypes include the 
CC genotype at rs12979860, TT at rs8099917 and AA at rs12980275.183,184 
These polymorphisms of the IL28B gene are strongly associated with race/
ethnicity. Favourable genotypes are more likely to be found in some East Asian 
and white populations.
 Implementing treatment programmes for HCV infection in resource-limited 
settings does not require the use of prognostic marker tests (e.g. IL28B testing) 
for predicting treatment response; when available, they are prognostically 
useful but the absence of availability of these tests should not delay initiation of 
treatment programmes.
Contraindications to treatment
Treatment for hepatitis C is contraindicated in persons with a number of 
conditions. Table 8.1 lists these conditions, which are based on the guidelines of 
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the American Association for the Study of Liver Diseases (AASLD) and European 
Association for the Study of the Liver (EASL). Treatment of persons who have 
decompensated cirrhosis (Child–Pugh B or above) with IFN or PEG-IFN is 
risky, as such persons can develop life-threatening infections and accelerated 
decompensation leading to death. Pregnant women should not receive RBV 
as it causes fetal malformations. Because of this risk, sexually active women 
of childbearing age and their male partners are counselled to use double 
contraception (including condoms with spermicide) during and for six months 
after therapy. Many persons treated with IFN will develop depression; in those with 
pre-existing depression, it can become more severe. There are reports of suicide 
among persons receiving IFN therapy and therefore careful patient selection is 
required in persons with depression. 
TABLE 8.1  Contraindications to PEG-IFN/RBV therapy
Absolute contraindications
• Uncontrolled depression or psychosis
• Uncontrolled epilepsy
• Uncontrolled autoimmune disease
• Decompensated cirrhosis (Child–Pugh ≥B7 or B6 in HCV/HIV coinfection)
• Pregnancy or unwillingness to use contraception
• Breastfeeding women
• Severe concurrent medical disease including severe infections
• Poorly controlled hypertension
• Poorly controlled cardiac failure
• Poorly controlled diabetes
• Solid organ transplant (except liver transplant recipients)
• Chronic obstructive pulmonary disease
• Age less than 2 years
• Hypersensitivity to drugs used to treat HCV
Relative contraindications
• Abnormal haematological indices:
 - Hb <13 g/dL in men or <12 g/dL in women
 - Neutrophil count <1.5x109/L
 - Platelet count <90x109/L
• Serum creatinine >1.5 mg/dL
• Haemoglobinopathies (sickle cell disease or thalassaemia)
• Significant coronary artery disease
• Untreated thyroid disease
Source: Based on guidelines of the American Association for the Study of Liver Diseases (AASLD) and the European Association for the 
Study of Liver Disease (EASL)
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Absolute contraindications
• Uncontrolled depression or psychosis
• Uncontrolled epilepsy
• Uncontrolled autoimmune disease
• Decompensated cirrhosis (Child–Pugh ≥B7 or B6 in HCV/HIV coinfection)
• Pregnancy or unwillingness to use contraception
• Breastfeeding women
• Severe concurrent medical disease including severe infections
• Poorly controlled hypertension
• Poorly controlled cardiac failure
• Poorly controlled diabetes
• Solid organ transplant (except liver transplant recipients)
• Chronic obstructive pulmonary disease
• Age less than 2 years
• Hypersensitivity to drugs used to treat HCV
Relative contraindications
• Abnormal haematological indices:
 - Hb <13 g/dL in men or <12 g/dL in women
 - Neutrophil count <1.5x109/L
 - Platelet count <90x109/L
• Serum creatinine >1.5 mg/dL
• Haemoglobinopathies (sickle cell disease or thalassaemia)
• Significant coronary artery disease
• Untreated thyroid disease
Monitoring for adverse reactions and treatment 
response
Monitoring of persons on treatment for HCV is required in order to prevent 
and manage toxicity, and to assess the efficacy of treatment. The application 
of stopping rules when a patient is unlikely to respond to therapy allows the 
cessation of potentially toxic and expensive therapy. Side-effects range from 
mild to life threatening, and are detected by laboratory monitoring and on 
clinical review. Contraindications to therapy are shown in Table 8.1. A technical 
report on monitoring during treatment was carried out as part of the guidelines 
development process (Appendix 5). A summary of recommended sampling time 
points for monitoring is shown in Table 8.2.
TABLE 8.2  Monitoring time points recommended by the American Association for the Study 
of Liver Diseases (AASLD) and the European Association for the Study of Liver 
Disease (EASL) and drug-registration literature
a Time points recommended in EASL but not AASLD guidelines. Additional monitoring is required 1–2 weekly in patients with moderate-to-
severe anaemia, thrombocytopenia or neutropenia. 
b EOT at 12 weeks is applicable only for patients treated with sofosbuvir.
c EOT: end of treatment depending on genotype, response to treatment, presence of cirrhosis or HIV coinfection
d Sofosbuvir EOT at 48 weeks may be considered in patients with cirrhosis awaiting liver transplant
ALT alanine aminotransferase; BOC boceprevir; FBC full blood count; IFN interferon; RBV ribavirin; TEL telaprevir; SMV simeprevir; SOF 
sofosbuvir; EOT end of treatment
TOXICITY
Time FBC, 
creatinine, 
ALT
Thyroid  
function
Adherence, 
side effects
 Week 0 X X X
 Week 1a X X
 Week 2a X X
 Week 4 X X
 Week 8 X X
 Week12 EOTb X X X
 Week24 EOTc X X X
 Week 36 X X X
 Week48 EOTd X X X
 Week 12 after EOT X X
 Week 24 after EOT X X
EFFICACY
IFN/
RBV
IFN/
RBV 
TEL
IFN/
RBV 
BOC
IFN/
RBV 
SMV
IFN/
RBV 
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X X X X X
X X X X X
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X X
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X X X X X
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8.1 Monitoring for toxicity
The side-effect profile of IFN (and PEG-IFN) includes depression, fatigue, flu-
like symptoms, neutropenia, thrombocytopenia, anaemia, thyroid imbalance 
(hyper- or hypothyroidism), lowered absolute CD4+ T cell count in HIV-positive 
persons, alopecia, arthralgia, anorexia, pneumonitis, and ophthalmological 
disorders including retinopathy, retinal haemorrhages, cotton wool spots, 
papilloedema, optic neuropathy and retinal artery or vein obstruction (an eye 
examination is recommended prior to starting IFN therapy). There may also 
be marked interactions with other medications in patients with co-morbidity. 
RBV can cause haemolytic anaemia and is teratogenic. The addition of the 
PIs boceprevir or telaprevir for genotype 1 infection substantially increases the 
efficacy of treatment but also increases the likelihood of side-effects. Telaprevir 
may cause skin reactions, which range from mild to severe, as well as anal 
discomfort and itching. Boceprevir is associated with dysgeusia (an altered 
sense of taste) and may also occasionally be associated with rash. Simeprevir 
is associated with photosensitivity. In addition, an increased incidence of 
neutropenia, anaemia and thrombocytopenia has been observed in patients 
receiving triple (with boceprevir or telaprevir) rather than dual therapy. Persons 
with cirrhosis are at high risk of serious adverse events (40–57%), particularly 
anaemia and infection.171,172 Monitoring during treatment with IFN and RBV with 
or without PI therapy is therefore recommended at multiple time points (Table 
8.2). Monitoring at additional time points is required for persons with evidence 
of side-effects and in persons at highest risk (for example, persons with cirrhosis 
and HIV coinfection, and those on PI therapy). Additional monitoring of liver 
function is recommended in persons with cirrhosis, including albumin, bilirubin 
and coagulation (international normalized ratio [INR]). Patients with evidence 
of neutropenia, thrombocytopenia and anaemia require 1–2-weekly monitoring.
HCV/HIV coinfection
In persons with HCV/HIV coinfection, IFN-based treatment is associated with 
a reversible CD4 decline (average 140 cells/mm3) and a high rate of treatment 
discontinuation due to side-effects (25% of patients in the APRICOT study).169 
A serious concern was that liver failure occurred and was fatal in 6/14 patients. 
This was associated with cirrhosis with Child–Pugh scores of 5 or more at 
baseline and didanosine (ddI)-containing regimens.185 For this reason, ddI and 
stavudine (d4T) are contraindicated in patients receiving IFN/RBV therapy. More 
recent studies have shown fewer side-effects as such combinations are now 
avoided. Depression rates as high as 40% have been recorded when treating 
patients coinfected with HIV and HCV with IFN therapy. There are also reports of 
marked weight loss.186 Severe anaemia, thrombocytopenia and neutropenia are 
important dose-limiting factors when treating coinfected patients.  
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Persons coinfected with HCV/HIV treated with PEG-IFN/RBV with or without 
a PI or sofosbuvir who require treatment for HIV should receive compatible 
ART (Table 8.3).177 It is recommended that treating practitioners check 
potential interactions online as these are frequently updated (http://www.hep-
druginteractions.org). 
TABLE 8.3  Drug–drug interactions in HIV and HCV treatment 
Source: adapted from http://www.hep-druginteractions.org
HIV NRTIs Boceprevir Telaprevir Peg-IFN alfa Ribavirin
Abacavir
Didanosine
Emitricitabine
Stavudine
Zidovudine
HIV Protease Inhibitors Boceprevir Telaprevir Peg-IFN alfa Ribavirin
Atazanavir
Darunavir
Fosamprenavir
Indinavir
Lopinavir
Nelfinavir
Ritonavir
Saquinavir
Tipranavir
HIV NNRTIs Boceprevir Telaprevir Peg-IFN alfa Ribavirin
Delavirdine
Efavirenz
Etravirine
Nevirapine
Rilpivirine
HIV Entry/Integrase Boceprevir Telaprevir Peg-IFN alfa Ribavirin
Elvitegravir/cobicistat
Maraviroc
Raltegravir
No clinically significant interaction expected
No clinically significant interaction predictedPotential interaction
These drugs should not be co-administered
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TABLE 8.4  Dose modifications recommended in the product literature for pegylated interferon 
and ribavirin 
Liver cirrhosis
The CUPIC study171,172 found a very high risk of side-effects in treatment-
experienced patients with compensated cirrhosis treated with PEG-IFN, RBV 
and either boceprevir or telaprevir. Among patients who received at least 16 
weeks of treatment, 40% of patients developed a serious adverse event and 
11.7% had to cease therapy. Six patients died; five from severe infection and one 
from oesophageal variceal haemorrhage. Hepatic decompensation occurred in 
2.4% of patients (manifesting as ascites, encephalopathy or variceal bleeding).
 
8.2 Dose modification 
Recommendations for dose modification based on abnormal haematological 
parameters are summarized below and in Table 8.4, based on the relevant 
product literature.187,188
Reduce IFN dose Discontinue IFN 
Neutrophil count At <0.75 cells x109/L reduce to 135 μg 
PEG-IFNα2a. 
At <0.75 cells x109/L PEG-IFNα2b 
should be reduced in increments of 0.5 
μg/kg/week, e.g. from 1.5 μg/kg/week to 
1 μg/kg/week and then if required to 0.5 
μg/kg/week.
At <0.5 cells x109/L PEG-
IFNα2a treatment should be 
suspended until neutrophils 
reach >1.0 cells x109/L 
Reinstitute at a dose of 90 μg 
and monitor.
At <0.5 cells x109/L PEG-
IFNα2b should be permanently 
discontinued.
Platelets 25–50 cells x109/L reduce dose of IFN to 
90 μg or reduce PEG-IFNα2b as above.
<25 cells x109/L discontinue 
PEG-IFNα2a and PEG-IFNα2b. 
Haemoglobin When Hb <10 g/dL reduce RBV to 600 
mg/day when given with PEG-IFNα2a. 
When Hb <10 g/dL, the starting dose of 
RBV should be reduced sequentially by 
200 mg when given with PEG-IFNα2b 
(unless starting dose is 1 400 mg when 
reduction should be to 1 000 mg).
Discontinue PEG-IFN 
permanently if Hb is <8.5 g/dL.
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Dose adjustment of ribavirin
Anaemia is a common side-effect of RBV therapy and dose adjustment is often 
required. Patients whose haemoglobin (Hb) level falls below 10 g/dL should have 
their RBV dose reduced. A patient whose Hb level falls below 8.5 g/dL should 
discontinue therapy. For patients with a history of stable cardiovascular disease, 
RBV dose reduction is required if the Hb decreases by ≥2 g/dL during any 
4-week period. In addition, for these patients, if the Hb remains <12 g/dL after 4 
weeks on a reduced dose, the patient should discontinue combination therapy.
The dose of RBV in patients with renal failure must also be adjusted; patients 
with creatinine clearance <50 mL/min should not be treated with RBV and those 
on dialysis must have the dose lowered to 200 mg per day or take it three times 
per week. Increased monitoring is required in this group.
Dose adjustment of interferon
Discontinuation of PEG-IFNα2b is recommended if the Hb is <8.5 g/dL (or <12 
g/dL after 4 weeks of dose reduction in patients with cardiac failure), total white 
blood cell count <1.0 x 109/L, neutrophil count <0.5 x 109/L, platelet count <25 
x 109/L in patients with genotype 1 infection or <50 x 109/L in those with non-
genotype 1 infection, bilirubin (direct) 2.5 x upper limit of normal, total bilirubin 
(>4 mg/dL for >4 weeks), creatinine >2.0 mg/dL or ALT/AST 2 x baseline and 
>10 x upper limit of normal.
Discontinuation of PEG-IFNα2a is recommended if the platelet count is <25 x 
109/L, Hb <8.5 g/L or the Hb is <12 g/dL despite 4 weeks of dose adjustment in 
patients with cardiac failure.
In patients with end-stage renal disease (creatinine clearance 20–40 mL/min), a 
starting dose of PEG-IFNα2a of 135 μg once a week should be used. 
8.3 Monitoring for efficacy
Stopping rules and recommended duration of treatment depends on the stage 
of disease (cirrhosis versus mild-to-moderate disease), previous treatment 
failure response (null response, partial response or relapse), genotype and on 
the results of HCV viral load testing while on treatment (Figure 8.2). Treatment 
recommendations on stopping rules and monitoring for efficacy are illustrated 
further in Appendix 5 for persons with genotype 1 infection receiving PEG-IFN/
RBV and either boceprevir or telaprevir. Longer treatment regimens may be given 
in slow virological responders and persons with HIV or cirrhosis. For example, in 
the PRESCO study, higher weight-based dosing of RBV was used and treatment 
duration was extended from 48 to 72 weeks. This improved the SVR rate in 
genotype 1-infected HIV-positive persons (53% versus 31%).189 Premature 
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treatment discontinuation was common, however, and occurred in 45% in the 
prolonged treatment arm (2.6% due to severe anaemia). Extension of treatment 
duration from 24 to 48 weeks in genotype 2/3 infection also resulted in a higher 
SVR rate (82% versus 67%).
 
FIGURE 8.2A  Duration of pegylated interferon and ribavirin therapy for infection with HCV 
genotypes 1 and 4 
FIGURE 8.2B  Duration of pegylated interferon and ribavirin therapy for genotypes 2, 3, 5 and 6 
PEG-IFN and RBV used in combination to treat genotypes 1 and 4 chronic HCV infection may be given for varying durations depending 
on treatment response. If the viral load drops less than 2 log at 12 weeks or is detectable at 24 weeks of therapy, treatment should be 
stopped. An extended rapid virological response (eRVR) is associated with a high likelihood of SVR and therefore a reduced treatment 
duration of 24 weeks can be considered if the baseline viral load is <400 000–800 000 IU/mL. Conversely, if patients have a slow virological 
response with a detectable viral load at 12 weeks of treatment (and a ≥2 log drop) with a negative viral load at week 24 (delayed virological 
response; DVR), a prolonged 72-week course of therapy can be considered.
Pegylated IFN and RBV used in combination to treat chronic HCV infection with genotypes 2, 3, 5 and 6 may be given for varying durations 
depending on treatment response. If the viral load drops by less than 2 log at 12 weeks or is detectable at 24 weeks of therapy, treatment 
should be stopped. An extended rapid virological response (eRVR) is associated with a high likelihood of SVR and therefore a reduced 
treatment duration of 24 weeks can be considered. Conversely, if patients have a slow virological response with a detectable viral load at 
12 weeks of treatment (and a ≥2 log drop) with a negative viral load at week 24 (delayed virological response; DVR), a prolonged 48-week 
course of therapy can be considered.
a. A shortened course of 12–16 weeks of therapy may be considered in patients with HCV genotypes 2 and 3 and an RVR (there is a slight 
reduction in final SVR rates).
Viral load End of treatment (if baseline Viral load  
<400 000-800 000 IU/ml)
PEG-INF/RBV
Negative Negative
Week 0 24124
Viral load End of 
treatment
Positive Negative
Negative or  
STOP treatment
Week 0 24124
Viral load
Positive
≥2log drop or  
STOP treatment
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Week 0 24124 48 72
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treatment
Viral load End of treatment
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Week 0 24124
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Week 0 24124
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STOP treatment
Negative or  
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9. SPECIAL CONSIDERATIONS FOR 
SPECIFIC POPULATIONS
Specialist care needs to address the additional needs of special populations of 
patients, including PWID, persons coinfected with (or at risk for infection with) 
HIV, children and adolescents, and those with cirrhosis. 
9.1 People who inject drugs
Injecting drug use is prevalent in many countries around the world, affecting 
people in low-, middle- and high-income countries. Approximately 67% of PWID 
are infected with HCV; 10 million of 16 million people in 148 countries.6 PWID are 
at increased risk of HCV-related disease and all-cause morbidity and mortality, 
and therefore require specialized care.38 Related guidance is summarized below, 
and in section 2.4 and Figure 8.1. When caring for PWID, the central tenets of 
respect and non-discrimination should be followed, and additional adherence 
and psychological support given as required. 
Screening 
As an integral component of a comprehensive package of harm reduction 
interventions, WHO recommends targeted HCV screening of PWID as a 
population with a high prevalence of infection. Repeated screening is required 
in individuals at ongoing risk, and the possibility of reinfection after spontaneous 
clearance or successful treatment should also be considered. Those who have 
been previously infected should be retested using RNA testing, as the antibody 
remains positive after the first infection. HCV case-finding and treatment in 
specialist drug dependency services has also been shown to be cost–effective 
in high-income settings. The higher the treatment rates, the more cost-effective 
HCV case-finding becomes, as more of those identified will be treated, and a 
greater population impact could be seen.97 Screening for HBV and HIV is also 
recommended in PWID.
Care 
Treatment of HCV in PWID requires integration of services, as other health-care 
needs are often also present. Dependency on opiates or other substances may be 
present and alcohol excess is also a common problem in PWID. Harm reduction 
strategies are required in order to prevent acquisition of other bloodborne viruses 
such as HBV and HIV. At all times, avoidance of discrimination or stigmatization 
of PWID is essential. Care should be given only with informed consent.
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Drug dependency services may be required for the provision of opioid substitution 
therapy and sterile injection equipment. In addition, alcohol reduction strategies 
may be required and HIV treatment may also be necessary. Acceptability of 
services is a vital component of health care, and peer interventions may help 
with reducing injecting drug use and promoting safer injection practices.d 
Guidance on brief behavioural interventions is available as part of the WHO 
ASSIST package. 
PWID are at risk of infection with HBV and should be vaccinated using the 
rapid vaccination regimen, as described in other WHO guidance.190 Needle and 
syringe programmes should also provide sterile needles and syringes with low 
dead space to PWID. It is also suggested that peer interventions be offered to 
PWID to reduce the incidence of viral hepatitis.
Treatment
Treatment for HCV infection is both efficacious and cost–effective in PWID164,191,192 
and therefore WHO recommends that all adults and children with chronic HCV 
infection, including PWID, should be assessed for antiviral treatment. Treatment 
may also be effective as prevention, due to a reduction in transmission.97,98,99
Consideration must be given to potential drug–drug interactions – between both 
prescribed and non-prescribed drugs.e Methadone levels may be decreased 
in persons treated with PEG-IFN/RBV, for example. Although this interaction is 
usually subclinical, monitoring for symptoms of withdrawal is recommended.
Concurrent infection with HBV, HIV and/or TB is common in PWID and these 
require additional consideration, as discussed in Section 9.2.
9.2 Persons with HIV and HCV coinfection
Coinfection with HIV and HCV poses a challenge because of the large number 
of persons affected, the negative impact of HIV on the natural history of HCV 
infection, and the therapeutic challenges of dealing with interactions between 
the drugs used for treating HIV and HCV infections. 
Both ART and treatment for HCV infection may slow the progression of HCV-
related liver disease; therefore, treating both infections is a priority for persons 
with HIV/HCV coinfection.193 As the management of these infections is complex, 
it is advisable to provide treatment in an integrated fashion by clinicians familiar 
with the treatment of both infections. 
d. WHO advice on interventions for individuals using alcohol and recreational drugs is available at  
http://www.who.int/substance_abuse. 
 
e. Up-to-date guidance on prescribed and recreational drug interactions is available online at  
http://www.hep-druginteractions.org/.
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Treatment of HCV infection
In HIV/HCV coinfected persons, there is more rapid progression of HCV-related 
liver disease, and treatment for HCV may slow the progression of hepatic fibrosis 
and/or delay the onset of clinical consequences of decompensated cirrhosis. 
Therefore, treatment of HCV is a priority for persons with HIV/HCV coinfection.
The decision to initiate treatment for HCV is more complex than in those with HCV 
monoinfection, as response rates are lower, risk of potential toxicities is higher 
and treatment is complicated by a high pill burden, overlapping toxicities, and 
interactions between drugs used for treating HCV and HIV. In general, clinical 
stabilization of HIV disease with ART is advisable prior to starting treatment for 
HCV, especially in persons with advanced immunosuppression (CD4 count 
<200 cells/mm3). In these situations, since HCV RNA suppression is greater 
in coinfected persons with CD4 counts higher than 450 cells/mm3,194 it may be 
preferable to initiate ART and delay therapy for HCV until CD4 counts increase 
as a result of ART. 
HCV infection among persons with HIV coinfection can be treated with PEG-IFN/
RBV. (For comments regarding response rates and duration of treatment, see 
Section 7.1.) These persons can also be treated with PEG-IFN/RBV and boceprevir, 
telaprevir or simeprevir (for genotype 1 infection) and may also be treated with 
sofosbuvir/RBV or PEG-IFN/RBV/sofosbuvir. Persons coinfected with HCV/HIV 
treated with PEG-IFN/RBV with or without an additional agent (PI or sofosbuvir) 
who require treatment for HIV should receive compatible ART (Table 8.3).177
Persons with HIV require special consideration regarding the selection of an 
antiretroviral regimen. The safety profile in HCV/HIV-1 coinfected subjects treated 
with sofosbuvir is similar to that observed in HCV-monoinfected subjects. Elevated 
total bilirubin (grade 3 or 4) occurs extremely commonly in persons treated with 
sofosbuvir and atazanavir as part of the antiretroviral regimen. Tipranivir/sofosbuvir 
is not recommended but darunavir/ritonavir, efavirenz, emtricitabine, raltegravir, 
rilpivirine and tenofovir have been tested and no dose adjustment is currently 
recommended. 
Simeprevir is not recommended to be used with several HIV treatment regimens, 
including cobistat, the non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
efavirenz, nevirapine, delavirdine, etravirine and any HIV PI-containing regimen.196 
Antiretroviral therapy in persons with HIV/HCV coinfection
In 2013, WHO updated its recommendations on the use of ART in adults, 
adolescents, pregnant women and children.197 Tables 9.1 and 9.2 summarize 
the key recommendations on timing of ART and first-line ART regimens. These 
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recommendations state that ART among people coinfected with HCV should 
follow the same principles as in HIV monoinfection. Initiating ART regardless of 
CD4 cell count was not recommended because of lack of evidence regarding 
the benefit of ART for persons with a CD4 count higher than 500 cells/mm3. 
The choice of ART for persons with coinfection is the same as for those with HIV 
alone. The principal recommendations of the 2013 consolidated guidelines are 
summarized in Table 9.1.197
TABLE 9.1  Summary of recommendations for when to initiate ART in adults and 
adolescents197
• As a priority, ART should be initiated in all individuals with severe or advanced HIV clinical 
disease (WHO clinical stage 3 or 4) and individuals with CD4 counts ≤350 cells/mm3 
(strong recommendation, moderate-quality evidence).
• ART should be initiated in all individuals with HIV with a CD4 count between 350 and 500 
cells/mm3 regardless of WHO clinical stage (strong recommendation, moderate-quality 
evidence).
• ART should be initiated in all individuals with HIV regardless of WHO clinical stage or CD4 
count in the following situations:
 - Individuals with HIV and active TB disease (strong recommendation, low-quality 
evidence)
 - Individuals coinfected with HIV and HBV with evidence of severe chronic liver disease 
(strong recommendation, low-quality evidence)
 - Partners with HIV in serodiscordant couples should be offered ART to reduce HIV 
transmission to uninfected partners (strong recommendation, high-quality evidence)
 - Pregnant and breastfeeding women with HIV.a
• All children infected with HIV below five years of age, regardless of CD4 count or WHO 
clinical stage
 - Infants diagnosed in the first year of life (strong recommendation, moderate-quality 
evidence)
 - Children infected with HIV between one and less than five years of age (conditional 
recommendation, very low-quality evidence); severe or advanced symptomatic 
disease (WHO clinical stage 3 or 4) regardless of age and CD4 count (strong 
recommendation, moderate-quality evidence).
a. All pregnant and breastfeeding women infected with HIV should initiate a triple antiretroviral (ARV) regimen, which should be maintained 
at least for the duration of risk of mother-to-child transmission. Women meeting treatment eligibility criteria should continue lifelong ART 
(strong recommendation, moderate-quality evidence).
For programmatic and operational reasons, particularly in generalized epidemics, all pregnant and breastfeeding women infected with HIV 
should initiate ART as lifelong treatment (conditional recommendation, low-quality evidence).
In some countries, for women who are not eligible for ART for their own health, consideration can be given to stopping the ARV regimen 
after the period of risk for mother-to-child transmission has ceased (conditional recommendation, low-quality evidence).
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• As a priority, ART should be initiated in all individuals with severe or advanced HIV clinical 
disease (WHO clinical stage 3 or 4) and individuals with CD4 counts ≤350 cells/mm3 
(strong recommendation, moderate-quality evidence).
• ART should be initiated in all individuals with HIV with a CD4 count between 350 and 500 
cells/mm3 regardless of WHO clinical stage (strong recommendation, moderate-quality 
evidence).
• ART should be initiated in all individuals with HIV regardless of WHO clinical stage or CD4 
count in the following situations:
 - Individuals with HIV and active TB disease (strong recommendation, low-quality 
evidence)
 - Individuals coinfected with HIV and HBV with evidence of severe chronic liver disease 
(strong recommendation, low-quality evidence)
 - Partners with HIV in serodiscordant couples should be offered ART to reduce HIV 
transmission to uninfected partners (strong recommendation, high-quality evidence)
 - Pregnant and breastfeeding women with HIV.a
• All children infected with HIV below five years of age, regardless of CD4 count or WHO 
clinical stage
 - Infants diagnosed in the first year of life (strong recommendation, moderate-quality 
evidence)
 - Children infected with HIV between one and less than five years of age (conditional 
recommendation, very low-quality evidence); severe or advanced symptomatic 
disease (WHO clinical stage 3 or 4) regardless of age and CD4 count (strong 
recommendation, moderate-quality evidence).
TABLE 9.2  Summary of first-line ART regimens for adults, adolescents, pregnant and 
breastfeeding women and children197
First-line ART Preferred first-line regimens Alternative first-line regimensa,b 
Adults and adolescents 
(including pregnant and 
breastfeeding women and 
adults with TB coinfection 
and HBV coinfection)
TDF + 3TC (or FTC) + EFV 
as a fixed-dose combination
(strong recommendation, 
moderate-quality evidence)
AZT + 3TC + EFV
AZT + 3TC + NVP
TDF + 3TC (or FTC) + NVP
(strong recommendation, 
moderate-quality evidence)
Children ≥3 years ABC + 3TC + EFV ABC + 3TC + NVP
AZT + 3TC + EFV
AZT + 3TC + NVP
TDF + 3TC (or FTC) + EFV
TDF + 3TC (or FTC) + NVP
Children <3 years ABC (or AZT) + 3TC + LPV/r ABC + 3TC + NVP
AZT + 3TC + NVP
3TC lamivudine; ABC abacavir; ATV atazanavir; AZT zidovudine; d4T stavudine; DRV darunavir; EFV efavirenz; FTC emtricitabine; LPV 
lopinavir; NVP nevirapine; r ritonavir; TDF tenofovir
a. ABC or boosted PIs (ATV/r, DRV/r , LPV/r) can be used in special circumstances.
b. Countries should discontinue d4T use in first-line regimens because of its well-recognized metabolic toxicities (strong recommendation, 
moderate-quality evidence). For adults, using d4T as an option in first-line treatment should be discontinued and restricted to special 
cases in which other ARV drugs cannot be used and to the shortest time possible, with close monitoring. For children, d4T use should be 
restricted to situations in which there is suspected or confirmed toxicity to AZT and lack of access to ABC or TDF. The duration of therapy 
with this drug should be limited to the shortest time possible. 
Potential harmful effects of antiretroviral (ARV) drugs include their hepatotoxic 
effects. Several studies have shown that hepatotoxicity as a result of ART may 
be worsened in the presence of concomitant HCV infection.198-200 However, the 
highest rates of hepatotoxicity have been observed with ARV drugs that are no 
longer commonly used or recommended, including stavudine (d4T), didanosine 
(ddI), nevirapine (NVP) or full-dose ritonavir (RTV, 600 mg twice a day).201 For 
most HIV/HCV-coinfected persons, including those with cirrhosis, the benefits of 
ART outweigh concerns regarding drug-induced liver injury.
Raised liver enzymes may be the result of ART-induced drug toxicity and/or 
opportunistic infections, making interpretation of liver enzyme elevations more 
problematic than for patients with HCV infection alone. ALT and AST should 
be monitored at 1 month after ART initiation and then every 3–6 months. A 
significant elevation of AST/ALT may prompt careful evaluation for other causes 
of liver impairment (e.g. alcoholic hepatitis, hepatobiliary disease), and may 
require short-term interruption of the ART regimen or specific drug suspected of 
causing the elevation.
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Drug–drug interactions in persons with HIV/HCV coinfection
Assessment of potential drug–drug interactions is of critical significance in 
HIV-infected persons who are about to start HCV treatment (Table 8.3). Careful 
consideration of such interactions is important to avoid toxicity and to ensure 
efficacy of the regimens used to treat both HIV and HCV in order to avoid the 
development of ARV resistance and to increase the likelihood of SVR. Reported 
interactions are updated on a regular basis and therefore consultation with a 
frequently updated database is strongly recommended.f
Interactions between NRTIs have been reported in persons treated with dual 
IFN/RBV-based therapy. The use of ddI, d4T and AZT is associated with an 
increased risk of toxicities and these drugs are therefore contraindicated.202-205 
Abacavir (ABC) can be used with RBV, but a theoretical interaction has been 
reported to be associated with decreased SVR rates in some206 but not all 
studies;207,208 some guidelines have recommended that the use of RBV should 
be weight based and dose adjusted. Tenofovir (TDF) and emtricitabine (FTC) or 
lamivudine (3TC)-based regimens are appropriate. 
Additional drug–drug interactions must be considered when using other DAAs. 
If patients are commencing ART and DAAs are not being considered, standard 
first-line ART may be used (as long as this does not include zidovudine [AZT], 
d4T or ddI). Efavirenz may also be used but the dose of telaprevir must be 
increased. Boceprevir can be administered with raltegravir (RAL), TDF plus FTC; 
pharmacokinetic data also support the use of etravirine, rilpivirine and maraviroc 
as alternatives. Telaprevir can be used with either RAL or standard-dose RTV-
boosted atazanavir; pharmacokinetic data also support etravirine, rilpivirine and 
maraviroc as alternatives. 
Monitoring of therapy in persons with HIV/HCV coinfecion
IFN-based regimens are associated with a reversible CD4 decline (average 
140 cells/mm3) and a high rate of treatment discontinuation due to side-
effects (25% of patients in the APRICOT study).169 CD4 count monitoring is 
therefore recommended in coinfected persons on treatment. A higher risk of 
haematological suppression is also present in HIV-infected individuals; these are 
important dose-limiting side-effects, especially with co-administration of certain 
ARV drugs. 
Monitoring during IFN and RBV treatment with or without PI therapy is therefore 
recommended at multiple time points (Table 8.2). Additional time points may be 
required for persons with evidence of side-effects and in persons at highest risk 
(for example, persons with cirrhosis and HIV, and those on PI therapy). Additional 
monitoring of liver function is recommended in persons with cirrhosis, including 
f. Drug interactions can be checked at the Liverpool HIV drug interaction database (www.hep-druginteractions.org).
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albumin, bilirubin and coagulation tests. Persons with evidence of neutropenia, 
thrombocytopenia and anaemia require 1–2-weekly monitoring.
9.3 Children and adolescents
WHO defines a child as an individual 19 years of age or younger and an adolescent 
as a person between the ages of 10 and 19 years. In countries where adults have 
a high prevalence of HCV infection, an increased prevalence in children can also 
be expected. In Egypt, for example, approximately 2% of children are infected.209 
This rate is substantially higher in at-risk populations, such as those exposed to 
medical intervention. Iatrogenic transmission has been reported in hospitals34 and 
reduction of HCV transmission in health-care settings is a priority (strategies for 
reduction in HCV transmission as part of medical care are summarized in Table 
2.3). Seroprevalence rates of 10–20% have been reported among children who 
have been treated in hospital for malignancy, renal failure requiring haemodialysis, 
extracorporeal membrane oxygenation and those who have undergone surgical 
procedures.210-215 Treatment is licensed for children older than 2 years of age. The 
product literature for PEG-IFNα2a reports that paediatric subjects treated with RBV 
combination therapy had a delay in weight and height increases after 48 weeks of 
therapy compared with baseline. However, by the end of 2 years of follow up, most 
subjects had returned to baseline normative growth curve percentiles for weight 
and height (mean weight-for-age percentile was 64% at baseline and 60% at 2 
years post-treatment; mean height percentile was 54% at baseline and 56% at 2 
years post-treatment). 
Screening 
Targeted screening is indicated for children who have had medical interventions 
or who have received blood products in countries where screening of blood is 
not carried out routinely or where medical equipment is inadequately sterilized. 
Children born to mothers with HCV infection are also at risk; the risk of vertical 
(mother-to-child) transmission is approximately 5% and is substantially higher in 
infants born to HIV-infected mothers (17–25%).17,18
Care 
Integrated health care is a key aspect of child health-care provision. Linkage with 
maternal and child health services, primary care, services for PWID and, where 
necessary, referral for HIV care and treatment are necessary. 
Treatment
Treatment success rates are similar in adults and children, although fewer 
studies have been carried out in children. In particular, the use of DAAs 
has been inadequately studied in children as they were excluded from the 
phase III studies of these medicines.84,85 One systematic review reported on 
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the virological outcomes and adverse effects of IFN/RBV treatment among 
children.153 This review included four RCTs and 31 non-randomized studies. 
The overall SVR rate for PEG-IFN and RBV was 30–100%, which is comparable 
to SVR rates seen in adults. Adverse effects were primarily flu-like symptoms 
and neutropenia. 
9.4 Persons with liver cirrhosis
The spectrum of disease in those infected with HCV extends from mild fibrosis 
to cirrhosis and HCC. Between 15% and 30% of persons infected with HCV will 
go on to develop cirrhosis of the liver within 20 years and a proportion of these 
will progress to HCC. The risk is markedly increased in those who consume 
excess alcohol216 and in those coinfected with HBV and/or HIV, particularly those 
who do not have access to ART.60,61 Persons with compensated cirrhosis have 
the least time available for treatment, the most to lose and much to gain from 
achieving SVR. Treatment of HCV infection with IFN-containing regimens must 
be commenced before the onset of decompensated disease as it may precipitate 
liver failure and death if administered at this stage.  
Regular clinical examination and monitoring of serum bilirubin, albumin and 
blood clotting profile (INR) is necessary in persons with cirrhosis on IFN-based 
treatment in order to detect decompensated disease. The treatment of such 
persons with IFN-containing regimens carries a higher risk of serious side-
effects and the use of haemopoietic factors is recommended in settings where 
these are available.110
Assessment and follow up for the progression of disease and for evidence of 
HCC is an essential part of the care of persons with HCV-related cirrhosis. 
Compensated cirrhosis may also progress over time to decompensated cirrhosis 
associated with ascites, oesophageal and gastric varices, and eventually to liver 
failure, renal failure and sepsis, all of which are life-threatening. The diagnosis of 
decompensated liver disease is based on both laboratory and clinical assessment, 
and therefore a careful medical examination of patients must be made before 
starting treatment. Persons with cirrhosis (including those who have achieved a 
SVR) should be screened for HCC with six-monthly ultrasound examination and 
α-fetoprotein estimation, and should have endoscopy every 1-2 years to exclude 
oesophageal varices.110 
9.5 Persons with HBV and TB coinfection
HBV and HCV coinfection
HBV and HCV coinfection may result in an accelerated disease course; HCV is 
considered to be the main driver of disease. Persons coinfected with HBV and 
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HCV can be treated with antiviral therapy for HCV; SVR rates are similar to those 
of HCV-monoinfected persons.51,217 After HCV clearance, there is a risk of HBV 
reactivation and this may require treatment with concurrent anti-HBV antiviral 
therapy.199,g Telbivudine, in particular, may be associated with a higher risk of 
neuropathy if given with IFN-containing regimens.
TB and HCV coinfection
Severe concurrent infections such as TB should generally be treated before 
commencing therapy for HCV. WHO recommends regular screening of people 
living with HIV (including PWID) with a four-symptom screening algorithm to rule 
out TB. If the patient does not have any one of the following symptoms – current 
cough, fever, weight loss or night sweats – TB can be reasonably excluded, 
otherwise they should undergo further investigations for TB or other diseases. 
ART should be initiated with persons with HIV-associated TB as soon as possible, 
regardless of CD4 count. There are limited reported data on the co-management 
of persons coinfected with HCV, HIV and TB but such cases need sound clinical 
judgement in order to reduce the additive side-effects, pill burden and drug–
drug interactions. Potential interactions can be checked online.g  
9.6 Persons with renal impairment
Both ribavirin and PEG-IFN require dose adjustment in persons with renal 
failure, and baseline testing of renal function is required before initiating 
therapy. PEG-IFNα2a is cleared by the liver and PEG-IFNα2b via the kidneys. 
While a theoretical accumulation of PEG-IFNα2b could occur in persons with 
haemodialysis, no differences have been reported clinically.200,201 Sofosbuvir is 
excreted by the kidney; however, there are no data regarding the safety of this 
medication among persons with renal impairment. 
In persons with end-stage renal disease (creatinine clearance 20–40 mL/min), a 
reduced dose of PEG-IFNα2a 135 μg once a week is recommended. The dose 
of RBV must also be decreased. 
In persons with renal impairment receiving chronic haemodialysis, RBV may be 
administered at a dose of 200 mg daily or 200 mg every other day. Plasma RBV 
is removed by haemodialysis with an extraction ratio of approximately 50%. 
g. Drug–drug interactions can be checked online at http://www.hep-druginteractions.org.
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10. OPERATIONAL AND IMPLEMENTATION 
      ISSUES 
Scaling up access to treatment for people infected with HCV in low- and middle-
income countries requires careful consideration of resource availability in 
individual settings. A high-income model of specialist care with a high physician-
to-patient ratio and availability of advanced laboratory monitoring is not feasible 
in many countries and therefore service delivery plans need to be adapted 
accordingly. A public health care-based approach to improve access to health 
care for people infected with TB and HIV has been promoted by WHO and has 
resulted in improved health care in many resource-limited settings.219 The roll-out 
of screening, care and treatment for HCV in low- and middle-income countries 
will require an assessment of many of the same issues already addressed by 
TB and HIV treatment programmes, and similar approaches are likely to be 
effective. 
10.1 Service planning
Service planning requires an estimation of the local burden of disease, and 
an assessment of the availability of resources and infrastructure for rolling out 
treatment. National programmes are required to plan screening and treatment 
strategies. At present, many countries have poor documentation of the 
prevalence of infection; this is particularly the case in low-income countries. 
The Global policy report on the prevention and control of viral hepatitis, 2013 
provides country-specific information on policies and structures already in place 
to combat viral hepatitis.107 Building on these policies and structures will be 
necessary to increase the availability of treatment for those infected. Estimates of 
how many people are likely to be affected may be made by assessing populations 
at high risk as well as previously documented prevalence and incidence rates. 
Regular sentinel screening of targeted populations using serology and NAT is 
therefore required to facilitate service planning and is the first step in increasing 
access to care and treatment for HCV. Improvements in molecular tools for rapid 
screening, including dried blood spot and oral fluid testing, as well as polyvalent 
PCR platforms, would increase the numbers of infected patients identified. 
They would also allow the expansion of screening services into the field as well 
as among difficult-to-access populations such as PWID. Integration of HCV 
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screening with HIV, HBV and TB screening services may be suitable in many 
settings as the routes of transmission are common.
A central barrier to treatment roll-out is cost – this includes the cost of 
medicines, taxes, import charges, appropriate medical facilities and staff, as 
well as diagnostic and monitoring facilities. Negotiation on drug costs is required 
and prioritization of particular groups, for example, patients with advanced liver 
disease (≥F2 disease or, in more constrained settings, F4) may be required. 
Integration of services, for example, diagnostic and treatment facilities, may help 
to minimize costs and is likely to facilitate treatment delivery. Task-shifting is the 
process of sharing clinical management responsibilities with trained personnel 
such as nurses, clinical officers and pharmacists. Such personnel should have 
access to consultations with specialized team members as necessary and are 
likely to require training in order to facilitate adequate health-care delivery. 
Sourcing of medication and negotiation on pricing at a central level (using pooled 
procurement) may also minimize costs. Patent coverage and the availability 
of prequalified biosimilar agents or generic formulations is another central 
consideration – this is likely to be of key importance as new DAAs are licensed.
Clinical and laboratory facilities for screening and monitoring patients on 
treatment are an essential component of health-care provision. The development 
and implementation of simpler methods to assess HCV viral load and genotype 
as well as for the tests needed to monitor drug toxicity are important to increase 
accessibility of treatment in less well-resourced settings. Point-of-care HCV viral 
load testing may be required in some settings in order to facilitate appropriate 
treatment. Pharmacy facilities and drug storage space, including refrigeration 
space for IFN, should be included in the planning of new treatment centres. 
Sourcing and distribution planning is also required. The registration of new drugs 
in individual Member States may be time consuming and will require adequate 
planning. 
10.2 Service delivery
The key programmatic components of service delivery are adequate clinic 
infrastructure, laboratory and diagnostic services, reliable drug supply, human 
resources (doctors, nurses, trained persons to provide psychological support), 
a referral system, monitoring and evaluation, and civil society participation. 
Improving access to treatment requires the identification of infected patients. 
Implementation of screening for HCV therefore needs to be prioritized and 
targeted screening of high-risk populations carried out. Subsequently, persons 
with HCV infection require access to medical facilities for treatment, with ongoing 
follow up and monitoring for toxicity and efficacy. Integration with pre-existing 
services such as those already established for HIV would be of added value. 
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Service delivery may be achieved more readily by providing standardized, 
simplified treatment regimens at a population level. Decentralized service 
delivery has already enabled the treatment of large numbers of people infected 
with HIV. Service delivery should make use of simplified operational guidelines, 
training materials and approaches to clinical decision-making, as well as limited 
formularies. An initial clinical assessment is essential prior to commencing 
therapy in order to assess the presence of pre-morbid conditions that may rule 
out or delay treatment such as severe intercurrent illnesses, for example, TB, 
decompensated cirrhosis or pregnancy. A psychological assessment at this time 
and evaluation of potential drug–drug interactions are also essential. Disease 
education, patient preparation for side-effects while on treatment, support and 
appropriate informed pre- and post-test counselling are required. Access to 
appropriate diagnostic facilities for toxicity and efficacy monitoring is of critical 
importance and could be facilitated by utilizing the same or similar platforms 
currently being rolled out for HIV.4 
For treatment, standardized regimens should be used in combination with 
simplified clinical decision-making tools and standardized monitoring. Minimum 
packages for care and treatment require to be formulated locally, and treatment 
and monitoring algorithms (including algorithms for the use of first- and second-
generation DAAs) developed. Such algorithms should include information on 
when to start therapy, when to stop, follow up, side-effects and management 
flow sheets. Management of drug–drug interactions is important, particularly in 
those infected with HIV. For example, drugs such as AZT, ddI and d4T used 
widely in low-income settings are not recommended in persons treated with IFN 
and RBV. Monitoring and evaluation of centres treating persons for HCV is an 
essential component of appropriate management. Implementation of standard 
registers for tracking progress such as those developed for use in TB treatment 
programmes will allow monitoring and evaluation of progress after roll-out of 
treatment for HCV. Increased supervision of sites is likely to be important during 
the early stages of treatment roll-out. Other guidance on the delivery of treatment 
for HCV to people in low- and middle-income countries has been developed by 
Médecins Sans Frontières.166
10.3 Future considerations
The treatment landscape for HCV is in a phase of rapid transformation, and 
adaptations will be required as soon as new drugs are approved. Curative 
treatments that are more efficacious and less toxic than ever before have the 
potential to dramatically reduce the health and economic burdens associated 
with HCV infection around the world. The opportunity to address the massive 
HCV pandemic is now within reach and a global movement is needed to 
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create generalized access to HCV treatment in high-, middle- and low-income 
countries. This will require political will, financial investment, and support from 
pharmaceutical, medical and civil society organizations around the world.
10.4 Dissemination, monitoring and implementation of 
the Guidelines for the screening, care and treatment of 
persons with hepatitis C infection
The guidelines will be launched at the annual meeting of the European Society for 
the Study of the Liver (April 2014). The Secretariat will identify other international 
conference venues to present the recommendations. The Secretariat staff will 
work with the hepatitis points of contact in the WHO regional offices to ensure 
dissemination to WHO country offices and Ministries of Health as well as key 
international, regional and national collaborating centres (e.g. civil society, 
foundations, donors), and national programmes. In addition, the guidelines will 
be accessible on the WHO website with links to other UN/related websites. 
The successful implementation of the recommendations in these guidelines 
will depend on a well-planned and appropriate process of adaptation and 
integration into relevant regional and national strategies. It is a process that will 
be determined by available resources, existing enabling policies and practices, 
and levels of support from partner agencies and organizations.
Implementation of these guidelines can be measured by the number of countries 
that have incorporated them in their national treatment guidelines. This will be 
monitored through the biannual survey that forms the basis for the WHO Global 
policy report on the prevention and control of viral hepatitis. Ideally, the impact of 
the guidelines would be measured by monitoring the number of persons treated 
for HCV and the number cured. Currently, no monitoring system exists that can 
collect this information on a national level.
102
11. REFERENCES
1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology 
of hepatitis C virus infection: new estimates of age-specific antibody to HCV 
seroprevalence. Hepatology. 2013;57(4):1333–42.
2. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29 Suppl 
1:74–81.
3. Lemoine M, Nayagam S, Thursz M. Viral hepatitis in resource-limited 
countries and access to antiviral therapies: current and future challenges. 
Future Virol. 2013 Apr;8(4):371-380
4. Ford N, Kirby C, Singh K, Mills EJ, Cooke G, Kamarulzaman A, et al. 
Chronic hepatitis C treatment outcomes in low- and middle-income 
countries: a systematic review and meta-analysis. Bulletin of the World 
Health Organization. 2012;90(7):540-50.
5. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing 
burden of mortality from viral hepatitis in the United States between 1999 
and 2007. Ann Intern Med. 2012;156(4):271–8
6. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, et 
al. Global epidemiology of hepatitis B and hepatitis C in people who inject 
drugs: results of systematic reviews. Lancet. 2011;378(9791):571–83.
7. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus 
infection. Lancet Infect Dis. 2005;5(9):558–67.
8. Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder 
LS, et al. The role of parenteral antischistosomal therapy in the spread of 
hepatitis C virus in Egypt. Lancet. 2000;355(9207):887–91.
9. Singh S, Dwivedi SN, Sood R, Wali JP. Hepatitis B, C and human 
immunodeficiency virus infections in multiply-injected kala-azar patients in 
Delhi. Scand J Infect Dis. 2000;32(1):3–6.
103
10. Marx MA, Murugavel KG, Sivaram S, Balakrishnan P, Steinhoff M, Anand S, 
et al. The association of health-care use and hepatitis C virus infection in a 
random sample of urban slum community residents in southern India. Am 
J Trop Med Hyg. 2003;68(2):258–62.
11. Wang CS, Chang TT, Chou P. Differences in risk factors for being either a 
hepatitis B carrier or anti-hepatitis C+ in a hepatoma-hyperendemic area in 
rural Taiwan. J Clin Epidemiol. 1998;51(9):733–8.
12. Ho MS, Hsu CP, Yuh Y, King CC, Tsai JF, Mau YC, et al. High rate of hepatitis 
C virus infection in an isolated community: persistent hyperendemicity or 
period-related phenomena? J Med Virol. 1997;52(4):370–6.
13. Lin CC, Hwang SJ, Chiou ST, Kuan CL, Chen LW, Lee TC, et al. The 
prevalence and risk factors analysis of serum antibody to hepatitis C virus 
in the elders in northeast Taiwan. J Chin Med Assoc. 2003;66(2):103–8.
14. Saxena R, Thakur V, Sood B, Guptan RC, Gururaja S, Sarin SK. Transfusion-
associated hepatitis in a tertiary referral hospital in India. A prospective 
study. Vox Sang. 1999;77(1):6–10.
15. Candotti D, Sarkodie F, Allain JP. Residual risk of transfusion in Ghana. Br 
J Haematol. 2001;113(1):37–9.
16. El-Zanaty F, Way A, MACRO International. Egypt demographic and health 
survey, 2008. Final report. In: Measure DHS [website]. 2009. (http://www.
measuredhs.com/publications/publication-fr220-dhs-final-reports.cfm, 
accessed 20 January 2014).
17. Thomas DL, Villano SA, Riester KA, Hershow R, Mofenson LM, Landesman 
SH, et al. Perinatal transmission of hepatitis C virus from human 
immunodeficiency virus type 1-infected mothers. Women and Infants 
Transmission Study. J Infect Dis. 1998;177(6):1480–8.
18. Mast EE, Hwang LY, Seto DS, Nolte FS, Nainan OV, Wurtzel H, et al. Risk factors 
for perinatal transmission of hepatitis C virus (HCV) and the natural history of 
HCV infection acquired in infancy. J Infect Dis. 2005;192(11):1880–9.
19. Terrault NA, Dodge JL, Murphy EL, Tavis JE, Kiss A, Levin TR, et al. Sexual 
transmission of hepatitis C virus among monogamous heterosexual couples: 
the HCV partners study. Hepatology. 2013;57(3):881–9.
20. Valadez JJ, Berendes S, Jeffery C, Thomson J, Ben Othman H, Danon L, 
et al. Filling the knowledge gap: measuring HIV prevalence and risk factors 
among men who have sex with men and female sex workers in Tripoli, 
Libya. PloS One. 2013;8(6):e66701.
104
21. Tseng YT, Sun HY, Chang SY, Wu CH, Liu WC, Wu PY, et al. Seroprevalence 
of hepatitis virus infection in men who have sex with men aged 18–40 years 
in Taiwan. J Formos Med Assoc. 2012;111(8):431–8.
22. Price H, Gilson R, Mercey D, Copas A, Parry J, Nardone A, et al. Hepatitis C 
in men who have sex with men in London – a community survey. HIV Med. 
2013;14(9):578–80.
23. Tohme RA, Holmberg SD. Is sexual contact a major mode of hepatitis C 
virus transmission? Hepatology. 2010;52(4):1497–505.
24. Karuru JW, Lule GN, Joshi M, Anzala O. Prevalence of HCV and HCV/HIV 
co-infection among in-patients at the Kenyatta National Hospital. East Afr 
Med J. 2005;82(4):170–2.
25. Quaranta JF, Delaney SR, Alleman S, Cassuto JP, Dellamonica P, Allain JP. 
Prevalence of antibody to hepatitis C virus (HCV) in HIV-1-infected patients 
(nice SEROCO cohort). J Med Virol. 1994;42(1):29–32.
26. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence 
among patients infected with human immunodeficiency virus: a cross-
sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 
2002;34(6):831–7.
27. Rauch A, Rickenbach M, Weber R, Hirschel B, Tarr PE, Bucher HC, et al. 
Unsafe sex and increased incidence of hepatitis C virus infection among 
HIV-infected men who have sex with men: the Swiss HIV Cohort Study. Clin 
Infect Dis. 2005;41(3):395–402.
28. D’Oliveira A, Jr, Voirin N, Allard R, Peyramond D, Chidiac C, Touraine JL, 
et al. Prevalence and sexual risk of hepatitis C virus infection when human 
immunodeficiency virus was acquired through sexual intercourse among 
patients of the Lyon University Hospitals, France, 1992–2002. J Viral Hepat. 
2005;12(3):330–2.
29. Vandelli C, Renzo F, Romano L, Tisminetzky S, De Palma M, Stroffolini 
T, et al. Lack of evidence of sexual transmission of hepatitis C among 
monogamous couples: results of a 10-year prospective follow-up study. Am 
J Gastroenterol. 2004;99(5):855–9.
30. Eyster ME, Alter HJ, Aledort LM, Quan S, Hatzakis A, Goedert JJ. Heterosexual 
co-transmission of hepatitis C virus (HCV) and human immunodeficiency 
virus (HIV). Ann Intern Med. 1991;115(10):764–8.
31. Taylor LE, Swan T, Mayer KH. HIV coinfection with hepatitis C virus: evolving 
epidemiology and treatment paradigms. Clin Infect Dis. 2012;55 Suppl 1:S33–42.
105
32. Scheinmann R, Hagan H, Lelutiu-Weinberger C, Stern R, Des Jarlais DC, 
Flom PL, et al. Non-injection drug use and hepatitis C virus: a systematic 
review. Drug Alcohol Depend. 2007;89(1):1–12.
33. Jafari S, Copes R, Baharlou S, Etminan M, Buxton J. Tattooing and the risk 
of transmission of hepatitis C: a systematic review and meta-analysis. Int J 
Infect Dis. 2010;14(11):e928–e940.
34. de Oliveira T, Pybus OG, Rambaut A, Salemi M, Cassol S, Ciccozzi M, et al. 
Molecular epidemiology: HIV-1 and HCV sequences from Libyan outbreak. 
Nature. 2006;444(7121):836–7.
35. Kane A, Lloyd J, Zaffran M, Simonsen L, Kane M. Transmission of hepatitis 
B, hepatitis C and human immunodeficiency viruses through unsafe 
injections in the developing world: model-based regional estimates. Bull 
World Health Organ. 1999;77(10):801–7.
36. Global database on blood safety. Geneva: World Health Organization; 2011. 
(http://www.who.int/bloodsafety/global_database/en/ accessed 20 January 
2014).
37. Injection safety. Geneva: World Health Organization; 2010. (http://www.
who.int/injection_safety, accessed 21 January 2014).
38. Tillmann HL, Thursz M. Hepatitis C virus infection––its role in pathogenesis. 
J Infect Dis. 2007;195(2):168–70.
39. Marincovich B, Castilla J, del Romero J, Garcia S, Hernando V, Raposo M, 
et al. Absence of hepatitis C virus transmission in a prospective cohort of 
heterosexual serodiscordant couples. Sex Transm Infect. 2003;79(2):160–2.
40. Danta M, Brown D, Bhagani S, Pybus OG, Sabin CA, Nelson M, et al. Recent 
epidemic of acute hepatitis C virus in HIV-positive men who have sex with 
men linked to high-risk sexual behaviours. AIDS. 2007;21(8):983–91.
41. van de Laar T, Pybus O, Bruisten S, Brown D, Nelson M, Bhagani S, et al. 
Evidence of a large, international network of HCV transmission in HIV-positive 
men who have sex with men. Gastroenterology. 2009;136(5):1609–17.
42. Fierer DS, Uriel AJ, Carriero DC, Klepper A, Dieterich DT, Mullen MP, et al. 
Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-
infected men: a prospective cohort study. J Infect Dis. 2008;198(5):683–6. 
doi: 10.1086/590430.
43. Karmochkine M, Carrat F, Dos Santos O, Cacoub P, Raguin G. A case–control 
study of risk factors for hepatitis C infection in patients with unexplained 
routes of infection. J Viral Hepat. 2006;13(11):775–82.
106
44. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 
2006;44(1 Suppl):S6–9.
45. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, et al. 
Increasing mortality due to end-stage liver disease in patients with human 
immunodeficiency virus infection. Clin Infect Dis. 2001;32(3):492–7.
46. Crespo J, Lozano JL, de la Cruz F, Rodrigo L, Rodriguez M, San Miguel G, 
et al. Prevalence and significance of hepatitis C viremia in chronic active 
hepatitis B. Am J Gastroenterol. 1994;89(8):1147–51.
47. Pontisso P, Ruvoletto MG, Fattovich G, Chemello L, Gallorini A, Ruol A, et 
al. Clinical and virological profiles in patients with multiple hepatitis virus 
infections. Gastroenterology. 1993;105(5):1529–33.
48. Liu CJ, Liou JM, Chen DS, Chen PJ. Natural course and treatment of dual 
hepatitis B virus and hepatitis C virus infections. J Formos Med Assoc. 
2005;104(11):783–91.
49. Di Marco V, Lo Iacono O, Camma C, Vaccaro A, Giunta M, Martorana G, et al. 
The long-term course of chronic hepatitis B. Hepatology. 1999;30(1):257–
64.
50. Kaur S, Rybicki L, Bacon BR, Gollan JL, Rustgi VK, Carey WD. Performance 
characteristics and results of a large-scale screening program for viral 
hepatitis and risk factors associated with exposure to viral hepatitis B and 
C: results of the National Hepatitis Screening Survey. National Hepatitis 
Surveillance Group. Hepatology. 1996;24(5):979–86.
51. Potthoff A, Manns MP, Wedemeyer H. Treatment of HBV/HCV coinfection. 
Expert Opin Pharmacother. 2010;11(6):919–28.
52. Getahun H, Gunneberg C, Sculier D, Verster A, Raviglione M. Tuberculosis 
and HIV in people who inject drugs: evidence for action for tuberculosis, HIV, 
prison and harm reduction services. Curr Opin HIV AIDS. 2012;7(4):345–53.
53. Getahun H, Baddeley A, Raviglione M. Managing tuberculosis in people who 
use and inject illicit drugs. Bull World Health Organ. 2013;91(2):154–6.
54. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation 
of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis 
genome. Science. 1989;244(4902):359–62.
55. Simmonds P, Smith DB, McOmish F, Yap PL, Kolberg J, Urdea MS, et al. 
Identification of genotypes of hepatitis C virus by sequence comparisons in 
the core, E1 and NS-5 regions. J Gen Virol. 1994;75 (Pt 5):1053–61.
107
56. Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from 
genome to function. Nature. 2005;436(7053):933–8.
57. Simmonds P. Reconstructing the origins of human hepatitis viruses. Phil 
Trans R Soc B. 2001;356(1411):1013–26.
58. Thomson EC, Fleming VM, Main J, Klenerman P, Weber J, Eliahoo J, et 
al. Predicting spontaneous clearance of acute hepatitis C virus in a large 
cohort of HIV-1-infected men. Gut. 2011;60(6):837–45.
59. Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer 
A, et al. Acute hepatitis C: high rate of both spontaneous and treatment-
induced viral clearance. Gastroenterology. 2003;125(1):80–8.
60. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-
associated hepatitis C. New Engl J Med. 1995;332(22):1463–6.
61. Tremolada F, Casarin C, Alberti A, Drago C, Tagger A, Ribero ML, et al. 
Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J 
Hepatol. 1992;16(3):273–81.
62. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis 
progression rates in chronic hepatitis C virus infection: a meta-analysis and 
meta-regression. Hepatology. 2008;48(2):418–31.
63. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and 
molecular carcinogenesis. Gastroenterology. 2007;132(7):2557–76.
64. Freeman AJ, Law MG, Kaldor JM, Dore GJ. Predicting progression to 
cirrhosis in chronic hepatitis virus infection. J Viral Hepat. 2003;10:285–93.
65. Fletcher NF, McKeating JA. Hepatitis C virus and the brain. J Viral Hepat. 
2012;19(5):301–6.
66. Forton DM, Karayiannis P, Mahmud N, Taylor-Robinson SD, Thomas HC. 
Identification of unique hepatitis C virus quasispecies in the central nervous 
system and comparative analysis of internal translational efficiency of brain, 
liver, and serum variants. J Virol. 2004;78(10):5170–83.
67. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, 
et al. Liver fibrosis progression in human immunodeficiency virus and 
hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 
1999;30(4):1054–8.
68. Di Martino V, Rufat P, Boyer N, Renard P, Degos F, Martinot-Peignoux M, et 
al. The influence of human immunodeficiency virus coinfection on chronic 
hepatitis C in injection drug users: a long-term retrospective cohort study. 
Hepatology. 2001;34(6):1193–9.
108
69. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence 
of human immunodeficiency virus infection on the course of hepatitis C 
virus infection: a meta-analysis. Clin Infect Dis. 2001;33(4):562–9.
70. Pineda JA, Romero-Gomez M, Diaz-Garcia F, Giron-Gonzalez JA, Montero 
JL, Torre-Cisneros J, et al. HIV coinfection shortens the survival of patients 
with hepatitis C virus-related decompensated cirrhosis. Hepatology. 
2005;41(4):779–89.
71. Cohen MH, French AL, Benning L, Kovacs A, Anastos K, Young M, et al. 
Causes of death among women with human immunodeficiency virus infection 
in the era of combination antiretroviral therapy. Am J Med. 2002;113(2):91–8.
72. Martin-Carbonero L, Sanchez-Somolinos M, Garcia-Samaniego J, Nunez 
MJ, Valencia ME, Gonzalez-Lahoz J, et al. Reduction in liver-related hospital 
admissions and deaths in HIV-infected patients since the year 2002. J Viral 
Hepat. 2006;13(12):851–7.
73. Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, et al. 
Clinical progression, survival, and immune recovery during antiretroviral 
therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss 
HIV Cohort Study. Lancet. 2000;356(9244):1800–5.
74. De Luca A, Bugarini R, Lepri AC, Puoti M, Girardi E, Antinori A, et al. Coinfection 
with hepatitis viruses and outcome of initial antiretroviral regimens in previously 
naive HIV-infected subjects. Arch Intern Med. 2002; 162(18):2125–32.
75. Law WP, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham 
K, Lange JM, et al. Impact of viral hepatitis co-infection on response to 
antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. 
AIDS. 2004;18(8):1169–77. 
76. Rancinan C, Neau D, Saves M, Lawson-Ayayi S, Bonnet F, Mercié P, et 
al. Is hepatitis C virus co-infection associated with survival in HIV-infected 
patients treated by combination antiretroviral therapy? AIDS. 2002; 
16(10):1357–62.
77. Tedaldi EM, Baker RK, Moorman AC, Alzola CF, Furhrer J, McCabe RE, et 
al. Influence of coinfection with hepatitis C virus on morbidity and mortality 
due to human immunodeficiency virus infection in the era of highly active 
antiretroviral therapy. Clin Infect Dis. 2003; 36(3):363–7.
78. Vlahov D, Graham N, Hoover D, Flynn C, Bartlett JG, Margolick JB, et al. 
Prognostic indicators for AIDS and infectious disease death in HIV-infected 
injection drug users: plasma viral load and CD4+ cell count. JAMA. 
1998;279(1):35–40.
109
79. Celentano DD, Vlahov D, Cohn S, Shadle VM, Obasanjo O, Moore 
RD. Self-reported antiretroviral therapy in injection drug users. JAMA. 
1998;280(6):544–6.
80. Garcia-Samaniego J, Rodriguez M, Berenguer J, Rodriguez-Rosado R, 
Carbo J, Asensi V, et al. Hepatocellular carcinoma in HIV-infected patients 
with chronic hepatitis C. Am J Gastroenterol. 2001;96(1):179–83.
81. Hepatitis C test kit evaluations. Geneva: World Health Organization; 2001. 
(http://www.who.int/diagnostics_laboratory/evaluations/hepc/en/, accessed 
21 January 2014).
82. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication 
of hepatitis C virus infection and the development of hepatocellular 
carcinoma: a meta-analysis of observational studies. Ann Intern Med. 
2013;158(5 Pt 1):329–37.
83. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A 
sustained virologic response reduces risk of all-cause mortality in patients 
with hepatitis C. Clin Gastroenterol Hepatol. 2011;9(6):509–16.
84. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, 
Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C 
virus infection. N Engl J Med. 2011;364(25):2405–16.
85. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, 
et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J 
Med. 2011;364(13):1195–206.
86. Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, et al. Once-daily 
simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-
naive genotype 1 hepatitis C: the randomized PILLAR study. Hepatology. 
2013;58(6):1918–29.
87. Sulkowski MS, Rodriguez-Torres M, Lalezari JP, Fessel WJ, Mounzer K, 
Shuhart MC, et al., editors. All-oral therapy with sofosbuvir plus ribavirin for the 
treatment of HCV genotype 1, 2, and 3 infection in patients co-infected with HIV 
(PHOTON-1) [Abstract]. 64th Annual Meeting of the American Association for 
the Study of Liver Diseases (AASLD 2013) Washington, DC, USA: 1–5 November 
2013. Hepatology. 2013;58 Suppl 1. doi: 10.1002/hep.26791. (http://www.ncbi.
nlm.nih.gov/pubmed/24142553, accessed 28 January 2014). 
88. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, 
Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients 
without treatment options. N Engl J Med. 2013;368(20):1867–77.
110
89. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon 
SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. 
N Engl J Med. 2013;368(20):1878–87.
90. Legrand-Abravanel F, Sandres-Saune K, Barange K, Alric L, Moreau 
J, Desmorat P, et al. Hepatitis C virus genotype 5: epidemiological 
characteristics and sensitivity to combination therapy with interferon-alpha 
plus ribavirin. J Infect Dis. 2004;189(8):1397–400.
91. Fung J, Lai CL, Hung I, Young J, Cheng C, Wong D, et al. Chronic hepatitis 
C virus genotype 6 infection: response to pegylated interferon and ribavirin. 
J Infect Dis. 2008;198(6):808–12.
92. Noureddin M, Ghany MG. Pharmacokinetics and pharmacodynamics of 
peginterferon and ribavirin: implications for clinical efficacy in the treatment 
of chronic hepaititis C. Gastroenterol Clin North Am. 2010;39(3):649–58.
93. Fried MW. Side effects of therapy of hepatitis C and their management. 
Hepatology. 2002;36(5 Suppl 1):S237–44.
94. Sulkowski MS, Cooper C, Hunyady B, Jia J, Ogurtsov P, Peck-Radosavljevic 
M, et al. Management of adverse effects of peg-IFN and ribavirin therapy 
for hepatitis C. Nat Rev Gastroenterol Hepatol. 2011;8(4):212–23.
95. National Institute for Health and Clinical Excellence. Boceprevir for the 
treatment of genotype 1 chronic hepatitis C. 2012. (http://www.nice.org.
uk/nicemedia/live/13718/58913/58913.pdf, accessed 21 January 2014). 
96. National Institute for Health and Clinical Excellence. Telaprevir for the 
treatment of genotype 1 chronic hepatitis C [website]. 2012. (http://www.
nice.org.uk/nicemedia/live/13717/58912/58912.pdf, accessed 25 January 
2014).  
97. Martin NK, Vickerman P, Miners A, Foster GR, Hutchinson SJ, Goldberg DJ, 
et al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection 
drug user populations. Hepatology. 2012;55(1):49–57.
98. Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman 
M. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among 
injecting drug user populations? A modeling analysis of its prevention utility. 
J Hepatol. 2011;54(6):1137–44.
99. Durier N, Nguyen C, White LJ. Treatment of hepatitis C as prevention: a 
modeling case study in Vietnam. PloS One. 2012;7(4):e34548.
111
100. Obach D, Deuffic-Burban S, Esmat G, Anwar WA, Dewedar S, Canva V, et 
al. Effectiveness and cost-effectiveness of immediate vs. delayed treatment 
of HCV-infected patients in a country with limited resources: the case of 
Egypt. Clin Infect Dis. 2014 Feb 7. [Epub ahead of print]
101. The Universal Declaration of Human Rights [website]. Geneva: United 
Nations; 2013. (http://www.un.org/en/documents/udhr/index.shtml, 
accessed 21 January 2014).
102. World Medical Association [website]. Declaration of Geneva. Geneva: 
2006. (http://www.wma.net/en/30publications/10policies/g1/index.html, 
accessed 21 January 2014).
103. Handbook for guidelines development. Geneva: World Health Organization; 
2012. (http://apps.who.int/iris/bitstream/10665/75146/1/9789241548441_
eng.pdf, accessed 21 January 2014).
104. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE 
guidelines: 1. Introduction–GRADE evidence profiles and summary of 
findings tables. J Clin Epidemiol. 2011;64(4):383–94. 
105. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE 
guidelines: 2. Framing the question and deciding on important outcomes. 
J Clin Epidemiol. 2011;64(4):395–400. 
106. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et 
al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 
2011;64(4):401–6.
107. Global policy report on the prevention and control of viral hepatitis in WHO 
Member States. Geneva: World Health Organization; 2013. (http://apps.
who.int/iris/bitstream/10665/85397/1/9789241564632_eng.pdf, accessed 
21 January 2014).
108. National Institute for Health and Clinical Excellence (NICE). Hepatitis 
B and C: ways to promote and offer testing to people at increased risk 
of infection. London: NICE; 2012. (http://www.nice.org.uk/nicemedia/
live/14003/61863/61863.pdf, accessed 21 January 2014).
109. Centers for Disease Control and Prevention (CDC). Recommendations for 
the identification of chronic hepatitis C virus infection among persons born 
during 1945–1965. Morbid Mortal Wkly Rep MMWR. 2012;61(4). (http://
www.cdc.gov/mmwr/pdf/rr/rr6104.pdf, accessed 21 January 2014).
110. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: 
Management of hepatitis C virus infection. J Hepatol. 2014;60(2):392-420.
112
111. American Association for the Study of Liver Diseases (AASLD) and 
Infectious Diseases Society of America (IDSA). Recommendations for 
Testing, Managing, and Treating Hepatitis C. AASLD, IDSA Alexandria; 
2014. (http://www.hcvguidelines.org/sites/default/files/full_report.pdf. 
Accessed 13 March 2014).
112. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB, American 
Association for Study of Liver Diseases. An update on treatment of genotype 
1 chronic hepatitis C virus infection: 2011 practice guideline by the American 
Association for the Study of Liver Diseases. Hepatology. 2011;54(4):1433–44.
113. Allison RD, Conry-Cantilena C, Koziol D, Schechterly C, Ness P, Gibble J, et 
al. A 25-year study of the clinical and histologic outcomes of hepatitis C virus 
infection and its modes of transmission in a cohort of initially asymptomatic 
blood donors. J Infect Dis. 2012;206(5):654–61.
114. Piasecki BA, Lewis JD, Reddy KR, Bellamy SL, Porter SB, Weinrieb RM, 
et al. Influence of alcohol use, race, and viral coinfections on spontaneous 
HCV clearance in a US veteran population. Hepatology. 2004;40(4):892–9.
115. Ohkoshi S, Tawaraya H, Kuwana K, Harada T, Watanabe M, Higuchi S, 
et al. A retrospective study of hepatitis C virus carriers in a local endemic 
town in Japan. A possible presence of asymptomatic carrier. Dig Dis Sci. 
1995;40(2):465–71.
116. Rongey CA, Kanwal F, Hoang T, Gifford AL, Asch SM. Viral RNA testing in 
hepatitis C antibody-positive veterans. Am J Prev Med. 2009;36(3):235–8.
117. Scott JD, McMahon BJ, Bruden D, Sullivan D, Homan C, Christensen C, 
et al. High rate of spontaneous negativity for hepatitis C virus RNA after 
establishment of chronic infection in Alaska natives. Clin Infect Dis. 
2006;42(7):945–52.
118. Sheth SD, Vera-Llonch M, Lynch J, Werther W, Rubin R. Characterization 
of a cohort of incident hepatitis c patients in the US (2005-2010): 
Comorbidities, use of medications and diagnostic tests. Pharmacoepidemiol 
Drug Saf. 2012;21:91.
119. Rein DB, Wagner LD, Brown KA, Fallon MB, Krauskopf K, Massoud OI. 
Current practices of hepatitis C antibody testing and follow-up evaluation 
in primary care settings: a retrospective study of four large, primary care 
service centers. Hepatology. 2012;56:1094A.
120. Yoshino I, Kasai M. Analysis of cases of negative HCV-RNA with positive 
anti-HCV. Acta Hepatologica Japonica. 1996; p. 412.
113
121. Bonacini M, Lin HJ, Hollinger FB. Effect of coexisting HIV-1 infection on the 
diagnosis and evaluation of hepatitis C virus. J Acquir Immune Defic Syndr. 
2001;26(4):340–4.
122. George SL, Gebhardt J, Klinzman D, Foster MB, Patrick KD, Schmidt WN, 
et al. Hepatitis C virus viremia in HIV-infected individuals with negative HCV 
antibody tests. J Acquir Immune Defic Syndr. 2002;31(2):154–62.
123. Thio CL, Nolt KR, Astemborski J, Vlahov D, Nelson KE, Thomas DL. 
Screening for hepatitis C virus in human immunodeficiency virus-infected 
individuals. J Clin Microbiol. 2000;38(2):575–7.
124. Thomson EC, Nastouli E, Main J, Karayiannis P, Eliahoo J, Muir D, et al. 
Delayed anti-HCV antibody response in HIV-positive men acutely infected 
with HCV. AIDS. 2009;23(1):89–93.
125. Hutchinson SJ, Bird SM, Goldberg DJ. Influence of alcohol on the 
progression of hepatitis C virus infection: a meta-analysis. Clin Gastroenterol 
Hepatol. 2005;3(11):1150–9.
126. Brunet L, Moodie EE, Rollet K, Cooper C, Walmsley S, Potter M, et al. 
Marijuana smoking does not accelerate progression of liver disease in 
HIV-hepatitis C coinfection: a longitudinal cohort analysis. Clin Infect Dis. 
2013;57(5):663–70.
127. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, 
et al. The natural history of hepatitis C virus infection: host, viral, and 
environmental factors. JAMA. 2000;284(4):450–6.
128. Mughal TI, Patel SB. Hepatocellular carcinoma: a review of 140 cases. Ann 
Saudi Med. 1996;16(1):53–5.
129. Du WJ, Xiang YT, Wang ZM, Chi Y, Zheng Y, Luo XN, et al. Socio-demographic and 
clinical characteristics of 3129 heroin users in the first methadone maintenance 
treatment clinic in China. Drug Alcohol Depend. 2008;94(1–3):158–64.
130. Cepeda JA, Niccolai LM, Eritsyan K, Heimer R, Levina O. Moderate/heavy 
alcohol use and HCV infection among injection drug users in two Russian 
cities. Drug Alcohol Depend. 2013;132(3):571–9.
131. Fialho M, Messias M, Page-Shafer K, Farre L, Schmalb M, Pedral-Sampaio 
D, et al. Prevalence and risk of blood-borne and sexually transmitted 
viral infections in incarcerated youth in Salvador, Brazil: opportunity and 
obligation for intervention. AIDS Behav. 2008;12(4 Suppl):S17–24.
114
132. Adoga MP, Banwat EB, Forbi JC, Nimzing L, Pam CR, Gyar SD, et al. 
Human immunonodeficiency virus, hepatitis B virus and hepatitis C virus: 
sero-prevalence, co-infection and risk factors among prison inmates in 
Nasarawa State, Nigeria. J Infect Dev Ctries. 2009;3(7):539–47.
133. Rao HY, Sun DG, Yang RF, Liu F, Wang J, Feng B, et al. Outcome of hepatitis 
C virus infection in Chinese paid plasma donors: a 12–19-year cohort study. 
J Gastroenterol Hepatol. 2012;27(3):526–32.
134. Drumright LN, Hagan H, Thomas DL, Latka MH, Golub ET, Garfein RS, et al. 
Predictors and effects of alcohol use on liver function among young HCV-infected 
injection drug users in a behavioral intervention. J Hepatol. 2011;55(1):45–52.
135. Dieperink E, Fuller B, Thuras P, McMaken K, Lenox R, Isenhart C. 
Randomized controlled trial of motivational enhancement therapy to reduce 
alcohol in patients with chronic hepatitis C. Hepatology. 2012;56:579A.
136. Dieperink E, Ho SB, Heit S, Durfee JM, Thuras P, Willenbring ML. 
Significant reductions in drinking following brief alcohol treatment provided 
in a hepatitis C clinic. Psychosomatics. 2010;51(2):149–56.
137. Proeschold-Bell RJ, Patkar AA, Naggie S, Coward L, Mannelli P, Yao J, et al. 
An integrated alcohol abuse and medical treatment model for patients with 
hepatitis C. Dig Dis Sci. 2012;57(4):1083–91.
138. Watson B, Conigrave KM, Wallace C, Whitfield JB, Wurst F, Haber PS. 
Hazardous alcohol consumption and other barriers to antiviral treatment 
among hepatitis C positive people receiving opioid maintenance treatment. 
Drug Alcohol Rev. 2007;26(3):231–9.
139. Kaner EF, Dickinson HO, Beyer F, Pienaar E, Schlesinger C, Campbell F, et 
al. The effectiveness of brief alcohol interventions in primary care settings: 
a systematic review. Drug Alcohol Rev. 2009;28(3):301–23.
140. Klimas J, Field CA, Cullen W, O’Gorman CS, Glynn LG, Keenan E, et al. 
Psychosocial interventions to reduce alcohol consumption in concurrent 
problem alcohol and illicit drug users: Cochrane Review. Systematic 
Reviews. 2013;2:3. doi:10.1186/2046-4053-2-3.
141. The WHO ASSIST Package. Geneva: World Health Organization; 2011. 
(http://www.who.int/substance_abuse/publications/media_assist/en/index.
html , accessed 30 January 2014). 
142.  mhGAP intervention guide for mental, neurological and substance use disorders 
in non-specialized health settings. Geneva: World Health Organization; 
2010. (http://whqlibdoc.who.int/publications/2010/9789241548069_eng.
pdf, accessed 21 January 2014).
115
143. Intraobserver and interobserver variations in liver biopsy interpretation in 
patients with chronic hepatitis C. The French METAVIR Cooperative Study 
Group. Hepatology. 1994;20(1 Pt 1):15–20.
144.  Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. 
J Hepatol. 1991;13(3):372–4.
145. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological 
grading and staging of chronic hepatitis. J Hepatol. 1995;22(6):696–9.
146. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic 
hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 
1996;24(2):289–93.
147. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and 
reporting. Am J Surg Pathol. 1995;19(12):1409–17.
148. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. 
Formulation and application of a numerical scoring system for assessing 
histological activity in asymptomatic chronic active hepatitis. Hepatology. 
1981;1(5):431–5.
149. Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, et al. Performance 
of the aspartate aminotransferase-to-platelet ratio index for the staging 
of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 
2011;53(3):726–36.
150. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. 
Development of a simple noninvasive index to predict significant fibrosis in 
patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317–25.
151. Malaguarnera M, Restuccia S, Trovato G, Siciliano R, Motta M, Trovato BA. 
Interferon-alpha treatment in patients with chronic hepatitis C: a meta-
analytic evaluation. Clin Drug Invest. 1995;9(3):141–9.
152. Myers RP, Poynard T. Interferon for interferon nonresponding and 
relapsing patients with chronic hepatitis C. Cochrane Database Syst Rev. 
2002;(4):CD003617. 
153. Hu J, Doucette K, Hartling L, Tjosvold L, Robinson J. Treatment of hepatitis 
C in children: a systematic review. PloS One. 2010;5(7):e11542.
154. Koretz RL, Pleguezuelo M, Arvaniti V, Barrera Baena P, Ciria R, Gurusamy 
KS, et al. Interferon for interferon nonresponding and relapsing patients 
with chronic hepatitis C. Cochrane Database Syst Rev. 2013;1:CD003617.
116
155. Tine F, Attanasio M, Russo F, Pagliaro L. A decade of trials of interferon-
alpha for chronic hepatitis C. A meta-regression analysis. Contemp Clin 
Trials. 2005;26(2):179–210.
156. Carithers RL Jr, Emerson SS. Therapy of hepatitis C: meta-analysis of 
interferon alfa-2b trials. Hepatology. 1997;26(3 Suppl 1):S83–8.
157. Fabrizi F, Ganeshan SV, Lunghi G, Messa P, Martin P. Antiviral therapy of 
hepatitis C in chronic kidney diseases: meta-analysis of controlled clinical 
trials. J Viral Hepat. 2008;15(8):600–6.
158. Xirouchakis E, Triantos C, Manousou P, Sigalas A, Calvaruso V, Corbani 
A, et al. Pegylated-interferon and ribavirin in liver transplant candidates 
and recipients with HCV cirrhosis: systematic review and meta-analysis of 
prospective controlled studies. J Viral Hepat. 2008;15(10):699–709.
159. Kimer N, Dahl EK, Gluud LL, Krag A. Antiviral therapy for prevention of 
hepatocellular carcinoma in chronic hepatitis C: systematic review and meta-
analysis of randomised controlled trials. BMJ Open. 2012;2(5):10.1136/
bmjopen-2012-001313. Print 2012.
160. Iorio A, Marchesini E, Awad T, Gluud LL. Antiviral treatment for chronic 
hepatitis C in patients with human immunodeficiency virus. Cochrane 
Database Syst Rev. 2010;(1):CD004888. doi: 10.1002/14651858.
CD004888.pub2.
161. Hartwell D, Shepherd J. Pegylated and non-pegylated interferon-alfa and 
ribavirin for the treatment of mild chronic hepatitis C: a systematic review 
and meta-analysis. Int J Technol Assess Health Care. 2009;25(1):56–62.
162. Vezali E, Aghemo A, Colombo M. A review of the treatment of chronic 
hepatitis C virus infection in cirrhosis. Clin Ther. 2010;32(13):2117–38.
163. Brok J, Gluud LL, Gluud C. Ribavirin monotherapy for chronic hepatitis C. 
Cochrane Database Syst Rev. 2009;(4):CD005527. doi: 10.1002/14651858.
CD005527.pub2.
164. Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, et 
al. Treatment of hepatitis C virus infection among people who are actively 
injecting drugs: a systematic review and meta-analysis. Clin Infect Dis. 
2013;57 Suppl 2:S80–9.
165. Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, et al. 
Outcome of sustained virological responders with histologically advanced 
chronic hepatitis C. Hepatology. 2010;52(3):833–44.
117
166. MSF Access Campaign [website]. Diagnosis and treatment of hepatitis C: 
a technical landscape. MSF. Geneva: Medecins sans Frontieres; 2013. 
(http://www.msfaccess.org/content/diagnosis-and-treatment-hepatitis-c-
technical-landscape, accessed 21 January 2014).
167. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. 
Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, 
for chronic hepatitis C in HIV-infected patients: a randomized controlled 
trial. JAMA. 2004;292(23):2839–48.
168. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, 
et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus 
ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 
2004;351(5):451–9.
169. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia 
J, Lazzarin A, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis 
C virus infection in HIV-infected patients. N Engl J Med. 2004;351(5):438–
50.
170. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. 
Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl 
J Med. 2011;364(13):1207–17.
171. Hezode C, Dorival F, Zoulim T, Poynard P, Mathurin S, Pol D, et al. Real-
life safety of telaprevir or boceprevir in combination with peginterferon 
alfa/ribavirin, in cirrhotic non responders. First results of the French early 
access program (ANRS C020-CUPIC). J Hepatol. 2012;56(S2):S4. 
172. Hezode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, et al. 
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a 
multicentre cohort of the French Early Access Programme (ANRS CO20-
CUPIC) - NCT01514890. J Hepatol. 2013;59(3):434–41.
173. British HIV Association guidelines for the management of hepatitis viruses 
in adults infected with HIV 2013. HIV Med. 2013;14 (Suppl 4):1–71. (http://
www.bhiva.org/hepatitis-2013.aspx, accessed 27 January 2014). 
174. Rodriguez-Torres M, Rodriguez-Orengo J, Gaggar A, Shen G, Symonds B, 
McHutchison J, et al., editors. Sofosbuvir and peginterferon alfa-2a/ribavirin 
for treatment-naïve genotype 1–4 HCV-infected patients who are coinfected 
with HIV [Abstract]. San Francisco, CA, USA: Infectious Diseases Society 
of America (IDSA); 2–6 October 2013. (http://www.natap.org/2013/IDSA/
IDSA_24.htm, accessed 28 January 2014).
118
175. Osinusi A, Meissner EG, Lee YJ, Bon D, Heytens L, Nelson A, et al. Sofosbuvir 
and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment 
characteristics: a randomized clinical trial. JAMA. 2013;310(8):804–11.
176. Zeuzem S, Dusheiko G, Salupere R, Mangia A, Flisiak R, Hyland R. 
Sofosbuvir and ribavirin for 12 or 24 weeks for patients with HCV genotype 
2 or 3: the VALENCE trial [Abstract]. 64th annual meeting of the American 
Association for the Study of Liver Diseases (AASLD 2013); Washington 
DC, USA; 1–5 November 2013. (http://liverlearning.aasld.org/aasld/2013/
thelivermeeting/36038/undefined, accessed 26 January 2014). 
177. Lawitz E, Poordad F, Brainard DM, Hyland RH, An D, Symonds WT, et al., editors. 
Sofosbuvir in combination with pegIFN and ribavirin for 12 weeks provides high 
SVR rates in HCV-infected genotype 2 or 3 treatment experienced patients 
with and without compensated cirrhosis: results from the LONESTAR-2 study 
[Abstract]. 64th Annual Meeting of the American Association for the Study of Liver 
Diseases (AASLD 2013); Washington, DC, USA; 1–5 November 2013. (http://
www.natap.org/2013/AASLD/AASLD_23.htm, accessed 27 January 2014). 
178. U.S. Food and Drug Administration approves Gilead’s Sovaldi™ (Sofosbuvir) for 
the treatment of chronic hepatitis C. In: Gilead Sciences, Inc [website]. 2013. 
(http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID
=1882800&highlight=#sthash.vtTBKm1T.dpuf, accessed 26 January 2014).
179. Jacobson I, Dore GJ, Foster GR, Fried MW, Radu M, Rafalskiy VV, et al. 
Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic 
HCV genotype 1 infection in treatment-naïve patients: results from QUEST-1 
a phase III trial. J Hepatol. 2013;58(S1):S574.
180. Manns M, Marcellin P, Poordad F, Affonso de Araujo S, Buti M, Horsmans 
Y, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of 
chronic HCV genotype 1 infection in treatment-naïve patients: results from 
QUEST-2 a phase III trial. J Hepatol. 2013;58(S1):S568. 
181. Zeuzem S, Berg T, Gane E, Ferenci P, Foster GR, Fried MW, et al. Simeprevir 
increases rate of sustained virologic response among treatment-experienced 
patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology. 
2014;46(2):430–41.
182. Dieterich D, Rockstroh J, Orkin C, Gutiérrez F, Klein MB, Reynes J, et al., editors. Simeprevir 
(TMC435) plus peginterferon/ribavirin in patients co-infected with HCV genotype-1 and 
HIV-1: primary analysis of the C212 study. 14th European AIDS Conference (EACS 
2013); Brussels, Belgium, 16–19 October 2013. (http://www.professionalabstracts.com/
eacs2013/planner/index.php?go=abstract&action=abstract_show&absno=1083&, 
accessed 27 January 2014).
119
183. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto 
N, et al. Genome-wide association of IL28B with response to pegylated 
interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 
2009;41(10):1105–9.
184. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’Huigin C, et al. Genetic 
variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 
2009;461(7265):798–801.
185. Mauss S, Valenti W, DePamphilis J, Duff F, Cupelli L, Passe S, et al. Risk 
factors for hepatic decompensation in patients with HIV/HCV coinfection and 
liver cirrhosis during interferon-based therapy. AIDS. 2004;18(13):F21–5.
186. Bani-Sadr F, Carrat F, Rosenthal E, Piroth L, Morand P, Lunel-Fabiani F, et 
al. Spontaneous hepatic decompensation in patients coinfected with HIV 
and hepatitis C virus during interferon-ribavirin combination treatment. Clin 
Infect Dis. 2005;41(12):1806–9.
187. Roche Product information: Pegasys. (http://www.roche.com.pk/fmfiles/
re7259003/PI/Pegasys-PI.pdf, accessed 27 January 2014).
188. Merck Canada. Product monograph: Pegetron. 2013. (http://www.merck.ca/
assets/en/pdf/products/Pegetron-PM_E.pdf, accessed 21 January 2014). 
189. Ramos B, Nunez M, Rendon A, Berdun MA, Losada E, Santos I, et al. Critical 
role of ribavirin for the achievement of early virological response to HCV 
therapy in HCV/HIV-coinfected patients. J Viral Hepat. 2007;14(6):387–91.
190. Guidance on prevention of viral hepatitis B and C among people who inject 
drugs. Geneva: World Health Organization; 2012. (http://www.who.int/hiv/
pub/guidelines/hepatitis/en/index.html, accessed 21 January 2014).
191. Visconti AJ, Doyle JS, Weir A, Shiell AM, Hellard ME. Assessing the cost-
effectiveness of treating chronic hepatitis C virus in people who inject drugs 
in Australia. J Gastroenterol Hepatol. 2013;28(4):707–16.
192. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug 
users: a review of the available evidence. Clin Infect Dis. 2009;49(4):561–73.
193. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus 
infection in HIV-infected individuals and the impact of HIV in the era of highly 
active antiretroviral therapy: a meta-analysis. AIDS. 2008;22(15):1979–91. 
194. Avidan NU, Goldstein D, Rozenberg L, McLaughlin M, Ferenci P, Masur H, 
et al. Hepatitis C viral kinetics during treatment with peg IFN-alpha-2b in 
HIV/HCV coinfected patients as a function of baseline CD4 + T-cell counts. 
J Acquir Immune Defic Syndr. 2009;52(4):452–8.
120
195. Gilead Sciences. Sovaldi full prescribing information. 2013 (http://www.
gilead.com/~/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi_
pi.pdf, accsessed 25 January 2014).
196. Food and Drug Administration. Olysio (simeprevir) for the treatment of 
chronic hepatitis C in combination antiviral treatment. 2013. (http://www.
fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ucm377234.
htm, accessed 25 January 2014)
197. Consolidated guidelines on the use of antiretroviral drugs for treating and 
preventing HIV infection: recommendations for a public health approach. 
Geneva: World Health Organization; 2013. (http://apps.who.int/iris/
bitstream/10665/85321/1/9789241505727_eng.pdf, accessed 25 January 2014).
198. Den Brinker M, Wit FW, Wertheim-van Dillen PM, Jurriaans S, Weel J, 
van Leeuwen R, et al. Hepatitis B and C virus co-infection and the risk for 
hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS. 
2000;14(18):2895–902. 
199. Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD. 
Hepatotoxicity associated with protease inhibitor-based antiretroviral 
regimens with or without concurrent ritonavir. AIDS. 2004;19(18):2277–84. 
200. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity 
associated with nevirapine or efavirenz-containing antiretroviral therapy: Role 
of hepatitis C and B infections. Hepatology. 2002;35(1):182–189.
201. Nunez M. Clinical syndromes and consequences of antiretroviral-related 
hepatotoxicity. Hepatology. 2010;52(3):1143–55. 
202. Japour AJ, Lertora JJ, Meehan PM, Erice A, Connor JD, Griffith BP, et al. 
A phase-1 study of the safety, pharmacokinetics, and antiviral activity of 
combination didanosine and ribavirin in patients with HIV-1 disease. J 
Acquir Immune Defic Syndr Hum Retrovirol. 1996;13:235–46.
203. Harvie P, Omar RF, Dusserre N, Lansac N, Désormeaux A, Gourde P, et 
al. Ribavirin potentiates the efficacy and toxicity of 2`,3`- dideoxyinosine in 
the murine acquired immunodeficiency syndrome model. J Pharmacol Exp 
Ther. 1996;279:1009–17.
204. Perronne C. Antiviral hepatitis and antiretroviral drug interactions. J Hepatol. 
2006;44(S1):S119–25.
205. Alvarez D, Dieterich DT, Brau N, Moorehead L, Ball L, Sulkowski MS. 
Zidovudine use but not weight-based ribavirin dosing impacts anaemia during 
HCV treatment in HIV-infected persons. J Viral Hepat. 2006;13:683–9. 
121
206. Mira JA, López-Cortés LF, Barreiro P, Tural C, Torres-Tortosa M, de Los 
Santos Gil I, et al. Efficacy of pedylated interferon plus ribavirin treatment in 
HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine 
or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue 
backbone. J Antimicrob Chemother. 2008;62(6):1365–73.
207. Vispo E, Barreiro P, Pineda JA, Mira JA, Maida I, Martin-Carbonero L, 
et al. Low response to pegylated interferon plus ribavirin in HIV-infected 
patients with chronic hepatitis C treated with abacavir. Antiviral Ther. 
2008;13(3):429–37.
208. Laufer N, Laguno M, Perez I, Cifuentes C, Murillas J, Vidal F, et al. Abacavir 
does not influence the rate of virological response in HIV-HCV-coinfected 
patients treated with pegylated interferon and weight-adjusted ribavirin. 
Antiviral Ther. 2008;13(7):953–7.
209. El-Raziky MS, El-Hawary M, Esmat G, Abouzied AM, El-Koofy N, Mohsen N, 
et al. Prevalence and risk factors of asymptomatic hepatitis C virus infection 
in Egyptian children. World J Gastroenterol. 2007;13(12):1828–32.
210. Locasciulli A, Gornati G, Tagger A, Ribero ML, Cavalletto D, Cavalletto L, 
et al. Hepatitis C virus infection and chronic liver disease in children with 
leukemia in long-term remission. Blood. 1991;78(6):1619–22.
211. Rossetti F, Cesaro S, Pizzocchero P, Cadrobbi P, Guido M, Zanesco L. 
Chronic hepatitis B surface antigen-negative hepatitis after treatment of 
malignancy. J Pediatr. 1992;121(1):39–43.
212. Jonas MM, Zilleruelo GE, LaRue SI, Abitbol C, Strauss J, Lu Y. Hepatitis C 
infection in a pediatric dialysis population. Pediatrics. 1992;89(4 Pt 2):707–9.
213. Greco M, Cristiano K, Leozappa G, Rapicetta M, Rizzoni G. Hepatitis C 
infection in children and adolescents on haemodialysis and after renal 
transplant. Pediatr Nephrol. 1993;7(4):424–7.
214. Nelson SP, Jonas MM. Hepatitis C infection in children who received 
extracorporeal membrane oxygenation. J Pediatr Surg. 1996;31(5):644–8.
215. Ni YH, Chang MH, Lue HC, Hsu HY, Wang MJ, Chen PJ, et al. Posttransfusion 
hepatitis C virus infection in children. J Pediatr. 1994;124(5 Pt 1):709–13.
216. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, 
et al. The natural history of hepatitis C virus infection: host, viral, and 
environmental factors. JAMA. 2000;284(4):450–6.
122
217. Potthoff A, Wedemeyer H, Boecher WO, Berg T, Zeuzem S, Arnold J, et 
al. The HEP-NET B/C co-infection trial: A prospective multicenter study 
to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in 
patients with HBV/HCV co-infection. J Hepatol. 2008;49(5):688–94.
218. Pérez-Elías MJ, García-San Miguel L, González García J, Montes Ramírez 
ML, Muriel A, Machín-Lázaro JM, et al. Tuberculosis complicating hepatitis 
C treatment in HIV-infected patients. Clin Infect Dis. 2009;48(8):e82–5. 
doi: 10.1086/597503.
219. Gilks CF, Crowley S, Ekpini R, Gove S, Perriens J, Souteyrand Y, et al. The 
WHO public-health approach to antiretroviral treatment against HIV in 
resource-limited settings. Lancet. 2006;368(9534):505–10.
C
GUIDELINES FOR THE SCREENING, 
CARE AND TREATMENT OF PERSONS 
WITH HEPATITIS C INFECTION 
APRIL 2014
GUIDELINES
Global Hepatitis Programme  
Department of HIV/AIDS
20, avenue Appia 
1211 Geneva 27 
Switzerland
E-mail: hepatitis@who.int
http://www.who.int/hiv/topics/hepatitis/en/
978 92 4 154875 5
GUIDELINES FOR THE SCREENING, CARE AND TREATM
ENT OF PERSONS W
ITH HEPATITIS C INFECTION
